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Ductal carcinoma in situ (DCIS) is thought to be the earliest pre-invasive form of and non-
obligate precursor to invasive ductal carcinoma (IDC). There is an urgent need to identify predictive and 
prognostic biomarkers for breast cancers with a heightened risk of progression from DCIS to IDC. Our 
laboratory has previously discovered a novel TRIM family member, DEAR1 (Ductal Epithelium 
Associated Ring Chromosome 1, annotated as TRIM62) within chromosome 1p35.1, that is mutated and 
homozygously deleted in breast cancer and whose expression is downregulated/lost in DCIS. Previous 
work has shown that DEAR1 is a novel tumor suppressor that acts as a dominant regulator of polarity, 
tissue architecture, and TGFβ-driven epithelial-mesenchymal transition (EMT)1,2. Herein, I have shown 
by pan-cancer database analysis that chromosomal loss of DEAR1 is a moderately frequent event in 
multiple epithelial cancers and that targeted deletion of Dear1 in the mouse recapitulates the tumor 
spectrum of human tumor types undergoing DEAR1 copy number losses, including mammary tumors. 
Therefore, results indicate the relevance of the Dear1 mouse model to human disease and suggest that 
genomic alteration of DEAR1 could play a role in the etiology of multiple cancers, including breast 
cancer. Because DEAR1 is downregulated in DCIS and regulates polarity and EMT, I hypothesized 
DEAR1 mutations might be driver events in the progression of DCIS to IDC. Therefore I completed 
targeted ultra-deep sequencing of DEAR1 in FFPE samples of 17 Pure DCIS and 17 DCIS samples 
associated with invasive lesions. Deep sequencing of DCIS indicate DEAR1 is mutated in 71% of DCIS. 
Within these samples, multiple mutations within DEAR1, including exonic variants previously 
discovered in IDC and novel nonsense mutations were discovered and validated. Interestingly, variants 
in samples of DCIS associated with an invasive component indicate few variants shared between the two 
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components, possibly supporting an independent yet parallel evolution between DCIS and IDC. Further, 
functional screens were performed on a subset of mutations identified and demonstrated that indicated 
missense mutations can affect DEAR1’s regulation of tissue architecture and TGFβ signaling. 
Altogether, this data suggests that genomic alteration of DEAR1 is an important mechanism for its loss of 
function and may be of significance in early breast cancer. 
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 Chapter 1 
Introduction 
Role of Genetic Alterations in the Progression of Cancer 
Cancer as a Genetic Disease 
Cancer is in essence a genetic disease with genomic alterations being vital to the initiation and 
progression of cancer. The development of cancer is dependent on the accumulation of mutations and 
copy number changes across multiple years or decades, inducing changes which allow normal tissue to 
slowly progress to neoplastic disease, and in later stages to advanced metastatic disease
1
. Genetic 
alterations, which occur during tumor development and progression, can happen in either genes 
promoting tumorigenesis (oncogenes) or in genes that act to suppress cancer development and its 
progression (tumor suppressor genes). Oncogenes were first discovered through work with retroviruses. 
Peyton Rous described the first transforming retrovirus, Rous Sarcoma Virus (RSV), which caused the 
formation of sarcomas in chickens
3
. Subsequent molecular studies showed that the gene responsible for 
RSV’s transforming activity was v-Src, which was later identified as an integral oncogene in a variety of 
human solid tumors
4, 5
. This finding inspired the discovery of multiple other transforming genes, termed 
oncogenes by Huebner and Todaro, through gene transfer assays into NIH3T3 cells
6-8
. Oncogenes differ 
from their normal cellular counterparts through the acquisition of alterations such as point mutations, 
gene reduplication/amplification, or by translocation. These changes can alter the activity of an oncogene 
(point mutations/translocations) or increase its expression (gene reduplication/amplification)
9
. 
Oncogenes typically fall into four categories: growth factors and their receptors, signal transducers, 
transcription factors, and others, including anti-apoptotic cell death regulators, oncogenic miRNAs, as 
well as the newly described oncogenic role that members of the glycolytic pathway can play
9
. Genes 
which suppress oncogenic development and activity are called tumor suppressor genes. Tumor 
suppressor genes typically fall into five different categories: DNA repair genes, cell cycle regulators, 
inhibitors of growth factor receptors, pro-apoptotic genes, and intracellular proteins of which many 
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inhibit pro-tumorigenic cell signaling
9
. The concept of tumor suppressors came from the observation that 
non-tumorigenic clones resulted from the fusion of normal cells with tumor cells by somatic cell 
hybridization
10, 11
. The normal cells were hypothesized to be contributing genes which could suppress 
tumorigenesis and bring the cellular state back to homeostasis
11-17
. The first tumor suppressor gene 
identified was Retinoblastoma (Rb)
18, 19
. Rb was found to be mutated not only in the childhood eye 
cancer called by the same name, but also in lung, breast, esophageal, prostate and renal carcinomas, as 
well as sarcomas and leukemias
20
. Rb has been shown to be important in cell cycle regulation and in the 
suppression of tumorigenesis
20
.  Deregulation of the Rb pathway has been described as a quintessential 
mechanism in the acquisition of the insensitivity to anti-growth signals, a known hallmark of 
tumorigenesis
21
. After the identification of Rb, the second tumor suppressor identified was p53. p53 is 
known to play major roles in cellular stress mitigation through its regulation of the cell cycle, 
senescence, and apoptosis
22, 23
. Interestingly, p53 was originally identified as an oncogene, as the gene 
was first cloned from a cancer cell harboring a dominant negative mutation
24
. Later, studies using 
wildtype p53 revealed the tumor suppressive activities of the gene. p53 is mutated in up to 50% of all 
cancers and is also associated with the familial cancer syndrome Li Fraumeni, which has a very diverse 
tumor spectrum, including sarcomas, breast and brain cancers, as well as leukemias
22, 25
. The 
identification of Rb and p53 reflected major strides in understanding cellular mechanisms to prevent the 
onset of tumorigenesis. The formative work previously accomplished within the past century has not 
only informed of the general processes involved in cancer but has laid the groundwork for the current 
and future discoveries related to the complex nature of cancer genetics. 
Genes which undergo genetic alterations in cancer have been historically classified in one of 
three groups: caretakers, gatekeepers, and landscaper genes
26, 27
. Gatekeepers regulate the balance 
between cellular growth and death. This group is known to contain both tumor suppressor genes and 
oncogenes. One example of a gatekeeper gene is Retinoblastoma (Rb) which is vital to the regulation of 
the cell cycle. Caretakers are maintainers of genetic integrity with many members involved in the 
regulation of DNA damage response, such as the mismatch repair genes. Inactivation of caretaker genes 
13 
 
indirectly promotes tumorigenesis as loss of these genes can induce genetic instability leading to an 
increased mutation rate, causing further deregulation of pathways involved in cancer
27
. Another category, 
landscaper genes, are involved in processes related to the microenvironment conditions, especially in 
stromal-epithelial interactions
26. Changes in these genes, like TGFβ, can upset homeostasis within the 
microenvironment and produce conditions conducive for tumor progression. The accumulation of 
mutations within each of these classes of genes are essential for cancer’s initiation and progression27.  
Besides these classifications, genetic mutations in cancer can also be classified as being either passenger 
and driver mutations
28
. Driver mutations are within genes which are known to be integral to growth 
processes and whose alterations can become fixed within the tumor population due to their strong nature 
in promoting tumor growth. Adult sporadic tumors have been found to contain, on average, alterations in 
3-6 driver genes
1
.  The overall effect of these driver mutations, however, is estimated to be small, on the 
order of a 0.4% increase in cellular growth over cell death for each gene mutated
1
. Passenger mutations 
were originally defined as mutations which do not confer a selective advantage for the tumor and may 
only be fixed within the tumor populations through their co-presence with other strong driver mutations, 
essentially hitchhiking with these drivers to become fixed during tumor progression. This paradigm, 
however, is starting to change as research has shown that the accumulation of passenger mutations with 
moderate deleterious nature, whom by themselves cannot drive cancer progression, may cooperate with 
other moderately deleterious passenger mutations to produce an overall damaging effect
28
. These 
deleterious “passenger” mutations have a higher probability of becoming fixed within the tumor 
population than their less deleterious counterparts and the accumulation of these variants can help to 
prolong progression leading for the ability of the tumor to acquire many more mutations. Moreover, 
some of these deleterious “passenger” mutations may in their own right act as drivers during certain 
times during tumor progression or act synergistically with the alteration of certain other pathways in 
order to drive tumorigenesis
29
. For examples, landscaper genes, in synergism with other alterations, can 
drive cancer progression, as they help to make the environment more permissible for tumor progression 
despite not necessarily affecting tumor growth themselves. No matter what category particular cancer 
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genes exist in, tumor progression relies on the combination and synergism of multiple alterations to 
provide a selective advantage to the tumor and drive its progression.  
Tumor suppressors genes can fit into any of the previously mentioned classic categories of 
cancer genes and in many respects, inactivation of these genes can act as strong drivers of tumor 
initiation and progression. Tumor suppressor genes can be inactivated in multiple ways, such as through 
mutations and deletions. Often in cancer, these alterations occur through defective DNA repair processes 
(mutations) or by aberrant mitotic recombination and nondisjunction (deletions). A major development 
in the understanding of the genetic mechanisms of tumorigenesis came through the study of 
retinoblastoma. The observation that sporadic forms of retinoblastoma developed later in life than 
familial forms led to the development of the groundbreaking definition of the “two-hit hypothesis” by 
Alfred Knudson
30. The “two-hit” model described a mechanism for tumor initiation in which two alleles 
are required to be inactivated, whether by mutation or chromosomal loss, for the initiation of 
tumorigenesis. In familial cancer, one of the inactivating hits is inherited in the germline while the 
second hit occurs somatically; whereas for sporadic cancer, both inactivating hits are acquired 
somatically. The classical definition of tumor suppressors, defined by the “two hit” model, has been 
verified for many tumor suppressors genes.  In fact, a hallmark of tumor suppressor genes is the 
identification of deletions or mutations that completely knock-out the function of the gene, such as 
homozygous deletions and nonsense or frameshift mutations
31
. Of these, one of the more common 
mechanisms of tumor suppressor inactivation is through chromosomal deletion which has been shown to 
be important in tumorigenesis
32, 33
. However, as homozygous deletion is rare, often a combination of 
chromosomal deletion and gene mutation is needed in order to inactivate the tumor suppressor. For 
example, when the deletion of a wildtype allele occurs in a concomitant fashion with mutation of the 
other allele, the event is known as loss of heterozygosity (LOH) 
9
. As chromosomal deletions are a 
common event in cancer, LOH can be critical to the inactivation of classical tumor suppressors. Most 
tumor suppressor genes have been shown to follow the classic “two-hit” model, yet another class of 
genes have been found to exist in which the alteration of only one allele is sufficient to inactivate the 
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tumor suppressor
34, 35. This condition is known as “haploinsufficiency”34, 35. Classic examples of 
haploinsufficient genes are Arf, p27
kip1
, and PTEN
36
. It has been hypothesized that strong acting 
haploinsufficient genes may be more frequently inactivated than classical tumor suppressors because 
they only require the alteration of a single allele to become inactivated
37
. These haploinsufficient genes, 
through their higher propensity to become inactivated, have been proposed to contribute to an increased 
rate of tumor development and progression
37
. Nonetheless, no matter the mechanism of inactivation, the 
loss of tumor suppressor genes is critical to the onset of cancer and the progression of the disease.  
Multiple studies have shown the clinical importance of inactivating mutations and 
chromosomal alterations in tumor suppressors to cancer progression. For example, heterozygous or 
homozygous loss of Pten causes greatly reduced survival in a prostate cancer mouse model
37
. Dramatic 
reductions in survival as well as promotion of tumor progression have also been found to be associated 
with LKB1 inactivation via mutation or chromosomal deletions in cervical cancer patients
38
. Moreover, 
it’s been shown that amplification of the chromosomal location containing the Androgen Receptor (AR) 
gene, occurring in about 30% of prostate cancers, can be acquired during androgen deprivation therapy, 
effectively allowing for the continuation of tumor growth in the presence of low androgen conditions
39
. 
Particular alterations can also be associated with the acquisition of other certain genetic deficiencies in 
cancer as is typified by carriers of germline BRCA1 or BRCA2 mutations being associated with multiple 
specific chromosomal alterations in breast cancers
40
. Further, BRCA2 mutations are correlated with 
increased stage/grade of prostate cancer as well as reduced survival rates
41
. Lastly, matrix 
metalloproteinase (MMP) family member, MMP8, which is a landscaper gene important 
microenvironment regulation through its proteinase activities within the extracellular matrix, has been 
shown to be a tumor suppressor in melanoma and loss of function mutations within this gene can 
promote melanoma metastasis in vivo
42
. It is clear that genetic alterations in various types of pathways 
can influence the progression of tumorigenesis and subsequent survival rates. 
Chromosomal Alterations Can Be Integral Players in Tumor Progression 
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As mentioned previously, chromosomal alterations can act as drivers in tumor progression and 
are common across the majority of tumor types
43
. Cancer genomes experience a multitude of different 
types of chromosome alterations including aneuploidy, amplifications, double minutes, deletions, 
inversions, and translocations
33
. Structural changes often result in the gain or loss of specific genomic 
loci
33
. Further, these structural changes may also be balanced, resulting from either equal exchange of 
genetic material, or neutral, in which a deletion or amplification of chromosomal material is followed by 
an equal but opposing structural change 
33
. Across cancers, the average number of chromosomal 
alterations can vary greatly, with some tumors known to contain dozens of different alterations while 
other cancers may exhibit only a few
33
. Moreover, the spectrum of chromosomal alterations can vary 
between inherited and sporadic tumors of the same tissue origin. For example, hereditary non-polyposis 
colorectal cancer is associated with a general diploid genome yet sporadic colorectal cancer often tends 
to exhibit aneuploidy
33
. As the areas encompassing recurrent karyotypic abnormalities can demarcate 
loci encompassing genes important for tumor progression, chromosomal alterations have often been used 
to identify new oncogenes and tumor suppressor genes in both solid and hematological tumors
44
. The 
first chromosome abnormality associated with cancer was the Philadelphia chromosome translocation 
t(9;22) in Chronic Myelogenous Leukemia (CML), in which a portion of chromosome 9 is translocated 
onto chromosome 22
45, 36
. This translocation creates the oncogenic fusion of genes Bcr and Abl. 
Imatinib, a specific inhibitor for the Bcr-Abl gene fusion, was one of the first successful targeted 
therapies created
46
. The description of the Philadelphia chromosome in CML provided the first support 
that chromosomal aberrations can be tumor initiating events. Since this discovery, many other oncogenes 
and tumor suppressors have been identified that occur at or near chromosomal translocations and within 
areas found to be amplified or deleted in cancer. Chromosomal alterations can be focal, involving one to 
two genes, or they can affect large areas of the chromosome, with loss of entire chromosome arms being 
more common than focal alterations in cancer
43
. The limited number of genes involved in focal 
alterations can allow for easier identification of genes important for tumor progression, whereas larger 
chromosomal aberrations often involve tens to hundreds of genes, which make it hard to determine 
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which particular gene or genes are driving tumor progression. However, recent research has suggested 
that alteration of multiple genes involved in large chromosomal alterations can potentially act 
synergistically to cause changes in the expression of multiple driver genes
33
. In support of this, it has 
been shown that the loss of a single copy of a chromosome locus containing multiple tumor suppressor 
genes can confer a selective advantage to the tumor
47, 48
. Large chromosomal alterations can occur either 
by the alteration of a single unified region or through the newly discovered mutational pattern of 
chromosome shattering, termed “chromothripsis”49. Chromothripsis is thought to occur via aberrations in 
chromosomal segregation, exposure to ionizing radiation, or micronuclear fragmentation
50, 51
. 
Chromosome shattering can contribute to rapid tumor evolution and has been shown to be associated 
with poor prognosis in acute myeloid leukemia (AML), multiple myeloma, and melanoma
49, 51
.  These 
large alterations, whether through loss or gain of a single chromosomal section or through chromosomal 
shattering, can be integral for tumor progression by their ability to effect gene expression of both 
oncogenes, such as ERBB and MYC, as well as in tumor suppressors, including PTEN and CDKN2A
9
. 
Changes in gene expression and inactivation of important tumor suppressors through these chromosomal 
alterations can increase oncogenic potential by promoting cellular changes consistent with the hallmarks 
of cancer
52
. As indicated, chromosomal alterations can play major roles in the deregulation of important 
genetic drivers in cancer and in the promotion of tumor progression.  
The Cancer Genome Era Defines the Landscape of Cancer 
As genetic aberrations are critical to cancer initiation and progression, more emphasis during 
this current era of genome sequencing has been placed on fully characterizing the genetic nature of 
cancer. Large consortium sequencing projects, such as The Cancer Genome Atlas (TCGA) and the 
International Cancer Genome Consortium (ICGC), have become prominent within the scientific 
community. These projects have been largely successful in their identification of novel cancer related 
genes and subsequent clinical biomarkers, as well as the establishment of new cancer subtypes based on 
molecular and genetic data
53
. Analysis of the large genomic data sets that have come out of these projects 
have also revealed the mutational frequencies and the prevalence of somatic mutations across human 
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tumor types. Pediatric tumors have been shown to experience the lowest mutation frequency, where as 
environmentally driven tumors, such as lung cancer and melanoma, are associated with the highest 
mutation rate
54
. Pan-cancer analysis has shown that some cancers unexpectedly share common 
alterations across tumor types. For example, p53 mutations, the most altered gene in cancer, have been 
found to be a driver of high-grade serous ovarian, serous endometrial, and basal breast cancer
53, 55
. 
PIK3CA is the second most common gene mutated in cancer with an incidental frequency greater than 
10% in most cancers
55
. HER2 (ERBB2) mutations and amplification, which are known driver events in 
breast cancer and for which a targeted therapy has already been developed for, has also been found to 
occur in glioblastoma multiforme, gastric, serous endometrial, bladder and lung cancer
53
. The 
determination that targetable alterations can occur across tumor types increases the range of patients able 
to benefit from a targeted drug originally developed for another tumor type. Pan cancer sequencing 
analysis has also shown that genes which are significantly mutated in cancer fall into 20 different 
pathways or functional groups, with the largest categories being transcription factors/regulators, histone 
modifiers, genome integrity, receptor tyrosine kinase signaling, and cell cycle, as well as, signaling 
pathways mitogen-activated protein kinases (MAPK), phosphatidylinositol-3-OH kinase (PI(3)K), 
transforming growth factor β (TGFβ), and Wnt/β-catenin55. Of these, significantly mutated gene 
categorized within the histone modifiers, PI(3)K signaling and genome integrity categories are found to 
be mutated across cancer types. Further, mutational signatures have also been described that occur across 
cancer types as well. Most cancer types have been found to exhibit 2-6 mutational signatures, with each 
individual tumor displaying more than one signature
54
. For example, mutations characterized by C>T 
transitions at NpCpG trinucleotides have been linked to increased cancer age of onset and was found to 
be almost ubiquitous in all cancer types
54
. Moreover, some mutational signatures are associated with 
transcription coupled repair which tend to be enriched in C>T and C>A mutations in environmentally 
driven cancers such as lung and head & neck cancers that are linked to smoking, as well as UV driven 
melanoma
54
.  Another mutation signature has been shown to be caused by defective DNA repair or 
overly active DNA editing by members of the APOBEC/AID family which are associated with mutation 
signatures characterized by either small deletions and C>T substitutions linked to mismatch repair 
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deficiencies or C>T/C>G substitutions which are connected to the cytosine deaminase activity of 
APOPECs
54
. A surprising find which has emerged from the sequencing efforts by the large consortiums 
is the “long tailed” nature of cancer mutations, in which few repetitively altered driver genes are found to 
be mutated and implicated in cancer
56
. In accordance, the cancer genome landscape has been described 
as a collection of “mountains” and “hills”57. With “mountains” defining genes indicated to have a high 
frequency of alterations in cancer and “hills” describing genes which are known to experience only few 
mutations. As shown by whole genome sequencing of many cancers, rare mutation “hills” dominate the 
cancer genome landscape. However, through aggregation of the data across tumor types by pan-cancer 
analysis, these rare alterations have been able to be implicated as drivers as well
53
. Sequencing of large 
cohorts of cancer samples have shown that most solid tumors, though they are estimated to be driven 
only by 2-6 dominant driver mutations, also carry, on average, mutations in 33-66 genes that are 
predicted to be deleterious
1, 55
. Ninety-five percent of these mutations are single base pair substitutions, 
with 91% of these substitutions being missense mutations
1
. Only 8% of the substitutions typically result 
in nonsense mutations, causing an inappropriate and early stop codon within the protein coding region. 
In all, these large studies have revealed the striking patterns seen across cancer, with unexpected cancers 
sharing similar genetic alterations and signatures, as well as the dominance of mutational “hills” across 
the landscape of cancer.  
Genetic Heterogeneity of Tumors Can Drive Tumor Progression and Can Have Major Clinical 
Implications in Therapeutic and Survival Outcomes 
One of the more surprising aspects to come out of the genome sequencing era, concerning 
cancer, is the degree of heterogeneity that exists in cancer. Four types of heterogeneity have been 
reported: intertumoral, intratumoral, intermetastatic, and intrametastatic
1
. Intertumoral heterogeneity 
describes the heterogeneity that exists among patients
1. Most alterations within an individual’s tumor are 
distinct from alterations occurring within other individuals of the same cancer
53
. Those few mutations 
that are typically shared amongst patients tend to be in the significantly mutated genes that are classified 
as “mountains” within cancer. Intratumoral heterogeneity is defined as the heterogeneity that occurs 
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within an individual’s primary tumor1. Intratumor heterogeneity can exist in both a spatial and temporal 
manner and can develop as a result of newly acquired mutations that occur as the tumor progresses, with 
distinct and private mutations occurring in small subpopulations termed subclones. These subclones can 
be intermingled with each other or reside in distinct regions of the tumor
51
. Evidence for intratumor  
heterogeneity has been established in multiple tumor types including renal cell carcinoma, glioblastoma, 
and breast and pancreatic cancer
51, 58
. It has been noted that by the time of diagnosis, the vast majority of 
tumors consist of multiple different clones
59
. The degree of heterogeneity amongst these subclones can 
be rather extensive. A seminal paper by Gerlinger et al. found that only 34% of mutations within renal 
cell carcinoma patients were present throughout the entire tumor
58
. Further, Kandoth and colleagues 
determined that 35% of breast cancers and 44% of endometrial cancers contain the presence of 
subclones, though this is most likely an underestimate as only coding mutations were used in this 
particular study
55
. Moreover, there are times in which the intratumor heterogeneity is so profound that a 
single regional biopsy of tumor may be more similar to another patient than to biopsies of other regions 
within the same tumor
51
. The predominance of a particular individual subclone is dependent on 
principals similar to those found in evolutionary ecology, with the subclone exhibiting the greatest 
fitness establishing dominancy
60
. In respect to tumors, these principals establish that the dominant 
subclone will have acquired substantial phenotypic advantage compared to its surrounding subclones 
within a specific temporal and environmental context, and thus have outgrown the other tumor 
subpopulations
51
. The degree of heterogeneity as well as which individual subclone is predominant at a 
particular time, changes throughout the course of the disease
51
. Multiple theories have been proposed to 
account for the maintenance of intratumor heterogeneity throughout tumor progression. One theory 
suggests that each particular subclone exists due to its particular fitness within a given spatial niche in 
the tumor, whereby physical separation boundaries such as vasculature or  radial distance across the 
tumor can serve to induce its own version of  “allosteric speciation”51. Another theory has suggested that 
cancer stem cells can propagate heterogeneity as extensive heterogeneity has been reported in purported 
cancer stem cell populations
29
. Intratumor heterogeneity has been suggested to provide the seeds which 
may drive intermetastatic heterogeneity.  
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Metastatic lesions can exhibit heterogeneity in regards to the primary tumor, to other 
metastatic lesions within the same patient, as well as heterogeneity within the individual metastatic 
lesion
1
. Many times the primary and metastatic lesions show, to some degree, genetic similarities with 
additional mutations developing in the metastasis as well as enrichment of variant allele frequencies of 
shared mutations within the metastasis compared to the primary tumor. For example, ESR1 mutations, 
which can promote endocrine treatment resistance, have been found to be enriched, as assayed by variant 
allele frequencies, in metastatic lesions compared to the primary tumor
61
. Further, evidence has shown 
that, in many cases, the subclone which gave rise to the metastatic lesion often existed as a small 
population within the primary
29
. Intermetastatic heterogeneity describes the heterogeneity that occurs 
between multiple metastatic lesions occurring in an individual patient.  The presence of multiple 
metastatic lesions in advanced cancer patients tends to be quite common
1
. It is highly plausible that each 
metastatic lesion is founded by different subclonal cells with very dissimilar genetic alterations. In this 
case, curing the patient by chemotherapeutic agents would be impossible
1
. Individual metastatic lesions 
can also contain heterogeneity, which is called intrametastatic heterogeneity. Intrametastatic 
heterogeneity is similar to that which occurs in the primary tumor and, as such, develops similarly as 
intratumoral heterogeneity does. This is because the metastatic lesion is also under evolutionary pressure 
in its new environmental contexts. The acquired mutations which transpire after the seeding of the 
metastasis provide for the development of drug resistance
1
. The large degree to which heterogeneity 
exists across cancers, across patients, and within individual tumors have been found to play a large part 
in tumor progression, in adverse outcomes, as well as in treatment resistance in patients
62
. Subclonal 
mutations within genes, such as p53 mutations, have been found to be able to predict adverse clinical 
outcome in chronic lymphocytic leukemia and myelodysplastic syndromes
63-65
. Maley and colleagues 
found that the number of clones harbored within premalignant Barret’s esophagus lesions were able to 
predict relative risk to progression to esophageal adenocarcinoma
66
. Moreover, analysis completed 
retrospectively found progression of Ductal Carcinoma In Situ of the breast to invasive ductal carcinoma 
was associated with the presence of subclones harboring specific alterations, such as amplification of 
MYC, CCND1, and FGFR1
67
. Further, intratumor heterogeneity has been identified as one of the key 
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factors in primary drug resistance and relapse
67
. The degree of complexity as well as the presence of rare 
drug resistant mutations existing within the subclonal fractions of the tumor has been associated with the 
duration of treatment response and cancer progression
59, 60, 62
. Ding and colleagues showed that the 
majority of relapse tumors of acute myeloid leukemia (AML) resulted from the selection of a minor 
subclone harbored within the primary tumor
68
. Current clinical therapies have been found to often be a 
major driver in the clonal selection of subclones which harbor drug resistant mutations
60
. Further, it has 
been suggested that subclones with drug resistant mutations may not always drive clonal outgrowth of 
the particular subclone harboring the mutation but rather may act via paracrine signaling to promote the 
resistance of the bulk tumor to the treatment
59
. Better assessment and understanding of the nature of 
these subclones as well as their relationship to clinical outcomes and treatment will be able to help in the 
future to possibly circumvent drug resistance
59
. 
In accordance with alterations modulating tumor progression, a better understanding of the 
mutational landscape of cancer via cancer genome sequencing has been found to have major clinical 
implications by their ability to identify recurrent genetic alterations which can serve as prognostic or 
predictive biomarkers, or as therapeutic targets themselves
69
. One examples is the development of 
Herceptin, a monoclonal antibody against the HER2 receptor that is relatively quite effective in patients 
experiencing the recurrent chromosomal amplification of the HER2 locus in breast cancer, especially in 
combination with radiation
70
. Early results of targeted sequencing trials have revealed that an estimated 
40-60% of tumors contain at least one genetic alteration which may influence treatment decision 
making
56
. However, most targeted therapies against select genetic alterations have had varied response 
rates or tumors have shown a resurgence after initial successful response. This has led to multiple studies 
focusing on the discovery of mutations which have the ability to alter or predict sensitivity to particular 
targeted therapies
71
. Moreover, selective pressures like therapeutic treatments, as previously discussed, 
can cause tumors to acquire or select for mutations during the course of the treatment which can promote 
resistance to the targeted therapies and recurrence of the disease
70
. To this end, multiple sequencing 
efforts have begun to define the extensive nature of intra-tumor heterogeneity, as previously discussed, 
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which can have major implications for “precision” techniques focusing on targeted therapies, as the 
presence of sub-clones can moderate the degree of therapeutic efficacy or potentially can confer drug 
resistance and tumor relapse
56, 58
. It is of upmost importance for us to understand the acquisition of 
genetic alterations across various cancers, and at all tumor stages, to help with stratification of patients 
for prognosis and therapy, for the creation of new targeted therapies, and to create new strategies to treat 
and prevent tumor resurgence.  
The Proteasome Pathway is Integral to the Maintenance of Cellular Homeostasis 
Cellular homeostasis requires strict regulation of intracellular regulatory molecules, as altered 
protein levels of these molecules are common in pathological conditions. The ubiquitin-mediated 
proteolytic pathway is one mechanism of strict control of cellular short-lived regulatory molecules and is 
important to many cellular functions critical to normal cell physiology, including DNA repair, protein 
quality regulation, cell morphogenesis, signaling pathway modulation, and cell cycle control
72
. Central to 
the mechanism of this proteolytic pathway is the target molecule specificity that is mediated by E3 
ubiquitin ligases. The E3 ligases facilitate substrate specificity by binding to the molecule targeted for 
destruction with consequent complex formation with an ubiquitin bound E2 ligase, leading to the 
subsequent ubiquitination and degradation of the target molecule. There are three types of E3 ubiquitin 
ligases: RING, HECT, and RBR domain ligases 
73
. Of these three classes, the RING family is the most 
abundant type of E3 and is unique due to its ability of directly catalyze the transfer of ubiquitin from the 
E2 to the substrate
73, 74
. The other members require a two-step reaction, whereby the ubiquitin is 
transferred from the E2 to the HECT/RBR domain E3 ligase and then subsequently onto the targeted 
molecule
73
. Ubiquitination typically occurs on the canonical lysine (Lys-48) residue of the target 
molecule, leading to proteosomal degradation. However, non-canonical ubiquitination on the Lys-63 
residue can also occur which can be important in responses to stress, DNA repair, membrane trafficking, 
kinase activation, correct ribosomal functioning, and chromatin dynamics
72,75
.  
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The structures of these E3 ligases can exhibit great variance between the many different types 
of E3s, even within the same E3 class, and these multiple supplementary domains that exist in addition to 
the RING domain can help to recruit the target substrate protein. Moreover, E3 ligases can form 
homodimers or heterodimers, thus increasing the diversity of substrates that can be targeted by changing 
their associated binding partners
72
. One prominent family of RING E3 ligases, the TRIM family, is 
characterized by the addition of one or two B-box domains, a coiled coil domain, and alternative C-
terminal domains which are important for their diverse substrate binding specificity and the ability of 
TRIM proteins to either homodimerize or heterodimerize to other TRIM family proteins. More than 70 
TRIM proteins are now known to exist in humans and mice and are implicated in many diverse 
biological processes, including innate immunity, transcriptional regulation, cell death, and 
development
72
. Alteration of these TRIM family members, at the genetic, mRNA, or protein level, can 
lead to various pathological conditions; for example, developmental disorders, modified viral virulence, 
neurodegenerative diseases, and cancer can develop from modulation of these genes
72
.  
The Role of the TRIM Family Proteins as Tumor Suppressors in Cancer 
The role of the TRIM family in cancer has been shown to be complex, with their involvement 
being highly context dependent. Most of the activities currently described for the TRIM family genes are 
oncogenic. Functions for these TRIM family genes include, but are not limited to, mediating enhanced 
androgen receptor transcriptional activity (TRIM24), regulation of chromatin modification (TRIM24, 
TRIM28, PML-RARα fusion, and TRIM33), enhancing cell proliferation (TRIM25), promotion of p53 
degradation (TRIM24 and TRIM28) and cellular transformation (TRIM24-FGFR1 fusion)
72
. Despite the 
relatively reduced degree to which the tumor suppressive activities of this family have been described 
compared to their oncogenic counterparts, their activities in suppressing tumorigenesis are nonetheless 
just as highly potent. Many of the same cellular functions that TRIM proteins have been shown to use to 
promote tumorigenic potential, like regulation of proliferation, immune response, and migration, have 
also been reported as areas in which other TRIM proteins play large roles in suppressing in order to 
prevent tumorigenesis. Notable TRIM family members associated with tumor suppressive activities 
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include PML (TRIM19) and TRIM24. PML acts as a tumor suppressor through its recruitment of large 
protein complexes to form PML nuclear bodies, which are known to play critical roles in DNA repair, 
transcription, apoptosis, and stem cell self-renewal
76
. Loss of PML expression is found in multiple tumor 
types including central nervous system tumors, colorectal cancer, lung tumors, prostate adenocarcinoma, 
breast cancer, germ cell tumors, and non-Hodgkin’s Lymphoma77.  Its fellow TRIM family member, 
TRIM24, has also been described to have tumor suppressive functions. However, in contrast to PML, 
TRIM24’s tumor suppressive role is highly tissue-type dependent. TRIM24 has been well characterized 
as a tumor suppressor in hepatocellular carcinoma (HCC), with the formation of spontaneous liver 
tumors in Trim24 null mice
78
. TRIM family members play large roles in suppressing tumorigenesis, in 
manners both independent and dependent of their E3 ubiquitin ligase activity, through their integral 
activities in the maintenance of genomic integrity, cell cycle control, immune modulation, inhibition of 
migration, and promotion of differentiation and apoptosis
72, 79
. 
The TRIM Family Play Central Roles in Cell Cycle Regulation and Maintenance of Genomic Integrity 
Maintenance of genomic integrity and cell cycle control is integral to the inhibition of 
tumorigenesis. Loss of a cell’s ability to sustain correct control of the cell cycle during replicative 
checkpoints as well as preserving critical pathways important for DNA repair are not only themselves 
hallmarks of cancer, but also can enable the acquisition of other hallmarks of cancer vital to the 
formation and progression of tumors
52
. One TRIM family protein integral to genomic integrity is also 
one of the most notable tumor suppressors of this family. PML (TRIM19) is vital for genomic integrity 
through its promotion of subnuclear structures called PML nuclear bodies (PML-NBs). Within these 
PML-NBs, PML has been found to sequester more than 100 proteins, including transcription cofactors 
and chromatin modifiers like DAXX and SP100
76
. It is thought that these PML-NBs are critical for DNA 
repair as the foci of the damaged DNA marker, γH2AX, have been found to co-localize with the nuclear 
bodies
80
. Moreover, gamma irradiation has also been shown to increase the number of PML-NBs
81
.  It is 
thought that its role in DNA damage through these PML-NBs is very important for its tumor suppressive 
activity as evidenced by the absence of PML-NBs in  solid tumor cells
72
. Further, the dowregulation of 
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PML has also associated with tumor progression
72
. Besides genomic integrity, PML also plays important 
roles in stem cell self-renewal capacity, inhibition of AKT signaling, and in innate viral 
immunity
72,82
.However, as stated previously, the roles of the TRIM family proteins are complex in 
cancer and in accordance with this, PML has been found to undergo translocation ( t(15;17) ) to the 
retinoic acid receptor alpha (RARα) to form a fusion protein that is thought to have a dominant negative 
effect on multiple proteins, including PML, RARα, and RXR. The PML-RARα fusion impedes correct 
localization of PML and inhibits promyelocytic maturation 
83
. In leukemia, PML has been shown to be 
important in the maintenance of leukemic stem cells and as such, Chronic Myeloid Leukemia (CML) 
patients who exhibited lower PML expression showed higher rates of complete response than patients 
with high PML expression
84
. Further, PML has been shown to be overexpressed in basal and triple 
negative breast cancer and this overexpression in breast cancer was shown to be correlated with mutant 
p53 status, reduced disease free survival, and poor prognosis
85,86
.  
Another manner in which TRIM members can suppress tumorigenesis is through their direct 
interaction with cell cycle regulators to inhbit cell proliferation. For example, Trim3 suppresses tumor 
growth via sequestration of p21 from cyclin-D1/cdk-4, thus reducing cell proliferation
87,88
. Heterozygous 
loss of chromosomal locus 11p15.5, encompassing TRIM3, is observed in about 24% of gliomas
87,89
. 
TRIM3 has also been reported to be homozygously deleted in gliomas and Glioblastoma Multiforme 
(GBM) 
87,89
. Mice harboring intracranial Trim3 expressing GBM cells showed significantly longer 
survival than mice injected with GBM cells lacking Trim3
90
. Trim3 can suppress Pdgf-induced GBM 
development in mice
87
. Besides regulating proliferation, overexpression of TRIM3 has also been found 
to reduce anchorage independent colony formation
90
. Further, expression of TRIM3 can induce 
differentiation by its promotion of asymmetrical stem cell division via suppression of the Musashi-
Numb-Notch signaling axis
90
. TRIM3 is significantly downregulated in hepatocellular carcinomas 
(HCC) and GBM
90,91
. Low expression of TRIM3 has been clinically associated with tumor size, 
histological grade, and TNM stage
91
. Moreover, TRIM3 is an independent prognostic factor for overall 
survival
91
.   
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Another TRIM protein able to directly interact with cell cycle regulators is TRIM8. TRIM8 
participates in a feed forward loop with p53, in which p53 induction of TRIM8 can potentiate p53 
expression through TRIM8-mediated stabilization, activating the growth arrest arm of the pathway 
only
92
. Moreover, TRIM8 has been shown to be important in p53-mediated anti-proliferative action after 
Nutlin or Cisplatin treatment.  TRIM8 is downregulated in clear cell Renal Cell Carcinoma (ccRCC) and 
its low expression correlates with larynx squamous cell carcinoma nodal metastasis and is a verified 
growth suppressor in this tissue
93,94
.  
Regulation of Apoptosis by TRIM Family Members Can Promote Tumor Suppression 
Cellular homeostasis requires a balance between proliferation and cell death. Inability to 
properly control these two functions are known hallmarks of cancer
52. The TRIM family’s role in 
regulating proliferation and genomic integrity has already been described. However, their roles in the 
promotion of programmed cell death are just as important. TRIM proteins’ regulation of major survival 
pathways can play a critical role in their ability to regulate apoptosis. For example, TRIM31 is known to 
negatively regulates c-Src’s promotion of anchorage-independent survival via its binding to p52
shc95
. 
TRIM31 has been found to reduce clonogenicity of the colon cancer cell line, HCT-116
96
. Further, 
TRIM31 can inhibit proliferation and invasion of lung cancer cells and is associated with advanced TNM 
((T)umor  N(Lymph Node) (M)etastasis Classification of Malignant Tumors) stage as well as positive 
lymph node status in Non-Small Cell Lung Cancer
97
.  Another TRIM protein, TRIM13 (RFP2), can act 
as an E3 ubiquitin ligase for pro-survival genes MDM2 and AKT
98
. TRIM13’s proteosomal regulation of 
MDM2 stabilizes p53, activating the growth arrest/cell death arm of the pathway
99
. Its negative 
regulation of MDM2 and AKT can help to augment apoptosis rates following ionizing radiation
98
. 
TRIM13 has been shown to reduce clonogenicity levels through its negative regulation of NFκB’s pro-
survival arm
100
. TRIM proteins, like TRIM13, have been shown to regulate not only vital survival 
pathways often implicated in cancer but also the factors directly associated with the apoptotic pathway. 
For example, TRIM13 is a potent inducer of cell death upon endoplasmic reticulum stress through its 
transport of direct apoptosis activator, casapase-8, to the autophagolysosomes, leading to its activation 
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and subsequent initiation of the pro-cell death caspase cascade
101
. Its regulation of autophagic cell death 
has been shown to reduce clonogenicity of breast cancer cell line MCF7
102
. In accordance with its 
promotion of apoptosis, TRIM13 is downregulated and deleted in B-cell chronic lymphocytic 
leukemia
103
.  
TRIM17 (TERF) is another family member known to regulate direct cell death factors. 
TRIM17 is necessary for the induction of the mitochondrial associated intrinsic cell death pathway in 
cerebellar granule neurons (CGN)
104
. It regulates neural apoptosis through its ubquitination and 
subsequent degradation of major anti-apoptotic pathway member, Myeloid Cell Leukemia-1 (Mcl-1)
105
. 
TRIM17 can also promote apoptosis in CGN cells through its participation in a feed-forward loop with 
NFATc3, via its sumoylation activity
106
. Moreover, TRIM17 can negatively regulate breast cancer cell 
proliferation through its regulation of the mitotic spindle checkpoint, via its promotion of the degradation 
of the kinetochore complex member, ZWINT
107
. Lending to its tumor suppressive activities, focal 
deletion of TRIM17 has also been found in bladder and kidney cancer cell lines
108
.  
Other TRIM proteins shown to be important in the regulation of apoptosis factors include 
TRIM32 and TRIM39. TRIM32 has been shown to sensitize cells to TNF-α induced apoptosis via its E3 
activity against anti-apoptotic factor, X-linked Inhibitor of Apoptosis Protein (XIAP)
109
. Alternatively, 
TRIM proteins can also stabilize apoptosis promoter genes as exemplified by TRIM39’s ability to 
stabilize Modulator of Apoptosis-1 (MOAP-1) via competitive binding with MOAP-1’s inhibitor, 
APC/C
Cdh-1 110. TRIM39’s facilitation of increased levels of MOAP-1 enhances etoposide-induced, BAX 
mediated apoptosis. The TRIM family’s pro-apoptotic regulation has been shown to be important in 
maintaining homeostatic levels of cellular growth and in doing so, play a vital role in the prevention of 
tumorigenesis.  
TRIM Proteins’ Modulate Pro-Tumorigenic Inflammatory Response Driven by NFκB  
Long standing evidence has already implicated the importance of TRIM proteins in the 
immune system and in viral response
111
. Recent evidence suggests that TRIM family proteins can 
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regulate the immune system via regulation of Nuclear Factor κ- B (NFKB) signaling, in roles that both 
stimulate and suppress this integral pathway. NFKB is an important immune modulator as well as a 
regulator of both proliferation and apoptosis through its effects on apoptotic factors, adhesion molecules, 
and cytokines
79,112
. Negative regulation of this pathway by TRIM family proteins has been noted to occur 
in both the cytoplasm and in the nucleus through the regulation of upstream cytoplasmic pathway 
members and direct interaction with nuclear NFKB. Two examples of TRIM family members that 
regulate the NFKB pathway via proteosomal degradation are TRIM13 and TRIM45. TRIM13’s poly-
ubquitination of NEMO, a member of the IKK complex that regulates NFKB’s release to the nucleus, 
can induce proteosomal degradation of NEMO, suppressing NFKB pathway activation
100
. TRIM45 has 
also been found to suppress TNF induced NFKB mediated proliferation via its RING domain
113
. Inability 
to restrain the activation of the NFKB pathway in tumor associated immune cells within the tumor 
microenvironment can lead to paracrine activation of proliferation and anti-apoptotic pathways in nearby 
tumor cells, thereby promoting tumorigenesis
112
.  
Besides regulation of the NFKB pathway by the TRIM family proteins through ubiquitin 
mediated proteosomal degradation, ubquitination of activating NFKB pathway members can also lead to 
their degradation in manners independent of the proteasome. For example, mono-ubquitination of critical 
pathway activator IKKβ by TRIM21 is know to induce autophagy mediated degradation114. Further, 
TRIM30a mediates endocytic lysosomal degradation of the TAB2-TAB3-TAK1 complex which 
suppresses Toll-like Receptor (TLR) induced NFKB activation 
115
. Regulation of the localization of 
NFKB is also a major mechanism of fine-tuning pathway activation as NFKB subunits p65 and p50 
require nuclear localization in order to enact their transcriptional regulation. PML suppresses NFKB 
mediated transcription by sequestering of NFKB in PML nuclear bodies
116
. Moreover, TRIM9 has been 
shown to stabilize IκBα through its competitive binding for the NFKB inhibitor with β-TrCP E3 ligase, 
thereby effectively restricting NFKB to the cytoplasm and inhibiting inflammatory cytokine 
production
117
. TRIM40 is also important in IκBα stabilization, however TRIM40 maintains the pathway 
inhibitor’s protein expression through its post-translational neddylation activity 118. Moreover, an inverse 
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correlation between TRIM40 and NFKB expression has been found in gastric tumors and their associated 
inflammation sites
118
. By playing large roles in the suppression of the NFKB pathway, TRIM family 
proteins restrict pro-tumorigenic inflammatory signals from stimulating important pro-survival and 
proliferative pathways. 
TRIM Proteins’ Regulation of Differentiation and Migration are Integral to Tumor Suppression  
Two important factors associated with increased tumor aggressiveness are the loss of 
differentiation and the gain of enhanced migratory capacity. Through multiple mechanisms, many TRIM 
family proteins are important for regulating differentiation and migration, which is vital to preventing 
tumor progression. TRIM24 (Tif1α) has been shown to promote differentiation by its interaction with 
RARα in a ligand dependent manner, leading to constrained RARα associated transcription and 
subsequent tumor suppression in hepatocellular carcinoma
72,119
. Trim24-knockout in mice can induce 
formation and stepwise progression of pre-neoplastic lesions (clear-cell foci of altered hepatocytes or 
FCA) to hepatocellular adenomas and carcinomas within one year at high incidence rates
78, 120
. 
Additionally, double mutation of Trim24 and its known major binding partner, Trim33 (Tif1γ), can 
synergize to potently enhance HCC formation in mice more than either single mutant alone
78
. Besides its 
regulation of differentiation, molecular analysis has shown that ectopic expression of TRIM24 can stall 
cells in the G0/G1 phase of the cell cycle, effectively reducing cell growth, as well as inhibiting 
anchorage-independent colony formation
119
. Moreover, human hepatic cellular carcinoma (HCC) have 
been found to exhibit chromosomal loss of the 7q32 locus harboring TRIM24
72
.  
Besides its synergism with TRIM24, TRIM family protein TRIM33, also known as 
Transcriptional Intermediary Factor 1γ (TIF-1 γ), has shown in its own right to have tumor suppressive 
abilities through the regulation of differentiation factors. TRIM33 is important for normal hematopoiesis 
via its regulation of hematopoietic progenitor differentiation in response to TGFβ and in its interaction 
with SMAD4
121
. Targeted deletion of Trim33 in mice hematopoietic tissue alters the hematopoietic 
differentiation cascade by selectively expanding the granulo-monocytic progenitors, leading to 
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progressive hyperleukocytosis and severe hepatosplenomegaly in knock-out mice after or by 6 months of 
age
122
. In human Chronic Myelo Monocyticleukemia (CMML) and pancreatic ductal adenocarcinoma, 
both TRIM33 mRNA and protein levels were found to be significantly decreased
122,123
. Moreover, 
conditional knockout of Trim33 in the pancreas was found to cooperate with mutant Kras to induce 
pancreatic cystic tumors at 100% incident rate
123
.  
Increased migratory and invasive capacities are vital steps in the Epithelial-Mesenchymal 
Transition (EMT), which can promote metastasis to distant sites. Loss of some of the TRIM family 
members are known to singularly effect migration (TRIM15 and TRIM16) whereas others are known to 
be involved in multiple steps of EMT (DEAR1 and TRIM29). Cellular movements are coordinated 
through actin dynamics and the regulation of the turnover of these related proteins are important to the 
control of migration of cells. In accordance with this, TRIM15 has been shown to be able to regulate 
migration through its interacts with adaptors or scaffold proteins involved in actin dynamics
124
. Notably, 
TRIM15 has been found to prevent the phosphorylation and subsequent activation of CTTN, a regulator 
of actin polymerization that has been shown to be important for cellular migration. TRIM15 is 
downregulated in colorectal and gastric cancer
124,125
. Its expression in colon cancer cell lines decreases 
clonogenicity and tumor burden in mice inoculated with colon cancer cell lines expressing TRIM15, 
compared to tumors formed by the same cell lines lacking TRIM15 expression 
124
. Another TRIM 
protein, TRIM16, can act to suppress tumorigenesis by regulating not only by migration but 
differentiation activities as well. TRIM16 has been shown to both bind and modulate the expression of 
EMT marker vimentin in neuroblastoma, squamous cell carcinoma, and lung cancer, thereby leading to 
reduced migration capabilities 
126,127
. TRIM16 has also been found to effect migration, along with 
proliferation rates, through Interferon Beta 1(IFNβ1) in melanoma128. Consequently, its expression is 
downregulated during the transition from normal skin to squamous cell carcinoma
126
. TRIM16 has also 
been found to be differentially expressed in neuroblastoma, in concordance with the degree of 
histological differentiation, i.e. higher expression correlated to more differentiated regions
127
. In 
accordance, TRIM16 has been found to be able to induce differentiation within neuroblastoma and 
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keratinocyte cells
127,129
. Moreover, TRIM16 was found to have reduced expression in melanoma cell 
lines and was correlated with lymph node metastasis and poor prognosis
128
. In melanoma, TRIM16 was 
also able to serve as one mechanism for BRAF inhibitor Vemurafenib’s induced growth arrest and 
subsequently, could act as a predictive marker for this clinical inhibitor
128
.  Besides migration and 
proliferation, TRIM16 also suppress proliferation through its regulation of cell cycle progression and in 
accordance, was shown to be able to reduce tumor growth in vivo
126,127
 
130
. 
Two TRIM proteins, DEAR1 (Ductal Epithelium Associated RING Chromosome 1) and 
TRIM29, have been identified uniquely as regulators of both early and late steps of EMT, with the loss 
of these two genes being associated with aberrant polarity as well as increased migration and invasion 
capacity.  Knockdown of DEAR1 in Human Mammary Epithelial Cells (HMECs) in 3D culture results in 
mislocalization of polarity marker alpha-6-integrin and diffuse cell death leading to luminal filling of the 
breast acini, a hallmark of early breast cancer, Ductal Carcinoma in Situ
131
. Moreover, DEAR1 is a 
dominant regulator of TGFβ driven EMT through its activity as an E3 ubiquitin ligase for downstream 
TGFβ effector SMAD32. Loss of DEAR1 in the presence of TGFβ drives cellular migration and invasion 
in human mammary cells
2
. A more detailed discussion of DEAR1’s tumor suppressive activities are 
further described in the next section. Like DEAR1, TRIM29 (ATDC) also regulates both migration and 
invasion; however, its regulation of EMT is through its participation in a negative feedback loop 
regulating the prominent EMT promoter, TWIST1
132, 133
. Further, knockdown of TRIM29 identified this 
TRIM family member as a dominant regulator of acinar morphogenesis through its potent regulation of 
polarity and proliferation via inhibition of the Estrogen Receptor (ER) and Mitogen Activated Protein 
Kinase (MAPK) pathways
132
. TRIM29 is significantly downregulated in prostate and breast cancer and 
its lower expression levels are associated with larger breast tumors as well as lymph node spread
133,134,135
. 
Additionally, in early stage ER+ breast cancer without adjuvant therapy, TRIM29 expression was able to 
predict longer relapse free survival in women younger than 55
132
.  
Tumor Suppressor and TRIM Family Protein DEAR1 (TRIM62) is a Vital Regulator of Polarity and 
EMT, Whose Loss is Correlated with Important Clinical Parameters  
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As previously discussed, DEAR1 (TRIM62) is a TRIM protein that has been shown to be 
important in regulating both early and late steps of EMT, an integral process in tumor progression and 
metastasis. DEAR1 and TRIM29, despite being structurally different, are currently the only TRIM 
family proteins known to regulate EMT processes of polarity deregulation and migration/invasion, albeit 
through different mechanisms (see previous section for detailed discussion of TRIM29’s regulation of 
EMT). Knockdown of DEAR1 within Human Mammary Epithelial Cells (HMECs) in 3D culture 
resulted in loss of apical-basal polarity as well as diffuse and decreased cell death activity, leading to 
luminal filling of the acini
131
. Luminal filling within the breast ducts have been noted as a hallmark of 
Ductal Carcinoma in Situ (DCIS), one of the earliest forms of breast cancer
136
. Moreover, the importance 
of DEAR1’s regulation of acinar morphogenesis was shown by the reversion of the aberrant acinar 
morphology of metastatic breast cancer cell line 21MT to a smaller, more normal like morphology. 
Wildtype DEAR1 expression was shown to be able to restore apical-basal polarity and luminal cell death 
after genetic complementation of an inherent single nucleotide missense mutation in DEAR1 at codon 
187 
131
. DEAR1 has also been reported as an E3 ubiquitin ligase for downstream TGFβ effector, 
SMAD3
2
.  Knockdown of DEAR1 has been found not only to allow higher total and phosphorylated 
SMAD3 expression levels but higher nuclear expression of activated SMAD3 as well. Further, TGFβ-
SMAD3 dependent signaling was shown to be potentiated with DEAR1 loss of expression, including 
increased expression of downstream target genes and EMT effectors SNAIL1 and SNAIL2
2
. In HMECs 
and the normal mammary cell line MCF10A, the loss of DEAR1 in the presence of TGFβ prevented 
acini formation in 3D culture, upregulation of EMT markers, promotion of anoikis resistance, and drove 
migration and invasion of the cell lines
2
. DEAR1, however, is not the only TRIM family member known 
to be an E3 ligase for the TGFβ pathway. TRIM33 is also known to bind to TGFβ pathway members 
SMAD2/3 and SMAD4
137
. TRIM33’s binding to SMAD2/3 and SMAD4, unlike DEAR1’s binding to 
SMAD3, does not lead to degradation. TRIM33 acts in a dual manner in its interaction with SMAD 
proteins through its inhibitory mono-ubquitination of SMAD4 and its co-transduction of TGFβ signaling 
by complex formation with SMAD2/3
137
. These interactions have been found to be important in the 
differentiation axis of the TGFβ pathway, with no effect on TGFβ’s regulation of proliferation137. Like 
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TRIM33, DEAR1 does not effect the proliferation arm of the TGFβ pathway but rather is known only to 
modulate TGFβ induced migration and invasion131. Further, Dear1 loss can also synergize with mutant 
Kras to drive lung cancer cell migration and invasion through enhanced promotion of EMT, increasing 
metastatic potential in mice
138
. Previously reported results, as discussed here, have indicated that DEAR1 
is a dominant regulator of acinar morphogenesis and potent inhibitor of TGFβ-induced EMT, which are 
cellular functions that can be important in suppression of tumor progression. 
Loss of heterozygosity (LOH) has been found to be common amongst the TRIM family 
members who exhibit tumor suppressive activities and is a common mechanism of tumor suppressor 
inactivation 
2, 89, 103, 131, 139-141
. DEAR1 is localized to chromosome 1p35.1, a region which often undergoes 
chromosomal deletion in multiple epithelial cancers, including breast, lung, and colon cancer
142, 143
. As 
such, DEAR1 has been shown to be frequently heterozygously deleted as well as rarely homozygously 
deleted in many cancer types, including brain, breast, colorectal, lung, and endometrial carcinoma
2, 131
. 
Loss of Dear1 in mice resulted in late onset formation of multiple epithelial cancers comprising, but not 
limited, to lymphomas, sarcomas, lung adenocarcinomas, gastrointestinal carcinomas and breast 
adenocarcinoma
2
. Further, a few primary tumors were found to be associated with metastatic lesions. 
Dear1
-/-
 and Dear1
-/+
 mice formed tumors at similar rates, with evidence for Dear1 acting as a 
haploinsufficient tumor suppressor in lymphomas and a classical tumor suppressor, i.e. requiring two hits 
for inactivation, in epithelial tissues. The spectrum of human tumor types undergoing LOH at the DEAR1 
locus was able to be recapitulated by heterozygous and homozygous loss of Dear1 in a mouse model
2
.  
Moreover, DEAR1 undergoes rare mutation in multiple cancers in a spectrum similar to those tumor 
types which experienced LOH, including lung squamous, endometrial, colorectal, and breast cancer
2,131
. 
Currently, the highest frequency of mutation within DEAR1 is 13% (n=55) in invasive breast cancer, as 
identified by our lab
131
. Invasive breast cancer sequencing efforts by TCGA only report 1 mutation 
(frameshift) in 962 cases; however, sequencing coverage achieved by TCGA is typically low with a 
median of 20x coverage which has low sensitivity to find rare subclonal variants
144-146
. For example, 
TCGA failed to identify ESR1 mutations in invasive breast cancer, yet multiple investigators later 
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reported finding common mutation of the gene
147
.Pancreatic, stomach and colorectal cancer experience 
the next highest frequencies of mutation in DEAR1 at 3.6% (n=55), 1.8-3.3% (n=30,220,287), and 1.4-
1.9% (n=72,212,220) respectively
2, 145, 146
. Most of the mutations previously identified in DEAR1 are 
missense mutations; however, a small number of frameshift and nonsense mutations have been reported 
as well
2, 145, 146
. The DEAR1 missense mutation R187W that was identified within both an invasive breast 
cancer patient and in the metastatic breast cancer cell line 21MT, to our knowledge, represents the first 
identified loss of function missense mutation in TRIM family members in cancer, as confirmed by 
molecular analysis
131
. Many TRIM family genes have been found to be mutated in cancer, including the 
instances of nonsense and frameshift mutations, as shown by mutation catalogues COSMIC and cBIO; 
however, no TRIM family member, except for DEAR1, has been described by literature to have loss of 
function missense mutations in cancer 
145, 146, 148
. However, previously reported TRIM family loss of 
function missense mutations are associated with multiple developmental disorders including Limb girdle 
muscular dystrophy type 2I (TRIM32) and X-linked Opitz G/BBB syndrome (MID1)
149, 150
.   
Besides alteration at the genetic level, DEAR1 also is downregulated at the protein level. 
DEAR1 exhibits reduced expression in multiple epithelial cancers, including pancreatic cancer, acute 
myeloid leukemia (AML), lung cancer and breast carcinoma
2, 138, 151,131
. In pancreatic cancer, 62% of 
tumors showed downregulation of DEAR1, as assayed by immunohistochemistry
2
. In AML patients, 
DEAR1 showed reduced expression levels when compared to CD34+ cells from healthy controls
151
. 
DEAR1 was also found to show complete loss of expression in 64-87% of Non-Small Cell Lung Cancer 
(NSCLC), with a stepwise decrease in expression associated with progression of the disease from normal 
bronchial epithelium to NSCLC
138
. Similarly, in the transition from normal breast ductal epithelium to 
one of the earliest forms of breast cancer, DCIS, DEAR1was shown to be downregulated in 56% of early 
onset breast cancer lesions (ages 25-49 years) in premenopausal women
131
. Further, the frequent loss of 
expression of DEAR1 has been shown to be clinically important. DEAR1 has been reported as an 
independent marker of adverse prognosis in AML with low expression of DEAR1 associated with 
shorter complete remission and reduced overall survival
151
. Further, in early stage NSCLC, DEAR1 loss 
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of expression correlated with significantly shorter time to relapse
138
. DEAR1 also correlated with triple 
negative breast cancers with a strong family history and poor prognosis
131
. Moreover, DEAR1 was 
associated with reduced local recurrence free survival as well in early onset breast cancer
131
.  
Multiple classes of tumor suppressors have been proposed throughout the years which regulate 
different classes of cellular pathways critical to maintaining homeostasis, as previously discussed. One 
novel class of tumor suppressors that was proposed by Petersen and colleagues were described for their 
unique abilities to sense the microenvironment and thus regulate the organization of tissues in an 
appropriate manner
152
. Alterations leading to loss of function of these tumor suppressors would cause 
deregulation of spatial recognition through impeding proper cellular signaling and loss of spatially 
restricted localization of adhesion and polarity pathway members. Loss of polarity and weakening of 
cellular adhesion are early steps in EMT, and as such, tumor suppressors who sense the 
microenvironment and in accordance, regulate epithelial plasticity through correct spatial control would 
be important in suppressing tumor progression through EMT
153
. Examples of this type of tumor 
suppressor include p53, which has been reported to have gain of function mutations that can disrupt 
polarity, acinar morphogenesis and EMT, as well as polarity regulators LKB1 and SCRIBBLE which are 
noted to be downregulated in breast cancer and whose loss of function induces luminal filling, which is 
reminiscent of the luminal filling that occurs in DCIS 
154-159
. Similarly, DEAR1 has also been shown to 
be important in the regulation of acinar morphogenesis, polarity and EMT induced by extracellular 
signaling molecule, TGFβ. As such, it is plausible for DEAR1, as well as its fellow TRIM family 
member TRIM29, to be identified as the first two TRIM family proteins to fit within this novel class of 
tumor suppressors which sense factors from the microenvironment and regulate pathways involved in the 
control of cellular adhesions and polarity. Loss of DEAR1, through genetic aberrations or loss of 
expression in cancer, leading to the loss of a cell’s ability to sense the microenvironment and thus as a 
result, failure of the cell to regulate spatial control, can play a vital role in the progression of cancer and 
subsequently in determine patients’ prognosis.  
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Investigation of Genomic Alterations in DEAR1 Using Pan-Cancer Analysis and Ultra-Deep Targeted 
Sequencing in Ductal Carcinoma In Situ (DCIS) 
Given previous data supporting the importance of the loss of expression and function of 
DEAR1 in promoting tumorigenesis, the degree and potential functionality of genetic alterations within 
this gene were characterized.  I hypothesized that DEAR1 is mutated and chromosomally lost in multiple 
epithelial cancer types, consistent with a tumor spectrum associated with chromosome 1p loss, and that 
these alterations are genetic drivers in tumorigenesis. Further, it is important to specifically determine if 
DEAR1 is mutated in the earliest form of pre-invasive breast cancer, DCIS, as DEAR1 has been 
previously reported to be mutated in invasive breast cancer (IDC)
131
. Therefore, I hypothesized that 
mutations in the EMT regulator, DEAR1, not only exists but are functional and can act as genetic drivers 
in the progression from DCIS to IDC. To determine the validity of our hypothesis, the following aims 
were carried out:  
1. Characterization of DEAR1 as a 1p35 tumor suppressor 
1. Determine if DEAR1 undergoes copy number losses and mutation in cancers associated 
with chromosome 1p35 LOH.  
2. Determine if DEAR1 genetic alteration could be useful as a prognostic biomarker in 
breast cancer.  
2. Create a custom targeted Ampliseq panel for DEAR1 and characterize its analytical performance 
1. Design a DEAR1 ampliseq Panel and characterize its sequencing capacity 
2. Test DEAR1 ampliseq panel accuracy by novel spike-in assay 
3. Determine the sensitivity and specificity of DEAR1 targeted Ampliseq panel 
3. Determine if DEAR1 is mutated in DCIS and in DCIS associated with an Invasive Component 
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1. Complete ultra-deep targeted sequencing of DEAR1 on 17 Pure DCIS samples by next 
generation sequencing 
2. Microdissect 19 DCIS lesions and adjacent invasive component and complete ultra-deep 
targeted sequencing of DEAR1 on these components independently by next generation 
sequencing 
3. Analyze DEAR1 mutation spectrum in pure DCIS and compare to DCIS associated with 
Invasive components (DCIS/INV). 
4. Validate and functionally characterize variants found in DEAR1 in DCIS  
The results of the research herein, following these specific aims, describe a vast tumor 
spectrum associated with mutation or loss of the critical polarity and EMT regulator DEAR1 and how 
these alterations can act as functional drivers in tumorigenesis. The relevancy of the Dear1 knock-out 
mouse model has been validated for its ability to recapitulate the tumor types developed in humans that 
are associated with chromosome 1p loss. Heterozygous loss of DEAR1 has also shown the ability to 
synergize with amplification of EMT promoter SNAI2 to predict overall survival in IDC. Further, a 
highly sensitive, custom Ampliseq panel has been developed and used to complete ultra-deep targeted 
sequencing of DEAR1 in DCIS. Results indicated the high degree of frequency that DEAR1 is altered in 
these early lesions of breast cancer and evidence also supported a parallel yet independent model for 
tumor evolution for DCIS and IDC lesions. Future work is still needed to complete our understanding of 
the full role of DEAR1 in cancer, but our results hint at the importance of these alterations in driving 
tumorigenesis.  
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Chapter 2  
Identification of DEAR1 Alterations across Cancers Using Pan-Cancer Database Analysis 
This chapter is based upon Nanyue Chen, Seetharaman Balasenthil, Jacquelyn Reuther, Aileen Frayna, 
Ying Wang, Dawn S. Chandler, Lynne V. Abruzzo, Asif Rashid, Jaime Rodriguez, Guillermina Lozano, 
Yu Cao, Erica Lokken, Jinyun Chen, Marsha L. Frazier, Aysegul A. Sahin, Ignacio I. Wistuba, Subrata 
Sen, Steven T. Lott and Ann McNeill Killary. “DEAR1 Is a Chromosome 1p35 Tumor Suppressor and 
Master Regulator of TGF-β–Driven Epithelial–Mesenchymal Transition” Cancer Discovery 2013; 3: 
1172-1189. No permission is required for the reprinting of the article as Cancer Discovery states: 
“Authors of articles published in AACR journals are permitted to use their article or parts of their article 
in the following ways without requesting permission from the AACR. All such uses must include 
appropriate attribution to the original AACR publication. Authors may do the following as applicable: 
Submit a copy of the article to a doctoral candidate's university in support of a doctoral thesis or 
dissertation”. 
Introduction 
Tumor initiation and progression are processes dominated by the culmination of aberrant 
changes at the gene, transcript, and protein level. By understanding the aberrant landscape of the cancer 
at each of these levels, the possibilities for better assessment of cancer risk, improved earlier detection, 
and identification of new therapeutic targets are possible.  For solid tumors, elucidating a clear targetable 
pattern of genomic alterations has been difficult and only few success stories exist. Two examples of the 
relatively few targeted therapies in solid tumors that exist are Herceptin and Vemurafenib. A targeted 
therapy that has revolutionized treatment of breast cancer is Herceptin, a monoclonal antibody against 
HER-2 (ERBB2), a gene that is commonly amplified in breast cancer and marks an aggressive subtype 
of this disease. Herceptin has a 34% response rate as a single agent therapy in breast cancer patients 
experiencing HER2 amplification
160
. Moreover, Vemurafenib is a therapy that has been developed in 
recent years for metastatic melanoma as a selective mutant B-Raf inhibitor targeting cells exhibiting 
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mutations within codon 600 of the gene, with highest binding efficiency against mutant B-Raf V600E
161
. 
Vemurafenib has shown to be highly effective with greater than 50% of melanoma patients with mutant 
B-Raf responding to treatment with this targeted therapy
161
. Further, both Herceptin and Vemurafenib 
have shown the ability to synergize with other therapeutic treatments for even greater response rates
162, 
163
. The relative failure to find more targets which can be utilized for the treatment of solid tumor types is 
in part due to the complexity that exists at the genomic level in solid tumors that is unlike that which is 
found in sarcomas, leukemia, and lymphomas
33
.  Whereas sarcomas and liquid tumors have highly 
recurrent chromosomal arrangements and few mutations, solid tumors often have relatively low levels of 
recurrent chromosomal rearrangements and moderate to high frequencies of mutational alterations, with 
a mutational pattern that has been defined as “long tailed”, meaning that relatively few genes are altered 
at high frequencies in these cancer and rather the population is dominated by many genes mutated at low 
frequencies in these lesions
33,164,56
. Due to the complexity of genomic alterations observed in solid 
tumors, the relatively few recurrent chromosomal alterations and mutations which occur in these cancers 
signal important areas which may feature genes vital to tumor initiation and progression. For example, a 
fusion of the genes TMPRSS2 (21q22.3) and ERG (21q22.2) represent one of the most common 
chromosome rearrangements in human cancer and is associated with invasion in prostate cancer
165
. 
Moreover, another example includes the loss of the 1p chromosome arm, which is noted as a common 
feature of many epithelial cancers. Deletion resulting in loss of heterozygosity (LOH) has been known to 
occur at this chromosomal arm at a relatively high frequency in multiple epithelial tumor types (29-
72%), including stomach, breast, lung, kidney, and colorectal cancer, especially within regions 1p31 and 
1p34-35 which experience the highest frequency of chromosomal loss
143,142
. Moreover, LOH at the 1p 
locus has been associated with ER+ breast tumors and was linked to, in a multivariate analysis in breast 
cancer, with a 2.7 fold increase in relative risk of death 
142,166
. Often large scale deletions affecting the 
entire chromosome arm occur in cancer development and progression, suggesting a mechanism for the 
loss of multiple tumor suppressors at one time that reside within the genomic interval. For example, the 
chromosome 1p arm harbors p73 and CHD5 within 1p36, DEAR1 (TRIM62) at 1p35, and MUTYH at 
1p34. All of these genes exhibit important tumor suppressive activities. p73 and CDH5 are important 
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regulators of cell cycle control, apoptosis, and senescence
167-169
.  DEAR1 is a dominant regulator of 
acinar morphogenesis and polarity, as well as an inhibitor of TGFβ induced Epithelial to Mesenchymal 
Transition (EMT) and cellular invasion
2, 131, 138
. Lastly, MUTYH is a base excision repair gene important 
in DNA damage repair whose biallelic mutation is common in the inherited colorectal cancer syndrome 
MutYH Associated Polyposis
170
. The combined loss of important regulators of cell cycle control, 
apoptosis, polarity, invasion, and DNA repair can potentially greatly promote tumorigenesis via its 
allowance of uncontrolled cellular growth, increased mutation rate, and promotion of migration and 
invasion.  A better understanding is needed to fully comprehend the functional effect concerning the 
combinatorial loss of multiple important tumor suppressors in driving tumor progression.  
An indication of the importance of DEAR1 as a “bona fide” tumor suppressor as well as the 
critical nature of copy number alteration in DEAR1’s function as a tumor suppressor was discovered by 
targeted disruption of the Dear1 locus in the mouse
2, 131
.  TRIM family proteins have been noted to play 
significant roles in cancer and previous to this, our lab had shown that DEAR1 was mutated and 
homozygously deleted in breast cancer, indicating its potential importance in oncogenesis. Targeted 
disruption of the Dear1 locus in the mouse indicated that Dear1
-/-
 and Dear1
-/+
 mice developed late onset 
tumors with a frequency of 12.9% (8/62) and 17.7% (17/96), respectively
2
. The tumors that arose in the 
mice were diverse in spectrum and encompassed multiple epithelial tumor types; for example, they 
included hepatocellular, mammary, lung, and pancreatic tumors, as well as sarcomas and lymphomas
2
. 
Interestingly, Dear1
+/- 
mice developed tumors with similar frequencies as the Dear1
-/-
 mice. Moreover, 
many of the Dear1
+/- 
mice tumors exhibited further deletion of the wildtype allele, except tumors of the 
lymphatic system, which suggested that Dear1 is a classic tumor suppressor with the potential ability to 
act as a tissue dependent haploinsufficient tumor suppressor.  Therefore, loss of a single allele of DEAR1 
can potentially have significant effects upon gene dosage and function. Understanding the frequency of 
DEAR1’s loss in solid tumors and other types of alterations, including mutations and expression changes, 
is important for further elucidating the significance of the loss of the p arm of chromosome 1 in cancer. 
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Methods  
Databases including cBio (MSKCC), CONAN (Wellcome-Sanger), Catalogue of Somatic 
Mutations in Cancer (COSMIC) (Wellcome-Sanger), and Oncomine were investigated for information 
concerning genomic alterations and transcript expression in human tissue samples, The Cancer Genome 
Atlas (TCGA) cohorts, human cell lines, and other reported papers
145, 146, 148, 171
. Mutation functionality 
assessment was completed via PolyPhen2 software (V2.2.2) and SIFT
172, 173
. Survival curves were 
generated by cBio, using Kaplan-Meier analysis through querying complete tumor sets in the BRCA 
cohort for DEAR1 heterozygous loss and SNAI2 amplification
145, 146
. 
Results 
DEAR1 Displays Chromosomal Loss and mRNA Downregulation in Human Tumors Associated with 
Chromosome 1p Loss, in a Tumor Spectrum Similar to the Tumors Derived from the DEAR1 Knockout 
Mouse Model 
LOH of an important tumor suppressive chromosomal locus can greatly affect gene 
expression, especially if those genes involved are haploinsufficient, in which the loss of a single allele is 
enough to cause inactivation of the tumor suppressor and can thereby greatly potentiate tumor initiation 
and progression. Since previous data had hinted at the frequent recurrent loss of chromosome 1p and 
further, our lab had shown that loss of a single allele of Dear1 in the mouse model can potentiate tumor 
formation, it was determined if the tumor spectrum that was found in the Dear1 knockout mouse model 
recapitulated the human tumor spectrum associated with DEAR1 locus chromosomal loss. Large 
genomic characterization efforts from TCGA and the Broad Institute have led to an updated view of 
genomic alterations in many cancers. To determine if the Dear1 mouse model tumor spectrum was 
reflective of the spectrum found in human tumors associated with chromosome 1p loss, database analysis 
was conducted to ascertain the human tumor spectrum associated with DEAR1 chromosomal loss and 
gene mutation. DEAR1 was found to exhibit LOH in a similar tumor spectrum as the Dear1 knockout 
mice by analysis of human cell lines and tissues from the CONAN and cBIO databases, sharing an 
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association with intestinal, breast, lung, hepatocellular, pancreas, hematopoietic, and sarcoma tumors 
(Fig. 1). In the CONAN human cell line database, DEAR1 chromosomal loss was found in tissues 
including, soft tissue sarcomas (37%), pancreatic (31%), thyroid (50%), lung (32%), hepatocellular 
(33%), renal (33%), breast (18%), and gastrointestinal tumors (28%) (Fig. 1)
2, 148
. Further, the same 
tumor spectrum featuring LOH of the DEAR1 locus was found by analyzing data from human tumor 
samples in TCGA, accessed by cBio (Table 1) 
2, 145, 146
. Colorectal and hepatocellular cancer, as well as 
invasive breast cancer were found to have the highest frequency of LOH (Table 1; unpublished data) 
2
.  
Further, a putative homozygous deletion of DEAR1 was found in two samples of hepatocellular 
carcinoma and single samples of glioblastoma multiforme, low grade glioma, ovarian serous 
cystoadenocarcinoma, and breast carcinoma from the TCGA project, as accessed by cBio (unpublished 
data) 
2, 145, 146
. Previously, our lab had shown that the existence of a homozygous deletion in an invasive 
breast cancer sample, as well
131
.  Moreover, it was found that the heterozygous chromosomal loss of the 
DEAR1 locus, which occurs in about 32% of invasive breast cancer (IDC) patients, along with the 
genetic alteration of the Epithelial to Mesenchymal Transition (EMT) promoter SNAI2 which occurs in 
about 6% of IDC cases, significantly correlated with worse overall survival (p=0.016) (Fig. 2)
145, 146
. This 
data shows that chromosomal alterations of driver genes, even of a single allele, can potentially be 
important drivers in the progression of cancer.  
The concordance of downstream gene expression changes effected by chromosomal alterations 
is important to validate as this indicates the effectiveness of these alterations. Our group has 
demonstrated that, in multiple tissue types, DEAR1 chromosomal loss does correlate with mRNA 
expression via transcriptome sequencing in colorectal, lung adenocarcinoma, head and neck squamous 
cell carcinoma, hepatocellular, ovarian, serous cystadenocarinoma, prostate, stomach, and lung 
squamous cancer (unpublished data) 
2
 (Table 2). Besides these tumor types, DEAR1 also showed a 
general mRNA downregulation in glioblastoma and lymphoma, as well as protein downregulation in the 
transition of normal breast to DCIS, and DCIS to invasive breast cancer as our lab has previously shown. 
All of these tumor types known to exhibit mRNA alteration in accordance with chromosomal alteration  
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Figure 1. DEAR1 LOH in Various Cancer Cell Lines as Shown By CONAN-Copy 
Number Analysis (Sanger Institute) software. (A) LOH within chromosome 1p31 to 
1p36 involving DEAR1 in CONAN cell lines with empty boxes corresponding to loss 
of alleles and colored boxes indicative of retention of alleles. The x axis indicates the 
genomic interval within the p arm that is deleted and the y axis indicates the tissue 
type. Each line represents an individual cell line. (B) Table summarizing data 
visualized in (A) and describing the percentage of LOH of DEAR1 in multiple cancer 
types in the CONAN database. 
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Table 1- DEAR1 Exhibits Heterozygous Loss in Multiple Human Tumor Types. DEAR1 
was found to undergo heterozygous chromosomal loss in many epithelial tissues and 
moderate to low frequencies. Often, loss of DEAR1 locus was encompassed in the loss of 
the entire p arm of chromosome 1, an area containing multiple tumor suppressors.  
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Figure 2- DEAR1 Heterozygous Loss and SNAI2 Alterations Can Predict Overall 
Survival. This figure shows the effect of DEAR1 heterozygous loss and SNAI1/2 gene 
upregulation on survival of patients with invasive breast cancer. Survival curves were 
generated by cBio, using Kaplan–Meier analysis through querying complete tumor sets 
in the BRCA cohort for DEAR1 heterozgyous loss, SNAI1, SNAI2, TWIST1, and 
TWIST2. Alteration of SNAI1/2 and TWIST1/2 includes amplification, upregulation of 
mRNA/protein expression (if applicable) greater than two SDs from the mean. Figure is 
taken from Chen et al. 2013 (Figure 7c)
2
. 
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Table 2- DEAR1’s Expression is Downregulated in Multiple Tumor Types. Using 
data from the TCGA project (colorectal and brain), Sun et al. 2006 (brain n=81), 
and Piccaluga et al. 2007 (lymphoma), along with analysis from the Oncomine 
database (oncomine.org), DEAR1 is found to have significant downregulation in 
multiple tissue types. Significance was assessed using a Bonferroni corrected p-
value of 2.45 E-6 for colorectal cancer, 3.96 E-6 (2.55 E-6 for Sun 2006) for brain 
cancer, and 2.55 E-6 for lymphoma due to multiple comparisons. It is important to 
note that the data from colorectal cancer and lymphoma also reached a significance 
level associated with genome wide significance (5 E-8)●. Other data was shown to 
be approach significance in cecum adenocarcinoma and brain cancer Δ. Figure is 
taken from Chen et al. 2013
2
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are also known to undergo chromosomal loss of the 1p35 region
2, 131
. Thus, DEAR1 alterations at the 
genetic and transcript level in human tumors occur in multiple tumor types, with a tumor spectrum 
similar to what is observed in the Dear1 mouse model, suggestive that these alterations can potentially 
drive tumor progression in cancer. 
DEAR1 Exhibits Rare Mutation in Multiple Epithelial Cancers 
In addition to chromosomal alterations, genetic mutations play a large role in altering gene 
function. By analysis of data from the TGCA project and other sequencing projects, as accessed by 
cBIO, and COSMIC as well as by sequencing data produced by our own lab, DEAR1 is mutated at rare 
frequencies in multiple tumor types  (Table 3) 
2, 131
. DEAR1 has been found to be mutated in Lung 
Squamous (2.4%), Uterine (1.8%), Stomach (1.8%), Colorectal (1.8%), Melanoma (1%), Renal Cell 
Carcinoma (0.5%), Breast (13% MD Anderson cohort/ 0.1% TCGA cohort), and Bladder cancer (0.8%). 
Moreover, the DEAR1 mutation tumor spectrum of human tissue samples also reflected the tumor 
spectrum of the Dear1 knockout mouse, including breast, lung, pancreatic, and colorectal cancer, similar 
to those tissues that developed LOH at the DEAR1 locus
2
. To date, most of the mutations reported in 
DEAR1 are within the coding region and predicted by tools like PolyPhen2, MutationTaster, and SIFT to 
be potentially deleterious
2, 131, 174
. Further, sequencing by the Broad Institute and the TCGA project has 
discovered the presence of multiple variants that are highly abundant within the tumor samples, 
including a V40M exonic variant found in a Head and Neck patient residing in 50% of the tumor as well 
as a E138K exonic variant found in a melanoma patient in which their normal allele was lost leading to 
100% allele frequency of the variant
145, 146, 175
. These sequencing efforts have also, and more importantly, 
found the presence of ultra-rare frameshift and nonsense mutations which presumably knockout 
DEAR1’s expression.  Moreover, since chromosome 1p35 is known to undergo frequent chromosomal 
loss as previously discussed, a mutation in the retained copy or even a copy neutral event (deletion 
followed by a duplication event) could induce a homozygous mutant condition, thereby potentially 
increasing the functional effect of the mutant. On this note, analysis of the TCGA data has also shown 
the rare co-occurrence in patients with mutation and copy number alteration of DEAR1. For example, 
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Table 3- DEAR1 Undergoes Rare Mutation in Multiple Tumor Types. Mutation 
frequencies of DEAR1 as detailed by Lott et al. 2009, Chen et al. 2013, and 
Memorial Sloan Kettering Cancer Center’s (MSKCC) cBio Portal.  
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in the TCGA cohort, the variant D421G in colorectal cancer is associated with a chromosomal gain
145, 146
.  
Moreover, a Y439H variant in a renal clear cell carcinoma patient and a P270* frameshift variant in an 
invasive breast cancer patient, also discovered through TCGA sequencing, was found to exhibit 
concomitant heterozygous loss of the other allele
145, 146
.  The co-occurrence of chromosomal gains or 
losses can alter mutation allele frequencies, thus promoting the deleterious effects of the driver 
mutations. The vast number of mutations in DEAR1 that are reported are missense mutations. Missense 
alterations can potentially play large roles in effecting the function of tumor suppressors if they are 
localized in areas known to be important for binding to other cell signaling regulators, thereby possibly 
effecting downstream signaling and resulting in large phenotypical changes.  For example, one of 
DEAR1’s exonic mutations, R187W, that was found in both an 87 year old breast cancer patient and the 
21MT breast cancer cell line series, has been shown to be functional, as the genetic complementation 
with wildtype DEAR1 into the mutant 21MT cell line restored acinar morphogenesis in 3D culture
131
. 
There is also potential for mutations to have the ability to stratify for recurrence, progression to invasive 
disease, or even therapeutic sensitivity. For instance, though only a small number of samples (n=10) 
were available with relevant clinical information, 70% of these mutations in DEAR1 were associated 
with lymph node involvement or metastasis (Table 4)
2
.   
Discussion 
Our lab has previously shown that DEAR1 is a pivotal tumor suppressor in breast cancer 
through its ability to regulate acinar morphogenesis and to suppress EMT, an important step for the 
dissemination of tumor cells to distant sites
2, 131
. DEAR1 loss of expression or loss of normal function 
leads to aberrant acinar polarity, luminal filling, and enhanced activation of downstream SMAD3 targets 
in the presence of the TGFβ ligand2, 131.  Heterozygous or homozygous loss of the DEAR1 allele has been 
shown in the mouse model to result in late onset tumor formation, at similar rates respectively, in 
multiple epithelial tumors including intestinal adenocarcinoma and lymphoma as well as other epithelial 
cancers like mammary, lung, and pancreas
2
. Results of database analysis indicate that the spectrum of 
tumors formed in the mice upon Dear1 allelic loss is similar to the tumor spectrum associated with 
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Table 4- Correlation between DEAR1 Mutation and Clinical Outcome. Clinical information 
included records detailed to us by Dr. Kelly Hunt and Dr. Aysegul Sahin as well as clinical 
information provided by MSKCC’s cBio Portal. *Cases with Accessible Clinical Information. 
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chromosome 1p LOH in humans, including lung, colorectal, lymphoma, and breast cancer, indicating the 
relevancy of the mouse model as well as the importance of Dear1 to tumor development. Moreover, 
human mutation in DEAR1, despite occurring at a relatively low incident rate, was also found to be 
associated with the spectrum of tumors formed in the Dear1 knockout mouse model including colorectal, 
stomach, and renal cell carcinoma
145, 146
. However, current methods to sequence DEAR1 within large 
consortium sequencing projects and even previously by our lab involved low sequencing coverage 
techniques, meaning that these technologies may not be have been able to detect DEAR1 mutations if the 
variant allele frequencies occurred at levels below the sequencing platforms’ threshold of detection. It is 
possible that the incident rate of DEAR1 mutations in human cancer reported herein may be 
underestimated. Therefore, ultra-deep sequencing may be required to detect DEAR1 mutations that can 
occur at lower variant allele frequencies within small subpopulations of the tumors. In all, the 
recapitulation of the human tumor spectrum by the Dear1 mouse model indicates the significance of the 
loss of the Dear1 locus as well as how LOH and homozygous deletion of DEAR1 in human tumors can 
act as a potential driver in cancer.   
Recently it has been shown that germline variants and somatic genomic alterations explain 
about only 39% of all expression changes 
176
. Moreover, copy number alterations do not always correlate 
with mRNA expression, with only about 20% of cis-acting copy number alterations having been shown 
to effect mRNA expression
176
. This discrepancy between copy number loss and expression, therefore, 
shows not only the ability of cells to compensate for gene expression after the loss of a chromosomal 
locus, but also the importance of particular genes whose chromosomal loss does correlate with mRNA 
downregulation, as these genes may have important functions within the tumor. In credence with this 
theory, our lab has shown that DEAR1 chromosomal loss is associated with reductions in gene 
expression in multiple tumor types, many of which are reflective of the tumor types that developed 
within the Dear1 knockout mouse model. This is important as DEAR1 was shown to exhibit a relatively 
high frequency of LOH in multiple epithelial human tumor tissues, with largest frequencies in colorectal, 
breast, and hepatocellular carcinoma. In fact, heterozygous loss of DEAR1 was found to be the most 
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common form of genetic alteration of the gene in cancer. Moreover, through database analysis of TCGA 
via cBIO, DEAR1 has also been found to be homozygously deleted in multiple tumor types including 
hepatocellular and breast cancer. Knudson’s description of classical tumor suppressor inactivation 
requires two separate events to affect gene function
30
. It is possible that one of these events may be 
inherited through the germline, making one more susceptible to cancer development
30
. However, in most 
cases, both inactivating events occur after birth and are typically a combination of mutation and/or 
deletions. As such, DEAR1 has been described as both a classical tumor suppressor as well as a 
haploinsufficient tumor suppressor in a tissue dependent manner. In support of DEAR1 acting as a classic 
tumor suppressor in cancer, our lab had previously described secondary loss of the wildtype allele in 
Dear1 heterozygous mice
2
. Herein, additional evidence for DEAR1 acting as a classical tumor suppressor 
in human cancer  is described with the report of tumors exhibiting combinatorial heterozygous loss of the 
DEAR1 locus as well as the presence of DEAR1 mutation. These alterations are important in cancer due 
to their ability to fully inactivate the gene and allow for singular expression of the mutant allele. 
Therefore, synergism of copy number changes of the DEAR1 locus and mutations may lead to alterations 
in gene dosage and function that can potentiate tumor progression. 
It is well known that malignancy results from the accumulation of a diverse array of genetic 
alterations including mutations followed by the subsequent expansion of particular cellular clones that 
possess the greatest advantage at that particular time in tumor progression. The temporal nature of clonal 
expansion can hint at the importance of a particular set of mutations at a particular time in the timeline 
for tumor progression
177
. For example, some mutations may be highly prevalent in the primary tumor, 
indicating that these mutations may be within founding clones and therefore important in tumor 
initiation. Other mutations may be more prevalent in the invasive leading edge of the primary or in the 
metastasis, indicating their importance in invasion or re-colonization of the metastatic lesion
178
. Evidence 
has shown that 56% (n= 10/18; range= 22-100%) of DEAR1 variants with known allele frequencies 
within TCGA cohorts including glioblastoma multiforme, melanoma, stomach adenocarcinoma, and 
uterine corpus endometrioid carcinoma have variant allele frequencies greater than 20% (unpublished 
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data)
145, 146
. The majority of these variants were predicted to be deleterious as shown by algorithms from 
MutationAssessor and PolyPhen2
172, 179, 180
. These variants, if functional as many of them are predicted to 
be, represent a large proportion of altered cells that may have been evolutionarily selected for and could 
be important in the progression of the tumor.  
Genetic alterations including copy number changes and mutations have a long history of being 
used to stratify for prognosis and therapy due to their relative ease of determination in clinical samples. 
One of the first to be developed was Imatinib which targets the BCR-ABL gene fusion caused by the 
t(9;22)(q34;q11) translocation
181
. Imatinib has been shown to be highly effective in Chronic Myeloid 
Leukemia (CML) with an overall 5 year survival rate at 89%
181
.  Other BCR-ABL inhibitors which have 
been developed are Dasatinib and Nilotinib
71
. Crizotinib is also a targeted therapy which was developed 
to treat Anaplastic Lymphoma Kinase (ALK) translocations which are common in inflammatory 
myofibroblastic and anaplastic large cell lymphoma as well as less frequently in breast, colon, and 
lung
182
. Moreover, Trastuzumab and Laptinib were developed for patients exhibiting Erbb2 
overexpression or amplificaiton
71, 183
. Vemurafinib has been created as a B-RAF mutant specific therapy 
for melanoma patients
71
. Other therapies known to be effective against activating mutations are Erlotinib 
and Gefitinib which target mutated Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung 
Cancer (NSCLC)
71
. Further, chromosomal loss of 9p21 and gains of 20q11 and 1q21 have been shown to 
stratify survival outcomes in patients with renal cell carcinoma
184
. These are just a few examples of the 
genetic alterations that have been used to stratify patients for prognosis and treatment. Since DEAR1 was 
associated with a relatively frequency of chromosomal loss in invasive breast cancer and is a known 
suppressor of TGFβ induced EMT, it was ascertained if DEAR1 heterozygous loss could cooperate with 
alteration of a downstream effector of the TGFβ pathway. DEAR1 heterozygous loss and SNAI2 
amplification was shown to be able to act synergistically to predict overall worse survival in a TCGA 
invasive breast cancer cohort of 889 patients
2
. Recent additions of patient samples into the TCGA 
invasive breast cancer cohort (n=959), has shown that not only is the combined heterozygous loss of 
DEAR1 and amplification of SNAI2 still significant (p=0.016), but heterozygous loss of DEAR1 alone is 
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now able to predict overall survival (p=0.042) (unpublished data)
145, 146
. This data suggests that DEAR1 
and SNAI2 can potentially act as a clinical marker panel to stratify patients for overall survival. The 
development of a FISH assay to determine if clinical samples harbor DEAR1 heterozygous loss and 
SNAI2 amplification could assist in the determination of prognosis for invasive breast cancer patients. 
Clinical validation of these tests as well as clinical trials are needed to verify the ability of these markers 
to stratify patients. Altogether, the evidence presented has shown that DEAR1 is a driver in cancer that is 
inactivated via mutation and copy number alterations. Thus, it is possible in the future that we can 
capitalize on these alterations in order to better stratify patients that harbor these alterations for clinical 
prognosis.  
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Chapter 3 
Development and Performance Evaluation of a DEAR1 Ultra Deep Targeted Sequencing Assay for 
Ion Torrent Next Generation Sequencing Platform 
Introduction 
Next Generation Sequencing and Precision Medicine in Oncology Care 
The advent of next generation sequencing (NGS) technology has revolutionized genomic 
science and molecular diagnostics, brought on by the highly sensitive, quantifiable, and high throughput 
nature of NGS. This technology allows for simultaneous detection of single nucleotide variants, copy 
number alterations, large structural changes like translocations and inversions, as well as the presence of 
small and large insertions/deletions (INDELS). Current sequencing applications that have been used on 
this platform include DNAseq via whole genome, exome, and targeted resequencing, as well as RNA-seq 
and miRNA-seq. It is believed that NGS will be a major enabler for the dawn of global “precision 
medicine”, which involves the selection of therapeutic strategies based on the individual molecular and 
genetic information of each patient 
185
. Currently it is recognized that targeted panel resequencing is the 
most clinic ready form of NGS technologies 
186
. Targeted NGS is more applicable for the clinic currently 
than other versions of DNAseq for multiple reasons including lower cost, faster output, better quality and 
coverage achievable via the locus enrichment strategy, and reduction in ethical issues connected with 
unsolicited findings of unanticipated germline inherited disease
187
.  Moreover, targeted resequencing 
panels have already been shown to be able to detect clinically relevant variants in multiple diseases and 
assist in the treatment of patients (see Rehm et al. 2013 for a comprehensive review
188
). For example, 
Sehn and colleagues showed that targeted NGS panels can help in the clarification of diagnosis of 
oncology cases with ambiguous histology and may assist in redefining therapeutic approaches
189
. 
Moreover, custom targeted panels have shown that 20% of castrate resistant prostate cancer harbor 
BRCA2 gene deletions and ATM point mutations which can be clinically important, as germline BRCA 
alterations have been shown to indicate sensitivity to PARP inhibitors in prostate, breast and ovarian 
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cancer
190
. A 384 gene panel using Illumina based NGS found about half of the 44 gastric cancer samples 
sequenced had variants in TRAPP, which can affect the efficacy of HDAC and CHK1 inhibitors
191
. 
These studies have shown the usefulness of targeted panel based NGS and how this application can have 
a real impact on making “precision medicine” a reality.  
Sensitivity of NGS Platforms is Essential for the Identification of Clinically Important Rare Variants 
One major challenge to “precision medicine” that has been revealed by NGS is the great extent 
of intra-tumor heterogeneity. Gerlinger et al. showed in a seminal paper the existence of extensive 
regional heterogeneity in tumors, using renal cell carcinoma as a model, with only 31-37% of mutations 
being shared throughout the primary and the metastatic lesions
58
. Similar evidence has been found for 
other tumors such as high grade serous ovarian cancer
192
. This regional heterogeneity can have large 
implications for clinical treatments. A study reported that relapsed Non-Small Cell Lung Cancer 
(NSCLC) lesions resistant to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors 
(TKI) due to MET amplifications were evolutionarily selected from a low frequency subclone (<1%) that 
existed prior to therapy
193
. Moreover, Su and colleagues have shown that an EFGR variant T790M 
present at low frequency (<5% of tumor variant frequency) in a pre-treatment primary biopsy of NSCLC 
was found to be enriched in a post-treatment biopsy after treatment with an EGFR TKI
194
. Rare variants, 
despite their low frequency within a tumor, can have deleterious functional effects on a gene product, 
and thus, given a particular time in the tumor’s developmental history, can play a potential role in tumor 
progression
195
.  
Next generation sequencing is unique in its ability to truly assess the extent of intra-tumor 
heterogeneity due to its high degree of sensitivity compared to other technologies and its quantifiable 
nature. For example, ABI’s SOLiD NGS platform was found to be able to achieve about 93% sensitivity 
and 100% specificity
196
. Sikkema-Raddatz and colleagues found that targeted NGS by Sure Select 
capture and sequencing on Illumina’s MiSeq achieved 100% sensitivity (95% confidence interval: 97.76-
100%) and a non-concordance rate of 0.00315% when compared to Sanger sequencing
187
. Further, they 
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suggested high quality variants with adequate coverage (>30) may not need secondary validation by 
Sanger sequencing, as NGS technology seems to be superior to the previous gold standard. The 
sensitivity of NGS targeted resequencing technology has also been compared to real-time PCR’s ability 
to detect variants. A high concordance between 96.3-100% was found to exist between the two 
technologies, with real-time PCR detecting an additional four known variants and NGS detecting eight 
novel variants not detected by real-time PCR in FFPE NSCLC tumor tissue
197
. Moreover, Peter 
Campbell’s group has shown the ability to detect down to a 0.02% minor allele frequency using a nested 
PCR approach followed by 454 sequencing
198
. These assays have not only shown the high degree of 
sensitivity of NGS assays but have also shown their clinical utility. To that degree, the FDA has recently 
granted marketing authorization for Illumin’a MiSeqDx and Ion Torrent’s Ion PGM Dx for clinical use 
based on its accuracy across the genome, along with its precision and reproducibility
199, 200
. Moreover, in 
response, the College of American Pathologists has recently released its standards for the use of next 
generation sequencing in clinical tests. Further, there are over 80 clinical trials currently ongoing across 
the nation using NGS for oncology studies to assess and confirm the utility of this technology in cancer 
care (www.clinical trials.gov). 
Methods 
Design of Custom DEAR1 Targeted Ampliseq Panel 
Ion Ampliseq Designer version 1.2.8 (https://www.ampliseq.com; Life Technologies) was 
used to design an Ampliseq panel to target the genomic region of chr1: 33,610,351-33,681,308 (hg19). 
The custom DEAR1 Ampliseq panel contained primers for a highly multiplexed amplification reaction to 
amplify 150bp fragments tiled across the genomic region of interest.  
Creation of Ampliseq Spike-In for determination of Accuracy 
To understand our ability to accurately detect allele frequencies of a known population, a spike-
in assay was completed using variants with known frequencies to determine the capability of our custom 
DEAR1 ampliseq panel to detect accurate variant frequencies. Dr. Steven Lott designed the novel spike-
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in assay used in this study. Four amplicons were selected for this validation test that resided in the linear 
phase of coverage during test sequencing of Human Mammary Epithelial Cell line-76NE6 (HMEC-
76NE6). Coverage of amplicons from the sequencing of HMEC-76NE6 was plotted from lowest to 
highest and amplicons residing within the median range of coverage were chosen for use in the plasmid 
spike-in. An oligo was created featuring the full sequence of these four amplicons with barcode adapters 
at each terminal. Within each amplicon, marked changes to the reference sequence were made to make 
the amplicons contain various different types of variants that are known to frequently occur in 
sequencing data (Fig. 3; Appendix I). These variants included single and multiple nucleotide variants, as 
well as INDELS. The pMA-RQ vector plasmid containing the full sequence of the four amplicons with 
the manufactured variants and barcode adapters were generated using Life Technology’s GeneArt gene 
synthesis.  
 
Figure 3-Illustration of the Spike-in Plasmid. The plasmid contains the sequence of four amplicons with 
distinct artificial nucleotide changes including nucleotide substitutions and INDELS. The nucleotide 
changes occurred in both high complexity and low complexity (homopolymer) regions.  
The artificial plasmid was then spiked into control CEPH (sample with Northern and Western 
European ancestry residing in Utah) DNA NA12878 (Coriell-NA12878) based on genome equivalents. 
Plasmid to cell line DNA ratios were determined as shown below:  
A single human diploid cell has about 6.5 pg of DNA; therefore in a 200ng solution, there 
would be about 30,769 genomes (cells).  
The quantity of total genomes took into account both plasmid and cell line DNA. Therefore, the 
quantity of total genomes for a 10% spike-in of the plasmid genomes also accounts for 90% of cell line 
genomes. Thus in this situation, 90% of the control NA12878 DNA accounts for 34,188 genomes and 
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10% of the artificial plasmid spike-in equates to 3,419 genomes for a total of 37,607 total genomes. 
However, the plasmid exists in a haploid condition and therefore needs to be doubled to reflect diploid 
conditions, as is represented in the control cell line DNA. Therefore, according to this, 6,838 genomes of 
the artificial plasmid is needed to equal 10% of the overall total genomes.  
Mass of the plasmid to add was calculated as follows: 
1894989.6𝑔
𝑚𝑜𝑙
∗ 
1 𝑚𝑜𝑙
6.02223
∗ 6838 𝑝𝑙𝑎𝑠𝑚𝑖𝑑𝑠 = 2.15−14𝑔 𝑜𝑟
21.5𝑓𝑔
100𝑢𝑙
 
Because the overall mass of the spike-in plasmid was miniscule, the mass of the plasmid in the 
solution was not figured into the dilution of the control DNA.  
Dilutions of artificial plasmid DNA into NA12878 control DNA were made for 10%, 5%, and 
1%. Additional dilutions were also made for 50%, 20%, and 0.5%. All dilutions were checked by 
PicoGreen Kit (Life Technology P7589) and TaqMan RNase P Detection Reagents Kit (Life Technology 
4316831) for validation of concentrations and then sequenced on either the Ion Torrent PGM or Proton 
sequencer. The PicoGreen assay was completed exactly as protocol stated 
(https://tools.lifetechnologies.com/content/ sfs/manuals/mp07581.pdf). TaqMan RNase P kit was 
preformed according to the protocol (“Measuring Template Efficiency” 
https://tools.lifetechnologies.com/content/sfs/brochures/ cms042785.pdf). Briefly, the standard Human 
genome DNA provided in the kit was serially diluted from 10ng/μl to 0.5ng/μl and each serial dilution 
was used to create a standard curve. For the 96 well PCR plate format, to each well was added: 3ul of 
FFPE DNA or diluted standards, 12.5ul 2 × Universal Master Mix (No AmpErase UNG) (Life 
Technologies 4364343), 1.25ul 20x RNAse P Probe/Primer Mix (from kit 4316831 Life Technologies), 
and 8.25ul RNase-free water. qPCR cycling was performed as follows: 50° Celsius (C) 2 min, 95°C 10 
min, and 40 cycles of 95°C 15 sec and 60°C 1 min. Using a standard curve amplification, quantities were 
determined for samples. Correlation of logarithmic best fit line of CT values of standards (Y axis) vs 
Concentration (X axis) was used to determine accuracy of quantities, with R
2
 typically being over 
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0.9900. Amplicon sequences were manually pulled out of bam files using the Extract Barcodes R script 
(Appendix II). 
Ampliseq Library Construction and Sequencing 
In order to amplify DEAR1 for sequencing, Ampliseq Designer version 1.2.8 (Life 
Technologies https://www.ampliseq.com) was used to design 150bp amplicons, spanning across a 48kb 
region on chromosome 1: 33,610,600-33,658,985 (hg19). The 184 amplicons, split into two pools, were 
used to complete library construction according to the Ion Torrent library construction protocol (Life 
Technologies MAN0006775 Revision 4.0 http://ioncommunity.lifetechnologies.com/docs/DOC-3254). 
Briefly, the Ampliseq panel was used to amplify DEAR1 in a highly multiplexed manner using 10ng of 
DNA for each primer pool as well as the Ion Ampliseq Library Kit 2.0 (Life Technologies 4475345). 
Specifically the FFPE DNA was added with 10ul of the 400nM 2x Ion Custom Ampliseq Primer 
Pool,and 4ul of 5x of the Ion Ampliseq HiFi Master Mix in each reaction. The following thermocycling 
protocol was used: 1 cycle at 99°C for two minutes followed by 19 cycles of 99°C for 15 seconds and 
60°C for four minutes. The primer sequences were then partially digested by the addition of 2μl of FuPa 
reagent to each samples that were then exposed to the following conditions: 50°C for 10 minutes, 55°C 
for 10 minutes, and then 60°C for 20 minutes. After the primer sequences were digested, the Ion Express 
Barcode Adapters were added (Life Technologies 4471250), in addition to Switch solution and DNA 
ligase, to the amplified library and subjected to the following temperature conditions: 22°C for 30 
minutes followed by 72°C for 10 minutes. The completed library was then purified with the Agencourt 
AMPureXP magnetic beads done according to Beckman Coulter protocol, with scaled volumes to fit the 
input volume (Beckman Coulter protocol # B37419AA).  
The purified libraries ran on the Ion Torrent PGM were amplified using a Platinum PCR 
SuperMix High Fidelity polymerase and a library amplification primer mix, using the following 
conditions: 98°C  for 2 minutes followed by 5 cycles of two steps including 98°C for 15 seconds and 
60°C for 1 minute. The amplified library was then re-purified with Agencourt AMPureXP magnetic 
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beads using the same conditions during the previous library purification as before (see above). For the 
samples ran on the Ion Torrent Proton, libraries were not amplified after purification. Once final purified 
libraries were created, the two libraries associated with the 2 different Ampliseq primer pools were added 
together in equal concentrations for each patient sample. Templates were then created with the 9x diluted 
pooled libraries by following the Ion PI and PGM Template OT2 200 Kit V2 protocol (Life 
Technologies 4480974 and 4485146; MAN0007624 
https://tools.lifetechnologies.com/content/sfs/manuals/MAN0007624.pdf). Briefly, the following 
reagents were added, at the specified amounts, to 65μl of the diluted library: Ion PI Reagent mix TL 
(750ul), Ion PI PCR Reagent B (450μl), Ion PI Enzyme Mix TL (75μl), Ion PI PCR Reagent X (60μl), 
and the Ion PI Ion Sphere Particles (100μl). Samples were then run on the Ion OneTouch 2 instrument. 
Template positive Ion Sphere Particles (ISPs) were recovered by centrifugation and then ~1.4mL of 
supernatant was removed. Beads were then washed twice with ~ 1.1mL of water and the pellet was 
resuspended in Ion PI ISP Resuspension Solution. Quality was assessed by Qubit 2.0 flourometer. The 
template-positive ISPs were then enriched on the Ion OneTouch ES by the attachment of ISPs to washed 
streptavidin C1 beads. The enrichment was completed by following the protocol as described in the Ion 
PI Template OT2 200 kit v2 manual: after the attachment of the ISPs to beads, subsequent washes as 
well as a melt-off reaction occurred on the OneTouch ES. Melt-off solution contained 40μl of 1M 
NaOH, 3 μl of 10% Tween 20 and 277μl of water.  
Enriched ISPs were then prepared for sequencing using the Ion PI or PGM Sequencing 200 Kit 
V2 (Life Technologies 4485149 and 4482006) as described by the Ion PI and PGM Sequencing 200 kit 
v2 protocol (MAN0007961 and MAN0007273 http://ioncommunity.lifetechnologies.com/docs/DOC-
7459 and http://ioncommunity.lifetechnologies.com/docs/DOC-6775). Briefly, the enriched ISPs were 
washed with water, followed by the addition of Ion PI Annealing buffer (15μl) and Ion PI Sequencing 
Primer (20μl) to the enriched ISPs and then amplified on a thermocycler with the following steps: 95°C 
for 2 minutes and 37°C for 2 minutes. After amplifying the ISPs, 10μl of the Ion PI Loading buffer was 
added and the final mixture was loaded onto a washed and calibrated Ion PGM 316 or Proton chip. The 
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chips were then washed with a foam created from 45μl of 50% Annealing buffer and 5μl of 2% TritonX-
100, followed by the loading of 55μl of 50% Annealing buffer. This was followed by the chips being 
centrifuged and flushed with Flushing solution and 100μl of 50% Annealing buffer. Ion PI Sequencing 
Polymerase was then flushed across the chip in a solution with 50% Annealing buffer. Upon completion, 
samples were then sequenced on Proton and PGM316 chips using the Ion PI and PGM 316 Chip Kit 
(Life Technologies 4482321 and 4483324). For samples barcoded on the Proton chips, Ion Torrent Suite 
was used to separate barcoded sequences and exported as individual BAM files.  
Sequence Analysis   
Sequencing bam files were analyzed by Torrent Variant Caller v.4.2 via customized DEAR1 
parameters, followed by its output as a Variant Calling Format (VCF) file
201
. The customized DEAR1 
parameters consisted of recommended Ion Torrent variant calling parameters with the following changes: 
Splice Site Size-20bp; Maximum Coverage-100,000; Data Quality Stringency- 8.5; Downsample to 
Coverage- 100,000; Snp Minimum Coverage Each Strand-7; Snp Minimum Allele Frequency-0.01; Snp 
Minimum Coverage-20; SNP strand bias-0.90; Mnp Minimum Coverage Each Strand-7; Mnp Minimum 
Variant Score-400; Mnp Min Allele Frequency- 0.01, Mnp Minimum Coverage-20; Mnp Strand bias-
0.90, Kmer length-19, Minimum Frequency of Variant Reported-0.15; Indel Minimum Variant Score-10; 
Indel Minimum Coverage Each Strand-3; Indel Minimum Allele Frequency- 0.05; Indel Minimum 
Coverage-20; and Indel Strand Bias-0.85. Sample VCF files were annotated by SnpEff/SnpSift using the 
tool’s inherent annotation as well as with Phase 1 Version 3 data from the 1000 Genomes project 202-204. 
SnpSift was also used to complete variant filtering in accordance with the following parameter 
requirements: quality score was required to have a greater than 30 phred score, as well as at least 1,000x 
overall locus coverage, 60x or greater coverage of the variant allele, and a minimum of 30x coverage on 
both forward and reverse strands. Stringency filters allowed for 13-66% reduction in incidental variants 
as well as the retention of noteworthy variants (Appendix III). Variants identified in both the tumor and 
normal samples were filtered out. However, a small number of potentially germline variants (allele 
frequencies around 50% or 100%) were found to exist in samples to which the matched normal sample 
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was unable to be sequenced. These unconfirmed potential germline variants were not filtered out of our 
analysis as there was no definitive proof these were in fact germline; therefore, our total variant count is 
slightly inflated by these variants. Genome Analysis ToolKit was used to determine overall coverage
205
. 
The R program for statistical computing packages’ ggplot2 were used to create figures detailing 
sequencing data, including coverage plots (Appendix IV)
202, 203, 206, 207
.  
Digital PCR 
Digital PCR was completed on either the QX200 Droplet Digital PCR System (Bio-Rad 186-
4001) or QuantStudio 3D  (Life Technologies 4489084) platform. Custom genotyping TaqMan 
(4331349) was ordered from Life Technologies using a dual reporter system with VIC fluorescence 
tagging the reference sequence and FAM tagging the mutant sequence. PCR reaction mix was created 
using dPCR master mix (Life Technologies 4482710), target probes, and diluted DNA (10-36ng) per 
manufacturer’s suggestion. TaqMan genotyping probes were first optimized for largest cycle separation 
between the VIC and FAM probes with at least 1.5x cycle difference using qPCR with the following 
conditions: 95°C for 10min with 40-50 cycles of 92°C for 15sec and 60-64°C for 1 min. For Bio-Rad, 
samples underwent droplet generation (Bio-Rad 186-4002) whereas the samples undergoing digital PCR 
on the Life Technologies platform were spread across a microchip featuring 20,000 wells using an 
autoloader (Life Technologies 4485507 and 4482592). PCR was preformed according to manufacturer’s 
protocol with specified cycle number and annealing temperatures as determined in preliminary qPCR 
optimization. Data was then analyzed by QX200 droplet reader (Bio-Rad 186-4003) or by QuantStudio 
3D (Life Technologies 4489084). Each variant was tested with 2-3 replicates. The R program for 
statistical computing packages’ ggplot2 were used to create figures detailing Digital PCR data (Appendix 
V)
202, 203, 206, 207
. 
Read Count Accuracy 
To determine the read count accuracy, the approximate number of cells present with a 
particular variant given a predicted allele frequency was determined. The model is based on assuming 
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diploid cell condition and extrapolated to 1,500 cells in the 10ng needed for Ion Torrent Ampliseq 
targeted sequencing based on the following calculations: 
3 million bp (human genome) * 2 (diploid) * 660g/mol (Avg MW dNTP) * 1.67*10-
12
 (weight 
of 1 dalton)= 6.6pg or 0.0066ng 
10ng input into Ampliseq amplification/0.006ng = 1,515 cells  
The percentage of cells with a variant was determined by the percentage of heterozygous cells 
needed to produce a given variant allele frequency based on the presence of 1,515 cells within the 10ng 
of input DNA. Further, the number of reads expected to be positive for a variant under a specified 
coverage was determined. For comparison to our actual sequencing data, examples of read counts for the 
particular allele frequency were given along with the experimental coverage received. Read coverage 
accuracy was calculated by the following equation: 
(𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡 𝑓𝑜𝑟 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞 × 
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 𝑓𝑜𝑟 𝑔𝑖𝑣𝑒𝑛 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞)
(𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡 𝑓𝑜𝑟 𝑔𝑖𝑣𝑒𝑛 𝑎𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞 × 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 𝑓𝑜𝑟 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞)
      ×  100 
Read counts and allele frequencies used to calculate read coverage accuracy originate from VCF files of 
the FFPE DCIS samples sequenced. VCF files were created through the use of the Torrent Variant Caller 
4.2 and the specific parameters mentioned in the previous method section detailing the sequence 
analysis. It is important to note that the read count accuracy was completed by manual determination and 
was not used as an empirical method to quantify the accuracy of the variant caller or sequencing 
platform. 
Sensitivity and Specificity 
To determine the sensitivity and specificity of the custom Ampliseq DEAR1 panel, VCF files 
of the lymphocyte DNA of normal Caucasian female NA12878 from the Coriell (Coriell NA12878) 
repository created using the DEAR1 Ampliseq panel on the Ion Torrent Proton and PGM platforms was 
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compared to the National Institute of Standards and Technology’s (NIST) highly confident integrated 
genotype calls of the same sample
208
. VCF files created from the Ion Torrent Proton and PGM platforms 
from our sequencing of NA12878 were generated via use of the automated Torrent Variant Caller 
according to parameters previously discussed in the sequence analysis section of the methods within this 
chapter. Moreover, the VCF files underwent additional variant filtration completed according to the 
protocols discussed within the sequence analysis section of the methods. Samples were noted for the 
absence or presence of variants (not including common single nucleotide polymorphisms) known to 
occur in the NIST’s NA12878 genotype calls as well as for variants in randomly chosen and randomly 
distributed nucleotides across the DEAR1 locus within areas covered by the Ampliseq. To determine if 
the degree of sensitivity and specificity was altered in homopolymers, samples were also noted for the 
absence or presence of variants within randomly chosen homopolymer areas across DEAR1. Using two 
by two contingency tables and the package “epiR” within the statistical software R, sensitivity and 
specificity was calculated as well as the 95% confidence interval for each factor (Appendix VI)
209, 210
.   
Results 
Determination of Appropriate NGS Platform for Experimental Procedure 
Multiple platforms exist for NGS applications, including Illumina’s MiSeq and HiSeq, 
Roche’s 454 GSJ system, ABI’s SOLiD platform, and the Ion Torrent system. The vast majority of these 
systems use labeled di-deoxy terminating nucleotides and imaging software to capture the incorporation 
of the labeled nucleotide. The Ion Torrent platform is unique in the way it detects nucleotide 
incorporation. This platform takes advantage of the natural chemistry that occurs upon the bonding of 
two nucleotides by detecting the release of proton molecules after the flow of specific nucleotides. This 
method bypasses some of the issues associated with image analysis many of the other NGS platforms 
have, like “dead” fluorophores and overlapping signals211.  Each platform has its own benefits and 
negatives, and each situation must be considered to determine which platform is best for the 
experimental design. Illumina platforms have higher throughput capability and thus lower sequencing 
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cost per gigabyte, but greater instrument costs and longer run times from 27hrs to 11 days on the MiSeq 
and HiSeq, respectively
212
. Their competitor, the Ion Torrent PGM sequencer platform is itself lower in 
cost and has a much lower run time, only 2 hours
212
. Further, each platform is associated with its own 
INDEL and substitution error rates
213, 214. The 454’s GSJ and the Ion Torrent PGM (using the 200bp 
sequencing kit) exhibit primarily INDEL errors and have a similar INDEL error rates per 100 basepairs 
(bp) at 0.40. The MiSeq platform has the lowest INDEL error rate per 100 bp with a rate of only 0.0009. 
The MiSeq is known to exhibit mostly substitution errors with an error rate of 0.09 per 100 bp. On the 
other hand, the 454’s GSJ had the second lowest substitution rate at 0.05 and the Ion Torrent PGM (using 
200bp sequencing kit) had the lowest rate at 0.03. Depending on the type of variant that is most likely 
expected in the experiment, the variant specific error rate corresponding to each type of platform can be 
very important in choosing which platform is best for the experiment planned.  
Our lab was interested in finding novel variants and determining the variant frequency in an 
early stage of breast cancer.  Previous analysis of genetic alterations of DEAR1, described in chapter 2, 
has shown that the majority of reported variants harbored within the gene are substitutions. Deletions 
involving the gene in cancer tend to encompass not only the entire gene itself but large regions of the 1p 
chromosome arm as well. As these large deletions can be found easily by other less expensive techniques 
than NGS and has been extensively described in cancer, our lab decided to focus on characterizing the 
substitution variants within DEAR1 in early stage breast cancer using NGS technology. Further, current 
sequencing efforts of breast cancer have experienced reduced sensitivity due to intra-tumor 
heterogeneity, normal tissue contamination within the samples, and lower median coverage rates, all 
reducing the degree of sensitivity to find rare alleles. By completing ultra-deep sequencing of DEAR1, 
we can potentially achieve greater sensitivity to detect those rare variants for which previous lower 
coverage sequencing may not have been able to discover. Ultra deep sequencing has previously been 
shown to be effective in detecting low prevalence somatic variants, mostly through amplicon based 
sequencing
215, 216
. The Ion Torrent platform was determined to be the appropriate fit for our experiment 
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because of its low substitution error rate, low cost, quick processing time and the proven history of 
amplicon based sequencing being able to detect rare somatic variants.  
Design of Ion Torrent Custom DEAR1 Targeted Ampliseq Panel 
The Ion Torrent System as described above is centered on an amplicon based strategy in which 
a large number of primers are designed to amplify small 150-200bp regions across an area of interest, 
thereby amplifying a large region in a tiled based manner. Due to the complexity of designing primers 
for large multiplexing reactions as required for the Ampliseq panel, it is best to use computer based 
algorithms that take into account GC-content, melting temperatures, primer-primer interactions, etc. 
ThermoFisher Life Technologies offers a free web-based Ampliseq design service that uses as input 
either a specified genomic range or a genes list. Using Ampliseq Designer version 1.2.8, a custom 
Ampliseq panel was designed to amplify a 71kb genomic region that included the reading frame of 
DEAR1 as well as a 33kb region upstream of the canonical promoter of DEAR1 to include variants that 
might influence the expression of the gene (Fig. 4). However, due to low complexity of the locus, a final 
184 amplicon panel was designed to cover a 48kb region which includes the DEAR1 locus. In general, 
there is a high concordance between the areas that were unable to be included in the coverage by the 
Ampliseq panel and the areas that are known to be genetically repetitive.  In fact, the vast majority of the 
33kb region upstream, as well as much of the intronic regions of DEAR1, were unable to be amplified 
due to their highly repetitive nature (Fig. 4b). When focusing on the DEAR1 locus, including intronic 
regions and a 11kb region upstream of DEAR1, 47% coverage longitudinal coverage was achieved. Of 
the non-repetitive areas, 100% coverage of the canonical promoter of DEAR1 as well as the exonic 
regions and 75% coverage of the 3’UTR was achieved. Areas able to be amplified by the DEAR1 custom 
Ampliseq panel include regions known to harbor variants previously identified in various cancers and 
catalogued in the COSMIC depository and cBIO
145, 146, 148
. These variants include the D421G mutation 
found in a TCGA stage IIIC rectal cancer patient who is listed by the project as having progressed and a 
frameshift at P270fs in a stage 2 breast cancer patient with positive lymph node involvement
145, 146
.  
Control Artificial Spike-in  
69 
 
       
F
ig
u
re 4
- Illu
stratio
n
 o
f C
u
sto
m
 D
E
A
R
1
 A
m
p
liseq
 D
esig
n
. A
 g
en
o
m
ic reg
io
n
 o
f ch
r1
:3
3
,6
1
0
,5
8
0
-3
3
,6
5
9
,6
8
0
 w
as su
b
m
itted
 to
 L
ife 
T
ech
n
o
lo
g
ies’ Io
n
 A
m
p
liseq
 D
esig
n
er (as sh
o
w
n
 b
y
 th
e b
lu
e IA
D
3
3
7
1
2
_
In
p
u
t U
C
S
C
 G
en
o
m
e B
ro
w
ser track
).  A
) T
h
e g
en
o
m
ic reg
io
n
s in
 w
h
ich
 
A
m
p
liseq
 o
lig
o
s w
ere ab
le to
 b
e d
esig
n
ed
 are in
d
icated
 b
y
 th
e g
reen
 IA
D
3
3
7
1
2
_
D
esig
n
 U
C
S
C
 G
en
o
m
e B
ro
w
ser track
. R
eg
io
n
s o
f th
e su
b
m
itted
 
g
en
o
m
ic lo
cu
s th
at w
ere u
n
ab
le to
 b
e co
v
ered
 b
y
 th
e A
m
p
liseq
 o
lig
o
s are in
d
icated
 b
y
 th
e red
 IA
D
3
3
7
1
2
_
M
issed
 U
C
S
C
 G
en
o
m
e B
ro
w
ser track
, 
w
h
ich
 m
o
stly
 co
rresp
o
n
d
s to
 th
e lo
w
 co
m
p
lex
ity
 reg
io
n
s as sh
o
w
n
 b
y
 th
e R
ep
eatM
ask
er U
C
S
C
 G
en
o
m
e B
ro
w
ser track
. A
reas th
at w
ere ab
le to
 
b
e co
v
ered
 in
clu
d
ed
 v
arian
ts p
rev
io
u
sly
 d
escrib
ed
 b
y
 th
e C
O
S
M
IC
 d
atab
ase, sh
o
w
n
 b
y
 th
e red
 C
O
S
M
IC
 U
C
S
C
 G
en
o
m
e B
ro
w
ser track
. B
) A
 
zo
o
m
ed
 in
 cap
tu
re o
f th
e A
m
p
liseq
 d
esig
n
s h
ig
h
lig
h
ts co
rresp
o
n
d
en
ce b
etw
een
 areas u
n
ab
le to
 b
e co
v
ered
 b
y
 th
e d
esig
n
 an
d
 rep
etitiv
e elem
en
ts. 
 A
 
B
 
70 
 
Interpretation of NGS data relies on the idea that a variant frequency is accurately represented 
in the NGS reads to the same extent the variant is represented in the sample itself. Understanding this 
degree of accuracy and having empirical data to bolster this idea is very important for one to have 
confidence in the variant data that the Ampliseq panel accrues. For this reason, a novel spike-in assay 
was designed to determine the precision of our variant frequency read outs. This was completed by the 
designing of an artificial plasmid containing 4 amplicons from our DEAR1 custom Ampliseq panel 
featuring inserted synthetic variants within these amplicons reflecting nucleotide variants as well as 
INDELS (Fig. 3). This plasmid was then spiked into control normal DNA NA12878 at various 
frequencies and sequenced. The results showed that for most of the amplicons, the sequencing data was 
able to accurately recapitulate the variant frequencies spiked into the control DNA (Fig. 5). Some 
amplicons were able to outperform others. For example, control C amplicon had 100% accuracy for the 
1% and 5% spike-in and less than 0.5% deviation for the 10% spike-in. Control A and control B 
amplicons had approximately 100% accuracy for the 1% spike in, whereas control D amplicon exhibited 
about a 1% deviation for the 1% spike-in. Control A and control D amplicons showed slight deviation 
from expected allele frequencies, within 1.5% frequency, for the 5% spike in. Moreover, control B 
amplicon showed significant deviations from expected variant frequencies in the 5% (2.5-4%) and 10% 
spike-ins (5-8%), despite no relatively reduced coverage of the amplicon in relation to the other 
amplicons. Control A and control D amplicons showed a 2-2.5% deviation from expected frequency for 
the 10% spike in. In support of our findings, library construction processing of DNA samples used in 
NGS sequencing have been shown to have a slight effect on variant frequency read-outs in sequencing 
data (personal communication from BioRad).  Overall, these data reflect the variability of the accuracy 
of sequencing data and how this may affect the precision regarding variant allele frequencies.  
Determination of Read Count Accuracy 
An important innovation of NGS technology is its ability to be quantitative regarding allele 
frequencies of a variant within a sample. This is accomplished by determining the ratio of the read count 
of the variant to the total coverage of the locus. The use of this innovative approach has recently revealed  
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Figure 5- Comparison of the Artificial Spike-In Frequency to Observed Allele Frequency in Next 
Generation Sequencing. The artificial plasmid detailed in Figure 2 was spiked in at 1%, 5%, and 10% (x-
axis). Figure details the correlation of the spiked-in frequency to the observed fraction of sequence reads. 
Figure was created with help from Dr. Steven Lott, Ph.D. 
 
 
72 
 
the large degree of intra-tumor heterogeneity within cancer samples, which can have major implications 
for therapeutic approaches
217
. Heterogeneity is often identified by the presence of variants within small 
sub-clonal populations. The sub-clonal populations can be quantified by the determination of variant 
allele frequencies of specific variants marking these populations. Allele frequencies of these variants are 
determined by the fraction of supporting read counts carrying the variant in relation to the total 
sequencing read counts of the locus. Therefore it is important to determine the accuracy of the read 
counts achieved by the targeted sequencing panel per given variant allele frequencies. Thus, in order to 
determine the read count accuracy of the sequencing Ampliseq panel, achieved sequencing read counts 
were compared to the number of read counts that would be predicted based on a given allele frequency in 
a diploid model (Table 5).  Further, determining the number of cells carrying a variant based on NGS 
allele frequency can be very important clinically if clinicians base therapeutic strategies on the potential 
sensitivity of a patients’ tumor to a therapy against that particular genetic alteration, and important to this 
discussion, the variant frequency within the tumor based on the read out by NGS technology. As an 
example to show how allele frequencies can relate to the number of cells positive for a variant for a 
given sampled population, the frequency of cell populations harboring a variant based on different 
sequencing allele frequencies was modeled (Table 5).  
As shown by Table 5, a heterozygous variant detected by NGS at an allele frequency of 25%, 
is actually harbored within 50% of the population sampled. Further, extrapolating that about 1,515 cells 
are contained within the 10ng sampled by the Ampliseq procedure, approximately 758 cells within the 
sampled population are carrying the variant. In the previously given example, the allele frequency given 
from the NGS read count determined that the variant was present in about a quarter of the sampled 
population of cells. However, with knowledge that the variant existed in a heterozygous state and at a 
loci that is diploid, it can be extrapolated that the variant actually is harbored in half the cells, a point that 
can be important clinically as this can affect the percentage of the tumor that may be affected if an 
oncologist were treating with a targeted therapy against this particular variant. Therefore, zygosity of the 
variant as well as copy number of the loci carrying the variant are very important determinants of the  
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abundance of a particular variant in terms of determining the number of cells positive for a variant in a 
given sampled population.  
Allele frequencies, as previously mentioned, are a determinant of the ratio of the number of 
unique reads of the alternative allele to the total number of unique reads of the locus (coverage). The 
coverage of the locus helps to determine the sensitivity of the sequencing in detecting rare alleles as 
these rare alleles will only be represented in a very small proportion of reads. Using our model, for 
instance, sequencing of a rare 1% variant in a NGS sequencing reaction that obtained about 200x 
coverage of the locus, will only attain 2 supporting reads for the variant. A 5% variant, also sequenced at 
200x coverage, will be detected in 10 reads. In contrast, a 1% variant sequenced under 9,000x coverage 
will be represented in 90 reads, giving large support for this rare allele. Variants receiving low supportive 
reads may be potential errors as library creation and next generation sequencing have inherent error rates 
which can induce false positive nucleotide changes that can be identified in sequencing data at various 
frequencies, including low frequencies which may be misinterpreted as a rare alleles. Thus, strict 
filtering methods need to be developed in order to identify potential errors which can be based on 
multiple factors including the sequencing platform error rate, sequencing depth, coverage of alternative 
allele, and quality score.   
To determine the precision of our read counts using our custom Ampliseq panel, the accuracy 
of the read counts in accordance with the predicted read counts for a given allele frequency was 
determined. The mean sample coverage across the Ampliseq panel was 29,054x. Results indicate that the 
sequencing coverage was detected at frequencies higher than above clinical 1000x standards and all 
variants were supported by at least 60 reads (Fig. 6). Across the DEAR1 locus, consistency of overall 
coverage varied, with amplicons in exon 3 exhibiting the lowest degree of variation and amplicons in 
exon 1 and the promoter exhibiting the highest degree of variation (Fig. 6).  However, variant read 
counts within our sequencing data, when compared to the expected reads for a given allele frequency and 
locus coverage, reflected high degrees of accuracy with a median accuracy of 99.08% (range 96.33%- 
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Figure 6- Coverage of the DEAR1 Ampliseq Panel Amplicons Within the DEAR1 Promoter 
and Exonic Regions. Figure represents the coverage obtained by the DEAR1 ampliseq panel 
within the 5’UTR and exonic regions of the gene. Each bar represents a single amplicon. 
Figure was created with help from Dr. Steven Lott, Ph.D. 
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99.97) (Table 5). Strong accuracy was even shown for variants reflective of 1% of the population, 
indicating the efficacy of our Ampliseq panel to detect rare variants.  
Sensitivity and Specificity of the Custom DEAR1Ampliseq Panel  
In order to fully understand the capacity of what is captured within ones sequencing data, it is 
important understand the sensitivity and specificity of the targeted sequencing panel. This helps to 
understand the degree of false-positive variants that may occur within the data as well as the number of 
true variants that may not be reflected in the sequencing data, also known as “false-negatives”.  To 
determine the sensitivity and specificity of the DEAR1 targeted Ampliseq panel, sequencing data of the 
normal control DNA NA12878 completed on our Ion Torrent PGM and Proton platforms was compared 
to the NIST’s highly confident integrated genotype calls for the same sample (Table 6). Using the 
NIST’s data set as “truth”, sequencing on the PGM platform showed a high degree of overall sensitivity 
and specificity, with a sensitivity of 0.92 (CI:0.73-0.99) and specificity of 0.93 (CI:0.81-0.99). The Ion 
Proton platform preformed similarly with an overall sensitivity of 0.96 (CI:0.71-1.00) and specificity of 
0.86 (CI:0.71-0.95). Both platforms showed low sensitivity to detect INDELs, as is well known not only 
for the Ion Torrent platforms but for other NGS platforms as well [sensitivity 0.5 (CI: 0.01-0.99) and 
specificity 0.95 (CI: 0.74-1.00)]
212
. When focusing on the performance of the sequencing platforms in 
their detection of substitutions, the main type of variant expected to be harbored in DEAR1 based on 
previous sequencing data, the platforms showed high sensitivity and specificity to accurately detect these 
type of variants [PGM: sensitivity 0.95 (CI: 0.77-1.00) and specificity 0.91 (CI: 0.72-0.99); Proton: 
sensitivity 1.00 (CI: 0.78-1.00) and specificity 0.78 (CI: 0.56-0.93)]. Both platforms also showed a high 
degree of sensitivity in their abilities to detect substitutions in homopolymer regions [sensitivity 1.00 
(CI: 0.28-1.00); PGM specificity 0.88 (CI: 0.62-0.98), Proton specificity 0.75 (CI: 0.56-0.93)]. The 
platforms both performed very well in FFPE tissue in a similar way to the cell line NA12878 DNA, 
indicative of the custom DEAR1 ampliseq panel’s ability to have a high degree of precision in clinical 
samples [PGM: sensitivity 0.95 (CI: 0.92-0.98) and specificity 0.92 (CI: 0.89-0.94); Proton: sensitivity  
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Samples “Truth” “Test” Variant Type Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
NA12878 v. 
NA12878 
NIST Ion 
Torrent 
Proton 
All combined 
variants 
0.96 (0.79, 1.00) 0.86 (0.71, 0.95) 
   Indels 0.50 (0.01, 0.99) 0.95 (0.74, 1.00) 
   Indels in 
homopolymers 
0.50 (0.01, 0.99) 1.00 (0.64, 1.00) 
   Substitutions 1.00 (0.78, 1.00) 0.78 (0.56, 0.93) 
   Substitutions in 
homopolymers 
1.00 (0.28, 1.00) 0.75 (0.48, 0.93) 
NA12878 v. 
NA12878 
NIST Ion 
Torrent 
PGM 
All combined 
variants 
0.92 (0.73, 0.99) 0.93 (0.81, 0.99) 
   Indels 0.50 (0.01, 0.99) 0.95 (0.74, 1.00) 
   Indels in 
homopolymers 
0.50 (0.01, 0.99) 1.00 (0.64, 1.00) 
   Substitutions 0.95 (0.77, 1.00) 0.91 (0.72, 0.99) 
   Substitutions in 
homopolymers 
1.00 (0.28, 1.00) 0.88 (0.62, 0.98) 
NA12878 v. 
NA12878 
Ion 
Torrent 
Proton  
Ion 
Torrent 
PGM 
All combined 
variants 
0.86 (0.68, 0.96) 1.00 (0.86, 1.00) 
 Ion 
Torrent 
PGM 
Ion 
Torrent 
Proton 
All combined 
variants 
1.00 (0.80, 1.00) 0.90 (0.77, 0.97) 
 Ion 
Torrent 
Proton  
Ion 
Torrent 
PGM 
Indels* 1.00 (0.09, 1.00) 1.00 (0.75, 1.00) 
 Ion 
Torrent 
Proton  
Ion 
Torrent 
PGM 
Indels in 
homopolymers* 
1.00 (0.01, 1.00) 1.00 (0.66, 1.00) 
 Ion 
Torrent 
Proton  
Ion 
Torrent 
PGM 
Substitutions 0.85 (0.66, 0.96) 1.00 (0.74, 1.00) 
 Ion 
Torrent 
PGM 
Ion 
Torrent 
Proton 
Substitutions 1.00 (0.79, 1.00) 0.82 (0.60, 0.95) 
 Ion 
Torrent 
Proton  
Ion 
Torrent 
PGM 
Substitutions in 
homopolymers 
0.75 (0.35, 0.97) 1.00 (0.64, 1.00) 
 Ion 
Torrent 
PGM 
Ion 
Torrent 
Proton 
Substitutions in 
homopolymers 
1.00 (0.42, 1.00) 0.86 (0.57, 0.98) 
FFPE Breast 
Tumors v. 
NA12878 
NIST Ion 
Torrent 
PGM 
All combined 
variants 
0.90 (0.87, 0.93) 0.92 (0.90, 0.94) 
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Samples “Truth” “Test” Variant Type Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
FFPE Breast 
Tumors v. 
NA12878 
NIST Ion 
Torrent 
PGM 
Indels 0.50 (0.32, 0.68) 0.95 (0.92, 0.97) 
   Indels in 
homopolymers 
0.50 (0.32, 0.68) 1.00 (0.97, 1.00) 
FFPE Breast 
Tumors v. 
NA12878 
NIST Ion 
Torrent 
PGM 
Substitutions 0.94 (0.91, 0.96) 0.90 (0.87, 0.93) 
   Substitutions in 
homopolymers 
0.91 (0.82, 0.97)   0.86 (0.81, 
0.90) 
FFPE Breast 
Tumors v. 
NA12878 
NIST Ion 
Torrent 
Proton 
All combined 
variants 
0.95 (0.92, 0.98) 0.92 (0.89, 0.94) 
   Indels 0.50 (0.27, 0.73) 0.95 (0.91, 0.98) 
   Indels in 
homopolymers 
0.50 (0.27, 0.73) 1.00 (0.95, 1.00) 
   Substitutions 1.00 (0.97, 1.00) 0.89 (0.84, 0.92) 
   Substitutions in 
homopolymers 
1.00 (0.87, 1.00) 0.86 (0.79, 0.91) 
 
 
 
 
 
 
 
 
 
 
 
Table 6- Sensitivity and Specificity of Custom DEAR1 Ampliseq Panel. Sequencing data of CEPH 
control cell line NA12878 from the Ion Torrent Proton and PGM sequencing platforms were compared 
to the NIST’s highly confident integrated genotype calls in order to determine the sensitivity and 
specificity of the Ampliseq panel. The data from the PGM and Proton platforms were also compared to 
each other in order to determine differences in sensitivity and specificity of each platform. *Indicates 
the sensitivity and specificity remained the same independent of which Ion Torrent platform was used 
as “truth”. PGM data used the 1st generation of the 200bp Ion Torrent Sequencing Kit whereas Proton 
data used the 2nd generation version of the sequencing kit. To note, library construction protocols with 
the Proton sequencing platform were slightly changed upon noticing one primer pool acted 
inconsistently. The following changes were implemented: the reactions were completed in half reaction 
volumes and the amplification of the final library was removed from the protocol. 
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0.90(CI: 0.87-9.93) and specificity 0.92 (CI: 0.90-0.94)]. It is important to note that the variants 
identified in the sequencing of NA12878 on the Ion Torrent PGM and Proton platforms underwent 
stringent variant calling parameters and filtration methods. Many low quality variants as defined by low 
quality scores, those exhibiting strand bias, or those in low coverage areas were removed during these 
variant calling and filtration steps, thus possibly removing potential spurious variant calls and improving 
the sensitivity and specificity of the data. As these variant filtration methods were used to determine the 
presence of variants in our clinical samples, the achieved sensitivity and specificity of the sequencing 
panel in FFPE samples has made us highly confident in our ability to detect true variants harbored within 
our clinical samples.  
Discussion 
NGS technology has shown its potential to revolutionize clinical medicine and has helped the 
field to begin to understand the molecular mechanisms behind therapeutic resistance. In order for NGS to 
be truly effective, the technology must show a high degree of accuracy, sensitivity, and specificity, 
especially over previous gold standard methods. Many studies have shown NGS’s ability to be as 
sensitive or more sensitive than Sanger sequencing or real time PCR, while also showing its ability to be 
more discovery based as well
189, 196, 197, 213, 218
. Multiple platforms exist for completing NGS, each with 
their own benefits and pitfalls. One must determine which platform best fits the specific experimental 
conditions one is planning. We determined that the Ion Torrent platform was most applicable platform 
for our experiment, as the Ion Torrent sequencing platform is known for its quick turn-around time and 
low substitution error rates.  
The Ion Torrent platform uses a highly multiplexed PCR reaction to target specific loci for 
sequencing. As reactions with hundreds of amplicons can have multiple off target and undesirable effects 
if the primers are not designed with great care, Life Technologies have created an Ampliseq designer to 
help in the process of designing the amplicons for a desired locus. The Ampliseq designer was used to 
design amplicons to amplify the DEAR1 locus, including the exonic and regulatory regions of the gene. 
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Moreover, in order to capture upstream regulatory regions, an 11 kb region upstream of the gene locus 
was included in the design. All non-repetitive areas were able to be captured in the design, as low genetic 
complexity was a major issue in amplicon primer design. Amplification by Ampliseq primer panels are 
affected by many of the traditional factors known to effect PCR efficiency, like GC content, primer-
primer interactions, issues with low complex areas, and amplification bias. Due to some of these 
difficulties, one will see variances in the performance of amplicons across the loci. Despite these 
challenges inherent with PCR based systems, our Ampliseq panel was able to achieve sequencing depths 
at the DEAR1 locus that have never been previously described in breast cancer as well as cover areas 
known to be harbor previously described variants aby COSMIC and cBIO.  
The inherent challenges associated with the PCR based Ampliseq reaction as mentioned 
previously can lead to variances in the quality of sequencing and its accuracy in detecting variant 
frequencies across the panel. As such, it’s important to understand the limitations along with the 
sensitivity and specificity of one’s system. This can be done in multiple ways. One popular method is 
population mixing, in which a population with a known variant is spiked-in at a particular percentage in 
relation to another population. However, one possible issue with this method is potential sub-clonal 
ploidy differences in the two sequenced populations that can change the variant frequencies, especially if 
the population harboring the variant is cancerous as tumor cells often exhibit ploidy differences.  One 
way to subvert this is to use an artificial plasmid harboring an amplicon with the variant and to spike this 
plasmid into a cytogenetically normal DNA sample. This novel method was used to determine the 
accuracy of our sequencing to detect known variant frequencies. The data presented herein show that, for 
the most part, the amplicons tested were able to recapitulate the variant frequencies that were expected, 
giving confidence to the variant allele frequencies represented in our sequencing data. Some observed 
variances were present compared to the variant allele frequencies expected; however, this could be due to 
difficulties associated with PCR reactions, as discussed above, since Ampliseq sequencing is a PCR 
based method. However, it is important to note that variants represented in the spike-in assay required 
variant calling by manual extraction of the amplicons that contained the variant as many of the variants 
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within the spike-ins were not called by automatic variant callers or identified after variant call filtration. 
The exclusion of present variants by the automated variant callers warns against the sole reliance on 
these automated sequencing pipelines and exemplifies the importance of manually checking the 
sequencing data in viewers like Integrative Genome Viewer (IGV). For example, the variants present as 
part of the spike-in could be seen when viewing the data in IGV but were not represented in the resultant 
VCF files from the automated Torrent Variant Caller. Loss of the representation of particular variants 
may be due to issues with sequencing alignment to the reference sequence, low coverage of the particular 
locus, poor quality calculations, or the presence of the variant in genetically low complex areas like 
homopolymer regions. Therefore, a combination of automated variant callers with manual overview of 
the data in sequencing data viewers is important for ensuring complete and correct calling of the present 
variants. Overall, through the combined use of manual and automated variant calling, the novel spike-in 
assay created to determine accuracy regarding variant allele frequencies indicated that we can have 
confidence in our variant frequencies given by the NGS read out, even at the rare 1% variant frequency.  
This confidence is further exemplified by the accuracy shown by the high concordance 
between our observed read counts and the predicted read counts within our model, given a specified 
variant frequency and overall locus coverage depth. Modeling of predicted read counts allows for a clear 
observation of the number of cell needed to carry a variant within a population in order to detect a 
specific variant allele frequency. This model can also help to demonstrate how certain variants may be 
filtered from the data due to lack of sufficient observations. Typical NGS practices require a minimum 
number of reads supporting the presence of a variant in order to reduce the chance that a particular 
variant could potentially be a sequencing error. Depending on the coverage achieved and stringency of 
variant filtering that is desired, rare variants may be filtered out due to not obtaining enough supporting 
reads to be determined a true variant rather than a sequencing error. However, as the DEAR1 Ampliseq 
panel achieved high coverage within our sequencing, we were able to attain large support for rare alleles. 
As determined by the comparison of the empirical read counts achieved in our sequencing to the 
predicted read count model, it was determined that the sequencing read counts had accuracies between 
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96-100%, giving us further confidence in our variant frequencies given by NGS read counts and 
increased assurances that the high coverage achieved for the variants were not representative of biases 
within the data. However, it is important to note that as higher coverage is obtained in order to increase 
the sensitivity to detect potential rare alleles within the samples, increased stringency of the variant 
filtering may be needed to reduce artifacts that occur during library construction or sequencing.  This 
issue was specifically addressed through stringent variant quality filtering to reduce potential false 
positives associated with ultra-deep sequencing (see methods for detailed filtering procedures).   
It is also important to note that there are limitations to our modeling of variant allele 
frequencies and expected read counts. Our model assumes very simple conditions, including diploid 
status, known zygosity of the variant, and no intra-sample heterogeneity. Clinical samples exhibit a high 
degree of complexity that is not recapitulated in our modeling. Tumor intra-heterogeneity has been 
shown to be highly common across cancers with very few variants being represented in the majority of 
the tumor population
58, 217, 219
. Both variants and chromosomal alterations can exhibit intra-sample 
heterogeneity with mixes of both wildtype and variant allele populations, as well as the presence of 
diploid and haploid/2n+ populations. Chromosomal alterations are common in tumors, with 
amplifications, copy number gains, and deletions all potentially causing modulations in variant allele 
frequencies. For example, if a diploid tumor population existed harboring a heterozygous variant in 20% 
of the bulk tumor cells within a sample, NGS of the entire sampled tumor population would indicate that 
the variant allele frequency of the particular variant is 10%. Given the estimate that about 1,500 cells are 
sequenced in 10ng of DNA, an estimated 300 tumor cells at this stage harbor the variant. As the tumor 
evolves and progresses, a cell from the original 20% of tumor cells harboring the variant may undergo 
loss of heterozygosity of the wildtype allele. After clonal evolution, the tumor population may now 
exhibit the variant in 40% of the entire tumor mass sampled, with 30% still being diploid at the variant 
locus and 10% of the cells now demonstrating loss of heterozygosity. In this condition, though 40% of 
the tumor mass sequenced harbors the variant, the variant allele frequency as shown by NGS is actually 
25%, with 600 of the 1,500 cells sequenced demonstrating the variant. This shows the importance of the 
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knowledge of zygosity status throughout the tumor population, specifically within the sub-clonal 
populations harboring variants of interests, and how intra-tumor heterogeneity of variants and copy 
number can play a large factor complicating the interpretation of NGS data. Furthermore, tumor purity 
can also affect variant allele frequency interpretation. Tumors, especially those of an invasive nature, are 
often marbled with multiple different types of normal cell populations, including stromal tissue and 
normal epithelium. The inclusion of these cell types within the sequenced sample can have profound 
effects on the ability to detect variants within the tumor cells, depending on the extent of normal cell 
contamination, simply due to reducing the number of cells of tumor origin being sequenced. For 
example, a 10ng tumor DNA sample sequenced which is noted for having 70% tumor purity is estimated 
to have around 1,050 tumor cells in the approximate 1,500 cells sequenced. Now, if a variant is present 
in only 30% of the tumor cells sequenced, it is predicted that only 315 cells of the 1,500 cells harbor the 
variant, or 21% of the cells sequenced.  If the variant is a heterozygous variant carried in a diploid 
condition, and further the sequencing coverage received at this locus is approximately 1,000x, it can be 
expected to receive about 105 supporting sequencing reads for the variant. Variant filtration under the 
methods performed during out filtration would still have called the variant as we required at least 60 
supporting reads for each variant. However, if tumor purity of the sample was only 35%, the variant 
would only be present in 157 cells within the sequenced population and, given about 1,000x sequencing 
coverage of the heterozygous variant, would only be present in 52 reads; thus, this variant would have 
been filtered out using our stringent variant filtration methods due to tumor purity alone. It is important 
to note that currently 1,000x coverage is typically only achievable via targeted sequencing methods. 
Therefore, using sequencing methods that are only capable of lower coverage presently, like whole 
genome sequencing, will further reduce that ability to detect these types of variants in heterogeneous 
populations. For example, given a sequencing coverage of 100x in the previous examples of 70% and 
35% tumor purity, only about 10 and 5 reads supporting the variant would be present, respectively. Other 
factors that can affect final variant allele frequencies are biased-amplification or allelic dropout, which 
are known issues associated with library construction, as well as the natural structure of the genomic loci 
of interests like GC content and chromatin structure, which can as mentioned previously affect targeted 
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amplification and sequencing capabilities. All of these factors can have potentially large impacts on 
coverage uniformity and the accuracy of variant allele frequencies.  
Due to these variances that can occur across the amplicons within the loci, it is imperative to 
quantify the degree to which one is capturing a true assessment of the data. This is often done by 
computation of the targeted sequencing panel’s sensitivity and specificity to determine the capacity of 
the sequencing data to detect all variants, with limited false positives.  Sensitivity and specificity was 
ascertained by comparing the sequence data of the CEPH normal control DNA NA12878 sequenced on 
our Ion Torrent platforms to the NIST’s highly confident, integrated genotype calls for the same sample. 
The results showed a high degree of sensitivity and specificity for both Ion Torrent platforms, with the 
Ion Torrent Proton showing slightly greater sensitivity and the Ion Torrent PGM having slightly greater 
specificity. When specifically looking at the custom Ampliseq panel’s abilities in FFPE clinical samples, 
the PGM platform preformed similarly to the performance of intact cell line genomic DNA; however, the 
Proton platform showed specificity improvements within these samples. Both of the Ion Torrent 
platforms struggled with INDELS, a known weakness for the Ion Torrent Variant Caller
212, 214
. It is due 
to this that all INDEL calls were disregarded in further contemplation of sequencing data. The degree of 
sensitivity and specificity able to be achieved on the platforms may have been slightly enhanced due to 
the use of pre-filtered genotype calls to compute these measures. Through stringent variant calling and 
filtration, low quality variants or variants within low coverage areas were removed before sensitivity and 
specificity was calculated. Inclusion of these poorer quality genotype calls which can represent 
sequencing or library construction errors would have led to a higher degree of false positive variant calls 
and reduced sensitivity performance of the DEAR1 ampliseq panel. The same variant calling and 
filtration methods used prior to sensitivity and specificity analysis performed herein were also used in the 
processing of the sequencing data of the clinical samples. Therefore, the sensitivity and specificity 
calculated reflects the performance of the complete processing of the final variant calls within the 
clinical samples, thus giving us assurance of the quality of final data produced. Overall, the Ion 
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Platforms showed great sensitivity and specificity in both the control NA12878 and FFPE data, giving us 
high confidence in the variants called by our Ampliseq panel.  
As described herein, a highly sensitive and specific custom Ampliseq panel was generated to 
detect variants within the DEAR1 locus, including upstream regulatory regions. DEAR1 is a novel tumor 
suppressor, which plays important roles in acinar morphogenesis and TGFβ driven EMT2, 131, 220.  
Understanding the spectrum of genetic alterations encompassed in DEAR1 within cancer can give further 
insight into the mechanism of DEAR1’s tumor suppressive actions as well as in understanding tumor 
progression in general. NGS technology is a major tool currently being used to describe the genomic 
landscape of cancer due to its highly sensitive and quantitative nature. However, it is important when 
using targeted sequencing panels with this technology, that the method for targeted capture allows for 
highly sensitive detection of variants. The custom DEAR1 Ampliseq panel that was generated has been 
shown to be capable of the highly sensitive detection of rare variants as well as the ability to make highly 
accurate genotype and variant frequency calls.  
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Chapter 4 
Characterizing DEAR1’s (TRIM62) Genetic Role in Ductal Carcinoma in Situ Progression 
Introduction 
Ductal Carcinoma In Situ and Its Progression to Invasive Disease 
Breast cancer is the number one diagnosed cancer in women
221
. It is estimated by the 
American Cancer Society that about 1 in 8 women will be diagnosed with invasive breast cancer (IDC) 
within their lifetime
221
. In 2014, 232,670 women were projected to be newly diagnosed with breast 
cancer, with 20-24% diagnosed with ductal carcinoma in situ (DCIS) 
221,222
. DCIS is defined as the 
presence of abnormal neoplastic cells filling the ductal lumen. As it is an in situ disease, the abnormal 
cells have not invaded through the basement membrane at this stage. DCIS accounted for 83% of in situ 
breast cancer, making it the most commonly diagnosed in situ breast lesion
221
.  
DCIS is the earliest form of breast cancer and is currently considered as a non-obligate 
precursor to its invasive form
223
. One of the single most important questions surrounding DCIS is why 
some lesions remain indolent and other lesions recur. Population-based studies have suggested that about 
18-20% of DCIS lesions recur as a local recurrence in patients who received surgical resection
224, 225
. 
Fifty percent of local recurrences are diagnosed as IDC 
226
. The lack of biomarkers to stratify these 
patients with a higher risk of invasive recurrence have led to variance in how these lesions are treated in 
the clinic. Twenty-four percent of patients with DCIS elect to undergo unilateral mastectomy, a 
procedure that recent studies have indicated is linked to high rates of overtreatment as mastectomy has 
shown no significant difference in recurrence rates when compared to the less stringent treatment of 
lumpectomy plus radiation 
227, 228
. Other studies have also indicated that lumpectomy plus radiation is a 
superior treatment modality as it is associated with a 50% decrease in invasive recurrence and higher 
overall event free survival (81% versus 91%), when compared to lumpectomy alone
225,229
. This has led to 
the American College of Radiation to release the Appropriateness Criteria on DCIS stating breast 
conservation therapy (breast conserving surgery (lumpectomy) with negative margins followed by whole 
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breast radiation) as an acceptable treatment and an alternative to mastectomy
230
. Due to this 
recommendation, there has been a large increase in the number of patients receiving breast conservation 
therapy, which now accounts for 43% of current chosen treatment modalities
227
. However, a portion of 
the women treated with the more stringent treatment modality will have harbored an intrinsically 
indolent lesion that would have never progressed, even without further radiation treatment
225
. This 
highlights the need for molecular and genetic factors that are able to stratify women for tailored 
treatment options according to their risk for invasive recurrence in order to reduce both over-treatment 
and under-treatment rates. The current recommended treatment option of lumpectomy plus radiation, 
though as mentioned previously is indicated to a have a higher overall event free survival and reduced 
invasive recurrence rate, is also associated with a high degree of over-treatment as 14 DCIS patients 
would need to be treated with lumpectomy plus radiation in order to prevent one local recurrence
231
. 
Further, under-treatment is also of clinical concern as more women are opting for lumpectomy alone
227
.  
For example, Van Leeuwen et al. 2011 has shown that patients undergoing surgery alone experienced a 
significant decrease in local recurrence free survival
232
. Due to the uncertainty of the progression of 
DCIS lesions, surgical oncologist have difficulty in determining the best methods of treatment to reduce 
recurrence but limit the occurrence of over-treatment.  
Many have attempted to determine the molecular mechanisms of DCIS progression in an effort 
to establish clinical biomarkers. The majority of studies have tried to understand the progression through 
determining distinctions between DCIS and IDC. Surprisingly, many of these comparison studies of 
DCIS and IDC have indicated that the lesions are very similar, molecularly. Hwang et al. 2004 showed 
chromosomal alterations tend to be synchronous between Pure DCIS and IDC, though the Pure DCIS 
lesions did show significant enrichment of particular chromosomal alteration differences associated with 
tumor grade
233
. Moreover, it has been shown that nuclear grade and the molecular subtypes associated 
with IDC (ER, PR, HER2, etc.) as well as cytokeratin 5/6 markers often corresponded between adjacent 
in situ and invasive lesions
223, 234
. Similarities between the two lesions have also been seen at the 
epigenetic level with multiple studies indicating comparable rates of promoter hypermethylation during 
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the progression of DCIS to IDC
223
. The high degree of synchrony between the early, non-invasive lesion 
and the invasive counterpart have led to the proposed “branched” model of progression of DCIS to 
IDC
235. The “branched” model describes a linear progression of DCIS to IDC, with different branches off 
the linear model describing the restriction of DCIS lesions progressing to IDC based on nuclear grade 
correspondence between the lesions, i.e. a low grade DCIS can only progress to a low grade IDC and 
visa-versa. This model indicates that differences exhibited during DCIS progression are not necessarily 
between the in situ and invasive tumors but are potentially associated more with differential grades of 
DCIS. Contrary to this model, another model, often called the “parallel” model has been described which 
proposes a common cell of origin but with subsequent independent yet synchronous progression of DCIS 
and IDC lesions
235
. Support for this model, also known as the “Sontag-Axelrod” model, is indicated by 
continued existence of progressed DCIS and IDC adjacent to one another as well as the possible limited 
chromosomal alterations that are confined to either the DCIS or IDC components reported by Johnson et 
al. 2012
233, 235-237
. Due to the convoluted nature of the relationship between DCIS and IDC, much more 
work is still needed in order to better understand the molecular mechanism of DCIS progression and to 
help in the development of biomarkers for the stratification of treatment for this disease.    
DEAR1 is an Important Regulator of Polarity and EMT 
To better understand the progression of breast cancer, our lab has studied the novel tumor 
suppressor gene, Ductal Epithelium Associated Ring chromosome 1 (DEAR1), also annotated as 
TRIM62, which is an E3 ubiquitin ligase often downregulated in breast cancer
2, 131
. DEAR1 is part of the 
TRIM family of proteins, which are known to play important roles in immunity, differentiation, cell 
death, and proliferation. The important roles TRIM family members play in normal homeostasis, upon 
deregulation, can be integral to cancer progression
72, 238
. DEAR1 has been shown to be a major regulator 
of polarity and acinar morphogenesis
131
. In breast cancer, DEAR1 is downregulated during the transition 
from normal epithelium to DCIS and the invasive lesion
131
. Knockdown of DEAR1 in human mammary 
epithelial cells (HMECs) grown in 3D culture was shown to be associated with luminal filling, a 
hallmark of DCIS
131, 136
. Moreover, we have shown that DEAR1 is a master regulator of TGFβ mediated 
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Epithelial to Mesenchymal Transition (EMT) through its ubiquitination of SMAD3 in mammary cells
2, 
220
. DEAR1, located at chromosome 1p35.1, resides in an area often hemizygously deleted in epithelial 
cancer and is mutated in a wide spectrum of tumors including breast, colon, and stomach cancer
2, 131
. We 
have shown that a subset of these mutations can be functional, exemplified by the ability of wild-type 
DEAR1 to correct, by genetic complementation, the aberrant acinar morphogenesis within the DEAR1 
mutated metastatic breast cancer cell line, 21MT
131
. DEAR1 has also been found to undergo nonsense 
(N) and frameshift (FS) mutations in tissues including bladder (N), melanoma (N), breast (FS) and lung 
(FS) cancer
145, 146
.  
Since DEAR1 has shown to be pivotal for the maintenance of correct acinar morphogenesis 
and prevention of TGFβ induced EMT, and with the knowledge that DEAR1 undergoes functional 
mutations that can promote aberrant acini formation in breast cancer, it was determine if DEAR1 is 
mutated in the earliest form of breast cancer, DCIS, and if these mutations can inform us about DCIS 
progression to IDC. A custom next generation sequencing panel was developed to complete targeted 
ultra-deep sequencing of DEAR1 that exhibited strong sensitivity and specificity. Using this DEAR1 
sequencing panel, Pure DCIS and DCIS adjacent to IDC were sequenced and found to contain DEAR1 
somatic variants in 71% of these lesions, including many predicted to be deleterious by PolyPhen2 and 
SIFT prediction tools as well as functional evidence for a subset of these variants. Excitingly, evidence 
for a potential germline variant in an early onset case of Pure DCIS was found. Lastly, data from the 
sequencing of DCIS lesions associated with IDC seem to support a parallel model of evolution for DCIS 
and IDC. Our work has described the ultra-deep targeted sequencing of an important tumor suppressor, 
DEAR1, which indicated the importance of variants within this gene in the earliest form of breast cancer, 
DCIS.  
Methods 
Human Specimen Collection  
All human tissues were identified by Dr. Aysegul Sahin (MDACC) and obtained without 
90 
 
  
           
      
 
      
 
 
Figure 7- Histological Representation of DCIS FFPE Samples Used in Sequencing. Serial H&E 
sections were taken prior to sample sections, followed by digital annotation for both Pure DCIS 
(A) and DCIS with invasive components (B). The in situ lesions were marked digitally in a 
green outline where the invasive lesions were marked in a yellow outline. Laser capture 
microdissection (LCM) was completed on DCIS with invasive component samples. 
Representation of the capture of the tissues is shown in C, where the remaining tissue after 
LCM is shown in D. 
A B 
C D 
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identifiers from the MD Anderson Cancer Center tumor bank according to the approved IRB protocol. 
Samples were chosen based on identification of sufficient amounts of DCIS and/or invasive components 
to acquire at least 10 nanograms of DNA. Cases were also selected on presence of recurrence follow up 
data as well as age of disease onset as equal numbers of early and typical age of onset was requested. For 
a list of samples sequenced for each patient see Appendix VII. 
DNA Extraction and Quantification 
One to three 10um of DCIS and matched normal FFPE tissue were sectioned and mounted on 
either positively charged glass slides (Pure DCIS: VWR  48312-013) or PEN membrane slides (DCIS 
adjacent to IDC: Life Technologies LCM0521). Before tissues were sectioned onto the PEN membrane 
slides, the slides was exposed for 30 minutes to UV light in order to help with tissue adherence. A serial 
tissue section was taken prior to each sample collection for hematoxylin and eosin (H&E) staining. H&E 
slides were digitally scanned on the Aperio AT Turbo whole slide scanner and tumor area were digitally 
annotated on Aperio eSlideManager/Aperio ScanScope by pathologist, Dr. Fei Yang (MDACC). Tissue 
for DNA extraction was collected by either scraping whole slide sections  (Pure DCIS/Normal) or by 
Laser Capture Microdissection (LCM) (DCIS adjacent to INV) on the Arcturus XT LCM system. For 
Pure DCIS and normal lymph node tissue undergoing extraction by scraping, samples were 
deparrafinized for two 5 minute 100% xylene washes followed by collection of tissue by scraping with a 
fresh scalpel. For DCIS with invasive component (DCIS/INV) cases collected by LCM, samples on PEN 
membrane slides underwent a 2 hour 65° Celsius (C) incubation to help with tissue adherence followed 
by a pre-staining procedure, completed as described by the Arcturus Paradise Plus staining protocol with 
a few modifications (Life Technologies KIT0312J; manual 1287200 
https://tools.lifetechnologies.com/content/sfs/manuals/1287200.pdf). Briefly, samples were hydrated by 
exposure to 100% xylene followed by decreasing concentration of ethanol, from 100% to 75%, and 
water for the duration and manner as stated in manual. This was then followed by staining with the 
Paradise Plus stain (Life Technologies KIT0312J) for 7 seconds and then dehydration of the samples by 
incubation with increasing concentrations of ethanol, from 75% to 95% for two 30 second exposure, 
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followed by two 1 minute 100% ethanol incubation and 10 minute 100% xylene exposure. All tissues 
were then subject to a 5-10 drying time after final xylene incubation. Discrete lesion components were 
isolated by LCM and processed independently after staining. LCM collection was managed by 
pathologist, Dr. Fei Yang.  
After tissue collection, DNA was extracted by PicoPure DNA Extraction kit (LifeTechnologies 
KIT0103), using the protocol for fixed tissue sections. Briefly, 150 μl or 30 μl of Proteinase K suspended 
in supplied reconsitution buffer was added to either scrapped tissue sections or LCM caps, respectively. 
The samples were then incubated at 65°C for 22-24 hours followed by an exposure to 95°C for 10 
minutes to inactivate the Proteinase K. For the LCM samples, after proteinase K inactivation, extracted 
DNA was pooled from the LCM caps originating from a single lesion component of a single sample.  
The extracted DNA samples were then purified by either Agencourt AmpPure XP (Beckman 
Coulter A63880) for the Pure DCIS samples or by a specialized ethanol purification technique for the 
DCIS/INV samples isolated by LCM. The Pure DCIS samples collected by scrapping were purified by 
AmpPureXP, according to the protocol. Briefly, the samples were incubated with 1.8x AmpPureXP 
beads for 5 minutes followed by magnetic separation. The beads were then washed twice with 600 μl of 
freshly prepared 75% ethanol and then dried before suspending in 20 μl of water. For the DCIS/INV 
samples isolated by LCM and scrapped normal samples, the DNA was purified by a modified ethanol 
purification protocol in which the samples were combined with 2 μl of Pellet Paint (EMD Millipore 
70748), 10% 3M Na Acetate pH 5.2, 1 μl GenElute LPA (Sigma 56575-1ML), and 2.5x of 100% EtOH 
and then incubated for 20 minutes at room temp. Afterwards, samples were centrifuged at 14,000rpm for 
5min and the pellet was then washed with freshly made 70% and then 100% ethanol with centrifugation 
followed by supernatant removal after each washing. The final pellet, collected after the two ethanol 
washes, was dried at 90°C for 5min. Pellet was then eluted with 10 μl of water. Lastly, DNA was 
quantified by qPCR using TaqMan RNAse P Detection kit (4316831 Life Technologies) using specified 
protocol (“Measuring Template Efficiency” https://tools.lifetechnologies.com/content/sfs/brochures/ 
cms042785.pdf). Briefly, the standard human genome DNA provided in kit was serially diluted from 
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10ng/μl to 0.5ng/μl to form a standard curve. For the 96 well PCR plate format, to each well was added: 
3 μl of FFPE DNA or diluted standards, 12.5 μl 2 × Universal Master Mix (No AmpErase UNG) (Life 
Technologies 4364343), 1.25 μl 20x RNAse P Probe/Primer Mix (from kit 4316831 Life Technologies), 
and 8.25 μl RNase-free water. For the 384 well format, added to each well was 2.5 μl of each diluted 
standard (from kit 4316831 Life Technologies) or 0.2x diluted FFPE DNA (1.5ul of DNA into 6ul of 
dH20), 5 μl 2 × Universal Master Mix (No AmpErase UNG) (Life Technologies 4364343), 0.5 μl 20x 
RNAse P Probe/Primer Mix (from kit 4316831 Life Technologies), and 2 μl RNase-free water. qPCR 
cycling was performed as follows: 50°C 2 min, 95°C 10 min, and 40 cycles of 95°C 15 sec and 60°C 1 
min. Using standard curve amplification, quantities were determined for FFPE samples. Correlation of 
logarithmic best fit line of CT values of standards (Y axis) vs Concentration (X axis) was used to 
determine accuracy of quantities, with R
2
 typically being over 0.9900. For samples quantified by 384 
well format, which underwent sample dilution, quantities based on RNAse P curve were then multiplied 
by dilution factor to receive final sample quantity.  
Ampliseq Library Construction and Sequencing 
In order to amplify DEAR1 for sequencing, Ampliseq Designer version 1.2.8 (Life 
Technologies https://www.ampliseq.com) was used to design 150bp amplicons, spanning across a 48kb 
region on chromosome 1: 33,610,600-33,658,985 (hg19). The 184 amplicons, split into two pools, were 
used to complete library construction according to the Ion Torrent library construction protocol (Life 
Technologies MAN0006775 Revision 4.0 http://ioncommunity.lifetechnologies.com/docs/DOC-3254). 
Briefly, the Ampliseq panel was used to amplify DEAR1 in a highly multiplexed manner using 10ng of 
DNA per primer pool with the Ion Ampliseq Library Kit 2.0 (Life Technologies 4475345). Specifically 
the FFPE DNA was added with 10ul of the 400nM 2x Ion Custom Ampliseq Primer Pool, and 4ul of 5x 
of the Ion Ampliseq HiFi Master Mix in each reaction. The following thermocycling protocol was used: 
1 cycle at 99°C for two minutes followed by 19 cycles of 99°C for 15 seconds and 60°C for four 
minutes. The primer sequences were then partially digested by the addition of 2μl of FuPa reagent to 
each samples that were then exposed to the following conditions: 50°C for 10 minutes, 55°C for 10 
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minutes, and then 60°C for 20 minutes. After the primer sequences were digested, the Ion Express 
Barcode Adapters were added (Life Technologies 4471250), in addition to Switch solution and DNA 
ligase, to the amplified library and subjected to the following temperature conditions: 22°C for 30 
minutes followed by 72°C for 10 minutes. The completed library was then purified with the Agencourt 
AMPureXP magnetic beads done according to Beckman Coulter protocol, with scaled volumes to fit the 
input volume (Beckman Coulter protocol # B37419AA).  
The purified libraries ran on the Ion Torrent PGM were amplified using a Platinum PCR 
SuperMix High Fidelity polymerase and a library amplification primer mix, using the following 
conditions: 98°C  for 2 minutes followed by 5 cycles of two steps including 98°C for 15 seconds and 
60°C for 1 minute. The amplified library was then re-purified with Agencourt AMPureXP magnetic 
beads using the same conditions during the previous library purification as before (see above). For the 
samples ran on the Ion Torrent Proton, libraries were not amplified after purification to prevent unequal 
amplification of the two primer pools. Once final purified libraries were created, the libraries associated 
with the two different Ampliseq primer pools were added together by sample accodingly. Templates 
were then created with the 9x diluted pooled libraries by following the Ion PI and PGM Template OT2 
200 Kit V2 protocol (Life Technologies 4480974 and 4485146; MAN0007624 
https://tools.lifetechnologies.com/content/sfs/manuals/MAN0007624.pdf). Briefly, the following 
reagents were added, at the specified amounts, to 65μl of the diluted library: Ion PI Reagent mix TL (750 
μl), Ion PI PCR Reagent B (450μl), Ion PI Enzyme Mix TL (75μl), Ion PI PCR Reagent X (60μl), and 
the Ion PI Ion Sphere Particles (100μl). Samples were then ran on the Ion OneTouch 2 instrument. 
Template positive Ion Sphere Particles (ISPs) were recovered from the One Touch 2 by centrifugation 
and then ~1.4mL of supernatant was removed. Beads were then washed twice with ~ 1.1mL of water and 
the pellet resuspended in Ion PI ISP Resuspension Solution. Quality was assessed by Qubit 2.0 
flourometer. The template-positive ISPs were then enriched on the Ion OneTouch ES by the attachment 
of ISPs to washed streptavidin C1 beads. The enrichment was completed by following the protocol as 
described in the Ion PI Template OT2 200 kit v2 manual: after the attachment of the ISPs to beads, 
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subsequent washes as well as a melt-off reaction occurred on the OneTouch ES. Melt-off solution 
contained 40μl of 1M NaOH, 3 μl of 10% Tween 20 and 277μl of water.  
Enriched ISPs were then prepared for sequencing using the Ion PI or PGM Sequencing 200 Kit 
V2 (Life Technologies 4485149 and 4482006) as described by the Ion PI and PGM Sequencing 200 kit 
v2 protocol (MAN0007961 and MAN0007273 http://ioncommunity.lifetechnologies.com/docs/DOC-
7459 and http://ioncommunity.lifetechnologies.com/docs/DOC-6775). Briefly, the enriched ISPs were 
washed with water, followed by the addition of Ion PI Annealing buffer (15μl) and Ion PI Sequencing 
Primer (20μl) to the enriched ISPs and then amplified on a thermocycler with the following steps: 95°C 
for 2 minutes and 37°C for 2 minutes. After amplifying the ISPs, 10μl of the Ion PI Loading buffer was 
added and the final mixture was loaded onto a washed and calibrated Ion PGM 316 or Proton chip. The 
chips were then washed with a foam created from 45μl of 50% Annealing buffer and 5μl of 2% TritonX-
100, followed by the loading of 55μl of 50% Annealing buffer. This was followed by the chips being 
centrifuged and flushed with Flushing solution and 100μl of 50% Annealing buffer. Ion PI Sequencing 
Polymerase was then flushed across the chip in a solution with 50% Annealing buffer. Upon completion, 
samples were then sequenced on the Proton and PGM 316 chips using the Ion PI and PGM 316 Chip Kit 
(Life Technologies 4482321 and 4483324). Pure DCIS samples were sequenced each on one PGM 316 
chip and DCIS microdissected samples as well as normal samples were barcoded and sequenced 10 
samples per proton chip. For samples barcoded on the Proton chips, Ion Torrent Suite was used to 
separate barcoded sequences and exported as individual BAM files.  
Sequence Analysis   
Sequencing bam files were analyzed by Torrent Variant Caller v.4.2 via customized DEAR1 
parameters, followed by its output as a Variant Calling Format (VCF) file
201
. The customized DEAR1 
parameters consisted of recommended Ion Torrent variant calling parameters with the following changes: 
Splice Site Size-20bp; Maximum Coverage-100,000; Data Quality Stringency- 8.5; Downsample to 
Coverage- 100,000; Snp Minimum Coverage Each Strand-7; Snp Minimum Allele Frequency-0.01; Snp 
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Minimum Coverage-20; SNP strand bias-0.90; Mnp Minimum Coverage Each Strand-7; Mnp Minimum 
Variant Score-400; Mnp Min Allele Frequency- 0.01, Mnp Minimum Coverage-20; Mnp Strand bias-
0.90, Kmer length-19, Minimum Frequency of Variant Reported-0.15; Indel Minimum Variant Score-10; 
Indel Minimum Coverage Each Strand-3; Indel Minimum Allele Frequency- 0.05; Indel Minimum 
Coverage-20; and Indel Strand Bias-0.85. Sample VCF files were annotated by SnpEff/SnpSift using the 
tool’s inherent annotation as well as with Phase 1 Version 3 data from the 1000 Genomes project 202-204. 
SnpSift was also used to complete variant filtering in accordance with the following parameter 
requirements: quality score was required to have a greater than 30 Phred score, as well as at least 1,000x 
overall locus coverage, 60x or greater coverage of the variant allele, and a minimum of 30x coverage on 
both forward and reverse strands. Stringency filters allowed for 13-66% reduction in incidental variants 
as well as the retention of noteworthy variants (Appendix III). Variants identified in both the tumor and 
normal samples were filtered out. However, a small number of potentially germline variants (allele 
frequencies around 50% or 100%) were found to exist in samples to which the matched normal sample 
was unable to be sequenced. These unconfirmed potential germline variants were not filtered out of our 
analysis as there was no definitive proof these were in fact germline; therefore, our total variant count is 
slightly inflated by these variants. Genome Analysis ToolKit was used to determine overall coverage
205
. 
The R program for statistical computing packages’ ggplot2 were used to create figures detailing 
sequencing data, including coverage plots (Appendix IV)
202, 203, 206, 207
. Mutation mapper was used to form 
figures detailing position of variants in DEAR1
145, 146
.  
Digital PCR 
Digital PCR was completed on either the QX200 Droplet Digital PCR System (Bio-Rad 186-
4001) or QuantStudio 3D  (Life Technologies 4489084) platform. Custom genotyping TaqMan 
(4331349) was ordered from Life Technologies using a dual reporter system with VIC fluorescence 
tagging the reference sequence and FAM tagging the mutant sequence. PCR reaction mix was created 
using dPCR master mix (Life Technologies 4482710), target probes, and diluted DNA (10-36ng). 
TaqMan genotyping probes were first optimized for largest cycle separation between the VIC and FAM 
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probes with at least 1.5x cycle difference using qPCR with the following conditions: 95°C for 10min 
with 40-50 cycles of 92°C for 15sec and 60-64°C for 1 min. For Bio-Rad, samples underwent droplet 
generation (Bio-Rad 186-4002) whereas the samples undergoing digital PCR on the Life Technologies 
platform were spread across a microchip featuring 20,000 wells using an autoloader (Life Technologies 
4485507 and 4482592). PCR was performed according to protocol with specified cycle number and 
annealing temperatures as determined in preliminary qPCR optimization. Data was then analyzed by 
QX200 droplet reader (Bio-Rad 186-4003) or by QuantStudio 3D (Life Technologies 4489084). Each 
variant was tested in 2-3 replicates. The R program for statistical computing packages’ ggplot2 were 
used to create figures detailing Digital PCR data (Appendix V)
202, 203, 206, 207
. 
Variant Functional Studies  
Luciferase reporter assays were completed in HEK293T by Dr. Nanyue Chen, as described 
previously
2
. Mutation primers and constructs of DEAR1 in pcDNA vectors were created using Stratagene 
Quickchange Lightning Site Directed Mutagenesis according to manufacturer’s protocol (Agilent 210518 
Primer Design Program: http://www.genomics.agilent.com/primerDesignProgram.jsp ; Mutagenesis 
Protocol: http://www.chem.agilent.com/library/usermanuals/Public/210518.pdf ). Wildtype and mutant 
DEAR1 with TGFβ Signal Transduction reporter luciferase plasmids were transfected into 293T cells 
with FuGENE HD according to manufacturer’s protocol (Promega E2311; TM328 
https://www.promega. 
com/~/media/files/resources/protcards/fugene%20hd%20transfection%20reagent%20quick%20protocol.
pdf) . At 24 h after transfection, the cells were lysed in lysis buffer (Promega E1910; https://www. 
promega.com/~/media/files/resources/protcards/dual-luciferase%20reporter%20assay%20and%20dual-
luciferase%20reporter%201000%20assay%20systems%20quick%20protocol.pdf) according to 
manufacturer’s protocol and luciferase activity was measured using a Monolight 2010 luminometer 
(Turner BioSystems). For the 3D culture assays, SKBR3 breast cancer cell lines were transfected with 
the same empty pcDNA or pcDNA plasmid containing wildtype DEAR1 or mutant DEAR1 (R187W or 
R254Q) as used for the luciferase asssays. After transfection and expression of the plasmids were 
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established, the cells were selected by Puromycin exposure for stable expression of the plasmids. Pooled 
stable clones were verified by western and cDNA sequencing. Pooled clones were then grown on 
Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix (Corning 354230) according to 
Debnath et al. 2003 method
239
. Cultures were grown with 5% FBS in RPMI for 10 days. Acini cultures 
were then fixed and immunostained according to Debnath et al. 2003 protocol using an antibody against 
alpha 6 integrin (EMD Millipore CBL458 ), Alexa Fluor 488 Donkey Anti-Rat Secondary Antibody 
(Life Technologies A-21208) and DAPI stain (Life Technologies D1306)
239
. Immunostained cultures 
were then imaged using Nikon 80i Microscope System. 
Results 
Ultra-Deep Targeted Sequencing Reveals High Frequency of Alteration of DEAR1 in DCIS 
Maintenance of polarity and constriction of migration are important in suppressing invasive 
capabilities
153, 240
. Our previous data has indicated an important role for DEAR1 in maintaining polarity 
and restricting TGFβ-mediated EMT2, 131, 220. Moreover, genetic alterations of DEAR1 has been shown to 
be able to alter DEAR1’s ability to regulate these tumor suppressive activities2, 131, 220. Therefore, DEAR1 
variants may play an important role in the progression from DCIS to IDC by their deregulation of 
DEAR1’s regulation of polarity and migration. To better understand DEAR1’s role in DCIS progression, 
ultra-deep targeted sequencing of the DEAR1 locus was completed in 17 Pure DCIS and 17 DCIS/INV 
using the ampliseq panel previously described in chapter 3. Patient characteristics used in this study are 
described in table 7. For the DCIS/INV, the individual lesion components were microdissected and 
sequenced separately in order to understand the concordance rate of genetic variants between the lesions, 
which can potentially provide insight to DCIS’s progression to IDC. Sequencing of Pure DCIS and 
DCIS/INV indicated that 71% of both Pure DCIS as well as DCIS/IDC lesions exhibited variants within 
DEAR1 following stringent filtering (please see methods for details and explanation of variant filtration). 
Sequencing of a 48kb locus encompassing DEAR1 identified of a median of 8.25, 15.3, and 35.9 variants 
per FFPE sample in the Pure DCIS, DCIS component of DCIS/INV, and the invasive component of  
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Clinical Characteristics Lesion Type Characteristic 
Information 
Median Age Pure DCIS  53 years old 
(range 34-85) 
 DCIS with IDC 55 years old 
(range 37-72) 
ER+ Pure DCIS  71% (12/17) 
 DCIS with IDC 94% (16/17) 
PR+ Pure DCIS  59% (10/17) 
 DCIS with IDC 94% (16/17) 
ER-/PR- Pure DCIS  29% (5/17) 
 DCIS with IDC 0% (0/17) 
Grade Status: Grade 1 Pure DCIS  0% (0/17) 
 DCIS with IDC 11% (2/17) 
                           Grade 2 Pure DCIS  35% (6/17) 
 DCIS with IDC 65% (11/17) 
                           Grade 3 Pure DCIS  65% (11/17) 
 DCIS with IDC 24% (4/17) 
  
 
Table 7- Patient Characteristics of Sampled Pure DCIS and DCIS with IDC Components. Table 
contains the information of age, hormone status, and nuclear grade for those samples sequenced 
with the targeted DEAR1 sequencing panel.  
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Figure 7- Variant Counts Per Sample in DEAR1 in DCIS.  A-E) Figures indicates the range and 
median of variants within the (A) 48kb locus sequenced, (B) 48kb locus sequenced zoom, (C) 
37kb locus of DEAR1, (D) 37kb locus of DEAR1 zoom , and (E) when C>T and G>A variants, 
often associated with formalin fixation in FFPE samples, are removed. F-H) Figures indicates 
the range and median of variants within the variants within Pure DCIS (F), DCIS component of 
DCIS/INV samples (G), Invasive component of DCIS/INV (H) when comparing the 48kb locus 
sequenced, the 37kb locus of DEAR1, and when C>T and G>A variants are removed. Statistical 
significance was established by a one-way Analysis of Variance (ANOVA). 
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DCIS/INV, respectively (no statistical difference between groups) (Fig. 7a and b). When focusing solely 
on the 37kb DEAR1 gene through the exclusion of the 11kb  intergenic region 5’ to DEAR1, the median 
variant count per sample was 7.6, 12.6, and 30.8 in the Pure DCIS, DCIS component of DCIS/INV, and 
the invasive component of DCIS/INV, respectively (no statistical difference between groups) (Fig. 7c 
and d). However, a large degree of the variants in the FFPE samples were transitions consisting of C<T 
or G>A alterations (52 variants in Pure DCIS, 187 and 465 variants in the DCIS and invasive lesions, 
respectively, in DCIS/INV samples). C>T and G>A transitions are known to be enriched in samples 
undergoing formalin fixation as this process can cause cytosine deamination, inducing the transition
218
. 
When C<T and G>A alterations were removed from the variant count, the median number of variants per 
sample was quite reduced. Specifically, the median variant count per sample in the 37kb DEAR1 gene 
was 4.6, 1.2, and 3.5 in the Pure DCIS, DCIS component of DCIS/INV, and the invasive component of 
DCIS/INV, respectively (Fig. 7e). Statistically significant or near significant reductions in variant counts 
per sample after the removal of C>T and G>A were seen for all lesion types (Fig.7f-h). Interestingly, 
after removal of the C>T and G>A variants, there was a statistically significant difference in the variant 
count per sample between the pure DCIS and the DCIS component of the DCIS/INV samples (p=0.0009) 
(Fig.7e). Analysis by one-way ANOVA showed no statistical difference in variant counts per sample 
between the full 48kb locus sequenced and the 37kb region encompassing DEAR1 for the pure DCIS as 
well as the DCIS and invasive components of samples with concurrent adjacent lesions (Fig.7f-h). 
DEAR1 exhibited variants in all protein domains as well as the regulatory UTR regions (Fig. 8, Table 8 
& 9; Appendix X). Some of these variants did occur at a moderate to high variant frequency (Table 10; 
see further discussion on pg 115). However, most of the variants across sample types were of intronic 
origin (80-88.5%) as expected. Digital PCR was used to validate a selection of exonic variants. 
Validation of 9 variants showed a 78% validation rate (7/9) and a 0.962 correlation rate between the 
variant allele frequencies observed from sequencing and those shown by digital PCR (Fig. 9).  
Sequencing of Pure DCIS Indicated the Presence of DEAR1 Exonic and Regulatory Variants  
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Figure 8- Distribution of Variants in DEAR1. A) Figure shows the frequency of variants within 
each region of DEAR1. B) Representation to functional classification of the variants in DEAR1. 
A 
B 
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Sample Mutation % Allele 
frequency 
Validated Area Within 
DEAR1 
PD03 D421G 4%  SPRY domain 
PD04 D240N 7%  Coiled coil 
domain 
PD05 D106V 4% Yes B-box domain 
 D421G 7% Yes SPRY domain 
PD06 D421G 6%  SPRY domain 
PD07 D106V 4% Yes B-box domain 
PD08 D106V 4% Yes B-box domain 
PD12 R187W 13% Yes Coiled coil 
domain 
 D240N 81% Yes Coiled coil 
domain 
 
 
 
 
 
 
 
 
 
Table 8- Full List of DEAR1 Variants in Pure DCIS FFPE Samples Within Exonic and Regulatory 
Regions. Table contains the list of variants in each Pure DCIS sample occurring in the exonic or regulatory 
regions of the gene, indicating the allele frequency, validation status, and region of DEAR1 variant is 
contained in.  
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Sample Mutation Lesion Type % Allele 
frequency 
Validated Area Within DEAR1 
DCIS of 
DCIS/ 
INV 
Invasive 
of DCIS/ 
INV 
D01 G349G X  4%  SPRY domain 
 T>C 
Chr1:33648206 
 X 16%  Upstream; 
GATA3/KAP1  
Binding site 
D04 R384C  X 3%  SPRY domain 
D05 T>C 
Chr1:33612419 
X X 3%DCIS 
15%INV 
 Upstream; 
GATA3/KAP1  
Binding site 
 E183K  X 4%  Coiled coil domain 
 
 L185L  X 3%  Coiled coil domain 
 A202A  X 4%  Coiled coil domain 
 Q233K  X 3%  Coiled coil domain 
 
 L255F  X 4%  Exonic 
 V356M  X 6%  SPRY domain 
 T361S  X 9%  SPRY domain 
 R374C  X 5%  SPRY domain 
 G376D  X 4%  SPRY domain 
 F386F  X 7%  SPRY domain 
 W404*  X 3%  SPRY domain 
 R410Q  X 3%  SPRY domain 
 c.*676AGGG> 
TCCC 
 X 43%  3’UTR (mir10b) 
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Sample Mutation Lesion Type % Allele 
frequency 
Validated Area Within DEAR1 
DCIS of 
DCIS/ 
INV 
Invasive 
of DCIS/ 
INV 
D06 R184R X  3%  Coiled coil domain 
 
 E370K X  4%  SPRY domain 
 S23S  X 4%  RING domain 
 G179D  X 4%  Coiled coil domain 
 
 V364M  X 4%  SPRY domain 
 G376S  X 3%  SPRY domain 
 I378M  X 3%  SPRY domain 
D08 G>A 
Chr1:33648250 
X  15%  Upstream; 
GATA3/KAP1  
Binding site 
D10 c.*676AGGG> 
TCCC 
 X 22%  3’UTR (mir10b) 
D11 E77E X  3%  Exonic 
 G257E X  3%  Exonic 
 N395N X  3%  SPRY domain 
 I128I  X 3%  Coiled coil domain 
 D130D  X 16%  Coiled coil domain 
 V336M  X 3%  PRY domain 
 R374H  X 5%  SPRY domain 
 G376D  X 4%  SPRY domain 
 S383N  X 3%  SPRY domain 
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Sample Mutation Lesion Type % Allele 
frequency 
Validated Area Within DEAR1 
DCIS of 
DCIS/ 
INV 
Invasive of 
DCIS/ INV 
D11 R410W  X 3%  SPRY domain 
D12 G>A 
Chr1:33648250 
X X 80%DCIS 
6%INV 
 Upstream; 
GATA3/KAP1  
Binding site 
 Q19* X  4%  RING domain 
 L208L  X 5%  Coiled coil domain 
 L420L  X 3%  SPRY domain 
D13 T>C 
Chr1:33648206 
 X 29%  Upstream; 
GATA3/KAP1  
Binding site 
 D130D  X 6%  Coiled coil domain 
  
c.*676AGGG> 
TCCC 
 X 68%  3’UTR (mir10b) 
D14 V364V X  3%  SPRY domain 
 
 
 
Table 9- Full List of DEAR1 Variants in DCIS FFPE Samples with Adjacent Invasive Components in 
Exonic and Regulatory Regions. Table contains the list of variants in each sample, indicating the lesion 
type each variant was found in as well as the allele frequency, validation status, and functional region.  
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Sample Mutation Lesion Type % Allele 
frequency 
Validated Area of 
DEAR1 Pure  
DCIS 
DCIS of 
DCIS/ 
INV 
Invasive  
of DCIS/ 
INV 
PD12 R187W X   13% Yes Coiled coil 
domain 
 D240N X   81% Yes Coiled coil 
domain 
D01 T>C 
Chr1:33648206 
  X 16%  Upstream; 
GATA3/KAP1  
Binding site 
D05 T>C 
Chr1:33612419 
 X X 3%DCIS 
15%INV 
 Upstream; 
GATA3/KAP1  
Binding site 
 c.*676AGGG> 
TCCC 
  X 43%  3’UTR 
(mir10b) 
D08 G>A 
Chr1:33648250 
 X  15%  Upstream; 
GATA3/KAP1  
Binding site 
D10 c.*676AGGG> 
TCCC 
  X 22%  3’UTR 
(mir10b) 
D11 D130D   X 16%  Coiled coil 
domain 
D12 G>A 
Chr1:33648250 
 X X 80%DCIS 
6%INV 
 Upstream; 
GATA3/KAP1  
Binding site 
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Sample Mutation Lesion Type % Allele 
frequency 
Validated Area Within 
DEAR1 
Pure  
DCIS 
DCIS of 
DCIS/ INV 
Invasive  
of DCIS/ 
INV 
D13 T>C 
Chr1:33648206 
  X 29%  Upstream; 
GATA3  
Binding site 
  
c.*676AGGG> 
TCCC 
  X 68%  3’UTR 
(mir10b) 
 
 
 
 
 
 
 
Table 10- List of High Variant Frequency (>10%) DEAR1 Variants in Functionally Important Areas. Table 
contains the list of variants in each sample that occurred at a higher allele frequency greater than 10%, 
indicating the lesion type each variant was found in as well as the validation status and functional region.  
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Figure 9- Validation of DEAR1 Variants Found Through Ultra-Deep Targeted Next 
Generation Sequencing by Digital PCR. A number of exonic variants found in sequencing 
were verified through the use of a TaqMan based digital PCR assay. Figure details the 
correlation of the observed frequency of the spike-in to the observed frequency detected by 
digital PCR. 
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Figure 10- DEAR1 Experiences Exonic Variants in DCIS of Which Few are Shared 
Within Lesion Components. Mutations mapper from cBio was used to visualize exonic 
variants from A) Pure DCIS and matched B) DCIS and C) Invasive components. D) Venn 
Diagram indicated the number of shared and private variants within samples. 
 
A 
B 
C 
D 
BBC 
BBC 
BBC 
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For those variants not harbored in the intron, Pure DCIS samples exhibited a frequency of 12% of 
variants within the 3’ UTR region and 8% of variants contained in the exons. The exonic variants within 
the pure DCIS samples tended to be repetitive in nature with multiple samples exhibiting missense 
variants at the same codon. Moreover, the missense variants were overwhelmingly predicted to be 
deleterious by PolyPhen2 and/or SIFT, with most (64%) showing a consensus by both functional 
prediction tools (Fig. 8b). Interestingly, no synonymous or benign variants were found in the pure DCIS 
samples. However, these samples contained notable exonic variants previously found by sequencing 
efforts completed by our lab and by The Cancer Genome Atlas (TCGA) project. These include missense 
variants D106V, R187W, D240N and D421G (Fig. 10a). Variants introducing the D106V missense 
mutation (c.317A>T), which is localized to the zinc finger domain in exon 1, were confirmed to be found 
in 3 Pure DCIS samples and was formally found in an invasive breast tumor from another cohort
2
. The 
D106V variant existed sub-clonally manner within the samples as the variant allele frequency within the 
tumors was about 4%. Another variant, the D421G c.1262A>G variant within the exon 5 Spry domain, 
was discovered and confirmed as another sub-clonal variant (variant allele frequency of 4-7%) in 3 Pure 
DCIS samples. The D421G variant was previously reported by TCGA (as accessed by cBIO) to also 
have existed in a CIMP-high, stage IIIC rectal cancer patient who also exhibited a low level gain of 
DEAR1
131, 145, 146, 241
. Further, a R187W (c.559C>T) confirmed somatic variant was discovered at a 
variant allele frequency of 13% in a luminal early onset (47 years old at time of diagnosis) patient from 
the Pure DCIS cohort. This same variant was also previously found in a metastatic breast cancer cell line 
(21MT) derived from an early onset patient as well as an invasive breast cancer tumor from another 
cohort 
2, 131
. The R187W mutation, harbored within the B-Boxed Coiled coil (BBC) domain of exon 3, 
was earlier reported by our lab to be important for abnormal acinar morphogenesis in the 21MT cell 
line
131
. Excitingly, the early onset patient who exhibited the R187W variant also contained a potential 
germline missense variant, c.718G>A D240N, which resided in the same domain as the R187W variant. 
Presence of the germline status of the variant was confirmed by droplet digital PCR from a matched 
normal adjacent breast tissue. Further, the D240N variant was also found to occur as a somatic variant in 
another pure DCIS patient who exhibited a more typical age of onset (60 years of age). The identification 
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of germline variants, especially exonic variants, with DCIS further supports the role of DEAR1 as a 
classic tumor suppressor that is important in breast cancer.  
Spectrum of Variants Found in DCIS with Invasive Components is More Complex than Pure DCIS and 
Share Relatively Few Variants between the Adjacent in Situ and Invasive Lesions 
Sequencing of DCIS lesions associated with IDC components revealed a much more complex 
spectrum of variants (Fig. 10b/c). Strikingly, the DCIS/INV samples showed a great reduction in the 
frequency of variants within repetitive codons (13%; 4/30 codons) in comparison to the pure DCIS 
samples (75%; 3/4 codons) (Fig. 10a/b). Interestingly, these repetitive codon variants happened to be 
private only to the invasive components of the DCIS/INV samples. Variants within the DCIS/IDC 
samples also had a greater diversity in the type of mutation and in their location within the gene. For 
example, the DCIS/INV samples contained variants in all domains of DEAR1 and included missense, 
nonsense and synonymous variants, whereas the Pure DCIS samples were not found to contain variants 
in the RING and PRY domains of DEAR1, and only consisted of missense variants (Fig 8b). Further, no 
single variant was found to coexist in both Pure DCIS and in DCIS/INV samples. 
When focusing only on the DCIS samples with an adjacent invasive lesion, these variants were 
for the most part, surprisingly, private to the individual components of the lesions. Only 25 of 712 
variants found to be shared between the DCIS and invasive components within the DCIS/INV samples 
(Fig 10d; Appendix XI). The vast majority of the variants common between the two lesion components 
were variants deep within the intronic region of the gene (17/25). These intronic variants were not 
centered in any one area but rather spread throughout the gene’s non-coding sequence.  The other 
variants shared between the lesions (8/25) were in areas upstream of the promoter of DEAR1. 
Interestingly, no exonic or regulatory UTR variants were shared between the two components. In 
comparing the variants private to each lesion component, variants harbored within the DCIS component 
were largely synonymous (63%), whereas synonymous variants played a much smaller role in the variant 
distribution of the invasive component (32%) (Fig. 7d). Further, the invasive component of the DCIS 
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lesions exhibited a larger frequency of missense variants within the exonic region featuring the SPRY 
domain as well as in the region between the BBC and PRY domains compared to the DCIS component. 
Overall, variants predicted to be deleterious occurred at a much higher frequency with the invasive 
components (54%) when compared to the matched DCIS components (37%) (Fig. 8b).  Sequencing of 
the invasive lesions indicated that 64% of the total variants resulted in missense changes, of which 78% 
of these missense variants (50% of total) were predicted to be deleterious by at least one of the 
deleterious prediction tools tested. In contrast, only 24% percent of the DCIS component variants were 
missense variants, yet a 100% of these missense variants were predicted to be deleterious. Therefore, 
though the adjacent invasive lesion showed a higher frequency of missense variants in DEAR1 in 
general, these variants displayed a varied ability to be tolerated, in contrast to missense variants in the 
DCIS component of the samples, of which all were predicted to be deleterious. Two codons found to be 
mutated in the sequencing of DCIS with invasive components were previously reported in Catalogue Of 
Somatic Mutations In Cancer (COSMIC). The mutation E370K, which was discovered as a private 
variant with the DCIS component, was also previously reported in endometrial cancer by the TCGA. 
Further, our sequencing indicated variance at codon 383 inducing a serine to asparagine codon change 
that was restricted to the invasive component of the particular sample. This codon is the same DEAR1 
residue shown to undergo a missense mutation by Abaan OD et al. (S383I) in the large intestine cell line 
HCT-15
242
. Further, the first reported DEAR1 nonsense variants described in breast cancer were 
discovered. These nonsense variants were restricted to DCIS/INV samples (Fig 10 b/c). The two 
nonsense variants were found in two different samples and occurred as small sub-clonal fractions (3-4% 
variant allele frequency), with both being private to either the DCIS or invasive component of the 
lesions. The nonsense variant harbored in the DCIS component occurred in an early onset patient (age 48 
years old at diagnosis) at codon 19 in the RING finger domain of exon 1. The nonsense variant within 
the IDC component of another sample, occurred in an early onset patient (age 44 years old at diagnosis) 
at codon 404 in the SPRY domain of exon 5. The restriction of the nonsense variants to only early onset 
samples may hint at a higher propensity for these types of variants to occur in early onset patients. The 
sequencing of more early onset samples are needed in order to determine if there is a statistical 
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association between DEAR1 nonsense variants and age of onset. Moreover, sequencing data of the 
DCIS/INV samples showed four DEAR1 residues exhibiting alteration in more than one sample, with all 
four residues being restricted to the invasive portion of the tumors. Three of the four codons repetitively 
altered were missense variants shown to occur at 3-5% variant allele frequency. All three variants 
(R374C, G376D/S, R410Q) were predicted to be of deleterious nature 
172, 173
. Variants in the c.376 and 
c.410 amino acids were indicated as having the strongest deleterious scores of the codons exhibiting 
variants in multiple samples (PolyPhen2: 1.00 and SIFT: 0.00) 
172, 173
.  Further, three samples showed the 
presence of a c.*676AGGG>TCCC variant in the 3’UTR of DEAR1, in a putative binding site of 
miR10b. All c.*676AGGG>TCCC variants were restricted to the invasive component of their samples 
and occurred at a relatively high variant allele frequency (22-68%). Additionally, variants that occurred 
upstream of DEAR1’s 5’UTR showed a slight enrichment in areas shown by the ENCODE project to be 
binding sites for the GATA3 (5/17 samples) and KAP1 (also annotated as TRIM28) (4/17 samples) 
transcription factors. These variants within the transcription factor binding sites existed at higher variant 
allele frequencies (8-29%).  These variants may indicate the importance of GATA3 and KAP1 in 
regulating DEAR1. GATA3 and KAP1 have both been associated with the regulation of migration and 
therefore, alteration of the transcriptional regulation of DEAR1 by these transcription factors may 
mediate GATA3 and KAP1’s pro-migratory capacity seen in breast cancer243, 244. The invasive 
components of the DCIS lesions were shown to exhibit multiple variants in both the coding and 
regulatory regions of DEAR1, many of which were predicted to be functionally important as well as 
restricted to the invasive component of the DCIS/INV samples. Therefore, the presence of these 
deleterious variants restricted to invasive lesions may indicate the significance of these particular 
variants within DEAR1 to the invasive phenotype exhibited by these lesions.  
DEAR1 Exhibits Functional Mutations in DCIS as Shown by Functional Assays 
In order to understand the role that the variants found in DEAR1 play in DCIS and how they 
may functionally affect the cell, functional assays to assess the deleterious nature of particular mutations 
were completed.  As mentioned previously, a missense variant in 3 Pure DCIS samples (c.317A>T), 
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which induced a codon change at codon 106 from Aspartic Acid to Valine (D106V) was identified. This 
variant was located within exon 1, proximal to the RING finger domain. RING finger domains are 
known to be often critical to the E3 ligase activity exhibited by TRIM family proteins. As such, the 
RING finger has been shown to be pivotal for the DEAR1 E3 ubiquitin ligase activity against TGFβ 
pathway member SMAD3
2
. Due to the proximity of the D106V variant to the RING finger (40 amino 
acids downstream from the 3’ end of the RING finger), it was determined if this missense variant could 
affect DEAR1’s ability to regulate TGFβ signaling. To assess this, a D106V mutant DEAR1 plasmid was 
produced through site directed mutagenesis and transient transfected with a plasmid containing the 
luciferase response element reporter for TGFβ signaling into 293T cells. In the presence of TGFβ, the 
D106V variant was found to greatly reduce DEAR1’s known ability to negatively regulate SMAD3 
dependent TGFβ signaling by increasing SMAD3 transcription factor activity over 4-fold, compared to 
wild-type DEAR1 (p=.04) (Fig. 11)
2
. The effect seen on TGFβ signaling transduction by D106V was 
similar to the effect seen upon deletion of the entire exon 1 of DEAR1. In contrast, a pancreatic cancer 
variant, R254Q, harbored with the BBC domain of DEAR1 was not shown to have any effect upon 
DEAR1’s regulation of TGFβ signaling. Therefore, the D106V variant may be important in mediating 
increased TGFβ induced signaling, which can be potentially important in promoting migration and 
invasion in DCIS in the presence of TGFβ.  
Further, sequencing efforts also revealed the presence of a confirmed somatic missense variant 
introducing a codon change from arginine to tryptophan at codon187 (R187W c.559C>T), harbored 
within the BBC domain of exon 3 in a luminal early onset patient from the Pure DCIS cohort. As 
previously stated, this variant occurred at a relatively higher allele frequency and was also previously 
implicated in IDC 
2, 131
. The R187W mutation has been shown to be important for the deregulation of 
acinar morphogenesis in the 21MT cell line, through genetic complementation
131
. To further confirm 
R187W’s ability to affect DEAR1’s regulation of acinar morphogenesis, SKBR3 breast cancer (HER2 
positive) cells stably expressing mutant DEAR1 were used for further assessment in 3D culture. The 
R187W mutation construct was created by site directed mutagenesis. Pooled stably expressing SKBR3 
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cell lines were generated through transfection of the mutant plasmid and G418 selection. SKBR3 cell 
line was chosen due to the absence of detectable protein expression of DEAR1 as well as DEAR1 
mutation, as determine by Western and Sanger sequencing, respectively. Moreover, this cell line is 
known to exhibit altered polarity and abnormal acinar morphogenesis in 3D culture
245
. Upon culturing 
the SKBR3 mutant DEAR1 cell lines in 3D culture, the clone exhibiting the R187W variant failed to 
revert the abnormal acinar morphology of SKBR3 breast cancer cell lines in contrast to the ability of 
wild-type DEAR1 to organize the SKBR3 acini (Fig. 12). The minimal degree of acinar organization 
resulting from the expression of R187W was similar to the degree seen in those cells expressing an 
empty vector plasmid. Further, in comparison, another variant construct reflecting the pancreatic cancer 
DEAR1 mutation R254Q that occurs in the same DEAR1 domain as R187W, was stably expressed in 
SKBR3 and showed comparable minimal abilities to revert abnormal acinar organization. The ability of 
two variants in the BBC domain to subvert DEAR1’s regulation of acinar morphology may potentially 
indicate the importance of the BBC domain in maintaining normal acinar morphology. In all, results 
indicated that a subset of the variants found in DEAR1 during the sequencing of DCIS samples are 
functional and can have profound effects on DEAR1’s regulatory capacity of important signaling events 
and cellular phenotypes. 
 Discussion 
Diagnosis of DCIS has greatly increased in recent years due to the upsurge of mammographic 
findings
221
. The lack of biomarkers able to stratify DCIS patients at greater risk for progression has led to 
a large variance in the methods used to treat these patients, leading to the possibility of both over-
treatment and under-treatment. One of the most important clinically relevant questions regarding breast 
cancer is deciphering the molecular relationship between DCIS and IDC as well as identifying drivers of 
DCIS progression which are able to predict invasive recurrence. Currently, no reliable and clinically 
validated biomarkers are available that predict an invasive recurrence after surgical treatment. Multiple 
histological markers have been proposed to be potential recurrence markers, including tumor size,  
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Figure 11- Mutation of DEAR1 Affects TGF-β and SMAD3 Signal Transduction. This figure shows the 
effect of tumor-derived mutation of DEAR1 on TGF-β signal transduction. Various DEAR1 mutations found 
by sequencing of breast and pancreatic cancer (D106V, R254Q) along with artificial deletion of the 1
st
 exon 
of DEAR1 (ΔE1) were co-transfected into HEK293T cells with CAGA12 reporter. After 24 hours, cells were 
treated with or without TGF-β (1 ng/mL) for 24 hours and luciferase activity was measured. Figure taken 
from Chen et al. 2013
2
. 
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Figure 12- DEAR1 Variants Can Effect Acinar Morphology in SKBR3 in 3D Culture. 
SKBR3 cells stable expressing empty plasmid control, wildtype or mutant DEAR1 in a 
pooled manner were grown in 3D culture and immunostained with Alpha-6-integrin (red) 
and DAPI (blue). Example of disorganized, grape cluster like nature of SKBR3 cells grown 
in 3D culture shown in A. A proportion of the cultures exhibited a more organized 
morphology shown in B. C) Quantification of organized population of SKBR3 stable cells.  
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nuclear grade, and surgical margins
246
. One of the more promising molecular biomarker studies, the 
DCIS Score, a derivative of the OncoType-DX predictive biomarker test, was shown to be able to use the 
gene expression signature of 7 cancer genes to predict recurrence in the non-randomized, prospective, 
multi-center trial ECOG E5194
247
. It is important to note that the DCIS Score was tested in a relatively 
small trial and under specific patient selection criteria. This gene expression biomarker panel study is 
promising but does have its limitations and has not been currently validated in a large clinical trial. 
Moreover, the gene expression signature used in the DCIS Score has not resulted in a better understand 
of the biology of the disease. Therefore, it is important to continue to search for biomarkers which not 
only inform on recurrence potential but also on the mechanisms of recurrence, of which can be important 
for future therapeutic developments.  In accordance with this, our lab has sought to understand the 
molecular and genetic role of DEAR1 in DCIS progression as well as its possible ability to act as a 
prognostic marker for DCIS. DEAR1, a dominant regulator of polarity and acinar morphogenesis, is 
known to undergo downregulation at the protein level during the transition from normal breast ductal 
tissue to DCIS
131
. Moreover, DEAR1 is an E3 ubiquitin ligase for SMAD3, a key signaling molecule in 
TGFβ pathway driven EMT2, 220. As loss of polarity and acquisition of invasive capacity are known 
hallmarks in tumor acquired EMT, it is possible that DEAR1 can play a role in the progression of DCIS 
and recurrence of the disease. As such, the expression of DEAR1 was found in a cohort of early onset 
breast cancer to be associated with a significantly higher rate of recurrence free survival
131
. It is plausible 
that alteration of DEAR1 expression or loss of its normal function via mutations may act as a driver in 
recurrence. In accordance, DEAR1 has been shown previously to be mutated and chromosomally loss, by 
both heterozygous and homozygous deletions, in multiple epithelial cancers including invasive breast 
cancer
2, 131
. With this knowledge, it was proposed that genetic alterations of DEAR1 may play an 
important role in DCIS progression. To determine this, a custom Ampliseq panel was designed to target 
the genomic locus encompassing DEAR1. This panel was used to complete ultra-deep targeted 
sequencing of DEAR1 on the Ion Torrent PGM and Proton platforms. Sequencing of Pure DCIS and 
DCIS/INV samples with this custom Ampliseq panel found that DEAR1 is mutated in 71% of DCIS. 
Other genetic drivers known to be mutated in DCIS, however at lower frequencies, include PI3KCA 
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(50%, n=12), p53 (21.6%, n=70), BRCA1 (0.8%, n=369), and BRCA2 (2.4%, n=369)
248-250
. The degree to 
which DEAR1 is altered in DCIS highlights the potential importance of genetic alterations in this tumor 
suppressor in early breast cancer. It is important to note, however, that the techniques utilized in these 
studies did not have the high sensitivity that the ultra-deep targeted next generation sequencing (NGS) 
method used in this study had. The application of ultra-deep NGS allows one to see rare sub-clonal 
populations that may be missed by other sequencing platforms, like Sanger, or other lower coverage 
applications of NGS, like whole genome or exome sequencing, due to the high depth of coverage able to 
be achieved. This is also a potential reason for the DEAR1 genetic alteration frequency being 
significantly higher in our cohort versus sequencing data of IDC from the TCGA cohort (0.1%; n=981) 
as well as our own previous sequencing data of IDC (13%; n=55)
131, 145, 146
.  
The high degree of sensitivity able to be achieved by ultra-deep targeted sequencing can be 
important for identifying potentially clinically relevant sub-clonal variants. The use of ultra-deep NGS 
for sequencing DEAR1 has revealed that many of the variants harbored within the gene occur as rare 
(<10% variant allele frequency) sub-clonal events. Current debate exists concerning the clinical and 
functional importance these rare sub-clone variants. It has been suggested that the high degree of intra-
tumor heterogeneity and presence of rare sub-clonal populations can serve as a method to increase tumor 
survival by making the tumor able to withstand different environmental and therapeutic assaults via its 
high degree of genetic diversity, a known population based survival mechanism within ecology
195
. 
Further, evidence has shown that genetically demarcated sub-clones can have differential functional and 
morphological features
251
. Multiple factors can influence the determination of which sub-clone acquires 
dominancy, including therapeutic applications and the acquisition of other genetic drivers that give the 
clone a large functional advantage. It is the ability of the tumor, by the presence of these sub-clonal 
populations, to be in a constant state of flux that allows the tumor to have a large advantage towards 
survival and progression.  
Though ultra-deep NGS represents a novel method for detecting these rare sub-clones, a trade-
off exists as the high degree of sensitivity able to be achieved by this method can allow errors to appear 
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to be valid variants which may be introduced during library construction or sequencing. Therefore, due 
to the use of ultra-deep targeted sequencing to find rare sub-clonal mutations within DEAR1, stringent 
variant filtering techniques was utilized to reduce the degree of errors that exist within the data (see 
methods for detailed filtering techniques). Multiple techniques for variant filtering stringency were tested 
in order to find the technique that minimized the degree of possible erroneous variant calls while still, in 
keeping with the discovery nature of the project, maximized the inclusion of variants than can be 
potentially deleterious (see Appendix III for differential filtering strategies tested and their effect on 
variant counts). Use of the clinically applicable requirement of at least 1,000x coverage at the variant 
locus reduced the possibility of spurious variant calls due to areas of low coverage while the requirement 
that the variant needed to obtain at least 60 supporting reads allowed for a high degree of substantiation 
of the variant yet still permitting the identification of sub-clonal variants that could be potentially 
clinically important. Further, variant calls were filtered against data compiled by the 1000 Genome’s 
project to remove any catalogued Single Nucleotide Polymorphisms (SNP) from the final variant list as 
common polymorphisms are less likely to be pathogenic
204
. Use of the population variation data 
assembled by the 1000 Genome’s project to assess the pathogenicity based on the variant frequency in a 
control population has been encouraged by the American College of Medical Genetics and Genomics 
(ACMG) and the Association for Molecular Pathology (AMP)
252. The 1000 Genome’s project 
theoretically accounts for all SNPs that occur in at least 1% of the populations studied, as stated by the 
project (www.1000genomes.org). However, a small number of variants that are known to occur in less 
than 1% of the population are still harbored within the data. Therefore, variant filtration to remove 
common population variants from the sequencing data by filtering against variants catalogued by the 
1000 Genomes data will not only remove common SNPs but also may remove rare variants that could 
possibly be pathogenic. Due to this, variant files were also assessed to determine the presence of variants 
annotated by the 1000 genomes project which were known to occur in less than 1% of the matched 
ethnic population of the clinical sample. Variants matching these criteria were retained in the final 
variant table. Further, half of the clinical samples used in this sequencing study also had matched normal 
samples, either normal adjacent breast or lymph tissue, sequenced as well. Germline variants were 
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removed from the final variant table for clinical samples in which the matched normal was able to be 
sequenced. For those clinical samples for which a matched normal quality DNA sample was unable to 
acquired, suspected potential germline variants were unable to be removed due to the lack of 
confirmatory evidence to their germline status. Suspected germline variants were identified by allele 
frequencies around 50% (heterozygous) or 100%. These potential germline variants have been marked in 
the full variant table within the appendix (Appendix X). However, other potential germline variants may 
exist that cannot be identified by the canonical heterozygous and homozygous allele frequencies, as 
variances in ploidy and heterogeneity within tumors can affect the variant allele frequencies identified by 
sequencing. For example, if a germline heterozygous variant undergoes loss of heterozygosity in 30% of 
tumor cells sequenced, the variant will be present in 65% of sequencing reads of the tumor bulk rather 
than the previous 50% variant allele frequency that was present at the germline. Therefore, for those 
samples in which a normal was unable to be sequenced, variants identified in these samples may include 
germline variants that were unable to be extracted.  
The variant spectrum found in Pure DCIS and DCIS with invasive components showed that 
the nature of the variants found in the lesion types are quite different. Pure DCIS lesions exhibited few 
exonic variants and of those that existed, the variants seemed to affect a limited number of sites. 
However, the DCIS associated with an adjacent invasive lesion showed a high degree of variability not 
only in the functionality of the variants but also in the degree of sites affected by variation. The increase 
in the number of exonic variants in the samples of DCIS with an invasive component compared to the 
Pure DCIS could be due to multiple factors. It is possible that DCIS lesions associated with invasive 
components experience different mutational processes. Both the DCIS and the invasive component of the 
DCIS/INV samples exhibited an 89-91% reduction in mean variant counts after the removal of C>T and 
G>A variants versus 40% reduction in the Pure DCIS. A larger enrichment of the C>T transition in the 
DCIS with invasive component may indicate a role in mutational mechanisms that enrich for these 
transitions in the pathogenesis of DCIS and its associated invasive lesion. In support of this idea, 
multiple proposed mutational signatures, many of which are associated with C>T transitions, have been 
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linked to different mutational mechanism like aging, APOBEC editing, UV radiation, Temozolomide 
treatment, and mismatch repair defects
253, 254
. Some of these signatures have been associated with certain 
subgroups of cancer, like the Signature B single-nucleotide substitution processes as described by 
Stephens et al. 2012 and its association with ER+ breast tumors 
255
. Moreover, these samples also 
underwent LCM, which utilizes a UV laser to assist in the removal of the tissue. The use of the UV laser 
may have induced C>T variants in DEAR1 in those cells exposed to the laser and the small fraction of 
these  associated variants could have been detected due to the use of highly sensitive ultra-deep 
sequencing. This is supported, as previously mentioned, by the reduction of variant counts per sample 
when C>T variants are removed, which are also known to be the predominant substitution associated 
with UV A exposure (Fig 7b). Further, it is important to note that the median rate of follow-up for our 
Pure DCIS samples was about 5 years. Recent evidence suggests that the rate of recurrence is twice as 
high within 15 years post-primary tumor development than at 5 years
256
. Therefore the possibility cannot 
be ruled out that the Pure DCIS lesions used in this study were later diagnosed with an invasive 
recurrence.  
For those variants that were found by our ultra-deep targeted sequencing of DEAR1, many of 
these discovered were predicted by PolyPhen2 and SIFT functional prediction tools to be deleterious. 
The potential functionality of these variants was also supported by molecular functional studies 
completed with these variants showing their importance in maintaining acinar morphology and 
regulation of TGFβ-induced signaling. As previously mentioned, our lab has identified DEAR1 as an E3 
ubiquitin ligase for TGFβ pathway member SMAD3, promoting SMAD3’s proteosomal degradation2. 
Multiple TGFβ antagonists are currently in various phases of development, such as the TGF-β 
neutralizing antibody, 2G7, and antisense TGFβ oligonucleotide, AP 12009, which are in phase III 
clinical trials
257
. DEAR1 mutation, such as the D106V variant, or deletion of the locus, which is known to 
be common in multiple cancers including invasive breast cancer, may be able to act as a predictive 
biomarker and thus stratify patients for the efficacy of therapies targeting the TGFβ pathway.  
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Our sequencing efforts of DCIS have uncovered not only novel variants, but also variants that 
have been previously described by other sequencing efforts to occur in cancer, including breast cancer. 
The first nonsense variants in DEAR1 in breast cancer were also described herein. Interestingly, the 
nonsense variants were restricted to those DCIS samples associated with an invasive component. 
Nonsense variants are essentially considered to be loss of function variants as they produce a codon 
change that instills a premature coding stop. The vast majority of transcript products containing nonsense 
variants are degraded via nonsense-mediated mRNA decay as a quality control method employed by the 
cell. These variants are one example of how the tumor cell can cause loss of DEAR1 expression, thereby 
allowing for deregulation of the pathways that DEAR1 regulates. Further, the detection of repetitively 
altered codons in DEAR1, occurring in both Pure DCIS and DCIS associated with invasive components, 
has been described. The recurring nature of these variants could indicate their importance in breast 
cancer. The repetitive variants found in our Pure DCIS samples excitingly had been previously described 
in past sequencing efforts in cancer, including two that are known to occur in breast cancer. Moreover, 
the incidence of recurring variants in DCIS associated with an adjacent invasive component were found 
to be, interestingly, restricted only to the invasive portion of the lesion and were all within the SPRY 
domain of exon 5. This data could suggest not only the significance of these particular variants in 
invasive breast tumors but also the importance of the SPRY domain in regulating essential pathways in 
IDC. Further work is needed to understand the detrimental effects of these variants and the role they play 
in DCIS.  
Contrary to expectation, the DCIS samples associated with an invasive component shared very 
few variants in common between the in situ and invasive components. If the DCIS progressed according 
to the “branched” model of progression, as described in Kaur et al. 2013, it would be expected to find 
that the vast majority of variants would be shared between the DCIS and invasive components, as has 
been found for copy number alterations in a number of studies
195, 235, 248
 (Fig. 13a). However, our data 
supports a model in which the DCIS and invasive components share a very early ancestor and then  
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Figure 13- Model of DEAR1 Variants Based on DCIS Progression Models. Both branched and 
parallel models of DCIS progression have been proposed. The * indicates where DEAR1 
mutations would be expected in DCIS within each model. As previous work has shown by other 
labs, most chromosomal changes are common between both lesions and are therefore an early 
event in DCIS progression A) This model is representative of the branched model of progression 
with invasive components (IDC) being a direct lineage from DCIS. Our data is unsupportive of 
this model as DEAR1 variants were found to mostly exist as private changes in both DCIS and 
IDC, which is unable to occur if DCIS is a direct ancestor of IDC. B) This model is representative 
of the parallel model of progression with an earlier lesions acting as the common ancestor for both 
the in situ and invasive lesions. In this model, the common ancestor splits off to form both DCIS 
and IDC. Very little variation is expected to be shared between these lesions in this model as the 
DCIS and the IDC continue to progress in independent yet parallel mechanisms, both 
accumulating different genetic alterations after the split. Our data supports this parallel model as 
very few variants in DEAR1 were shared between the two components.   
B A 
127 
 
evolve independently. Due to the minute degree to which DEAR1 variants were shared between the 
DCIS and invasive lesions, the data indicate that the DEAR1 variants mostly occurred after the split from 
the ancestral clone (Fig. 13b). Due to the few number of variants shared between the lesions, conclusions 
regarding DEAR1’s role in progression from DCIS to invasive disease is unable to be determined. 
However, our data seems to support the “parallel” model that was first described by Sontag and Axelrod 
in 2005 describing independent yet parallel evolution of the DCIS and invasive lesions
237
. Their model 
has been empirically supported by data from Newburger et al. 2013, in which they found evidence for 
“parallel” evolution in 2 of the 3 DCIS lesions sequenced, with the DCIS and invasive tumors sharing 
more in common with an earlier neoplasia lesion than with each other
258
. Therefore, future ultra-deep 
sequencing and molecular studies of earlier neoplasia lesions may reveal sub-clones which distinct 
genetic alterations that exhibit an increased invasive potential. The clinical implications of the “parallel” 
model may alter the way that DCIS lesions are currently treated, as the evidence purports that the DCIS 
lesions are not always the lesion of origin that progresses to invasive carcinoma but rather, the potential 
for invasion capacity may exist within a sub-clone of a much earlier cell of origin.  
Our study has described the high rate of existence of sub-clonal variants within an important 
tumor suppressor, DEAR1, including the identification of loss of function variants, in the earliest form of 
breast cancer through the use of ultra-deep targeted sequencing. Sequencing with our targeted 48kb 
Ampliseq panel has also provided evidence for the “parallel” model of the relationship between DCIS 
and IDC. Further studies are needed to definitively identify and empirically show the presence of rare 
sub-clones within an earlier cell of origin, potentially in a very early neoplastic lesion, which may give 
rise to a population with an increased propensity to be invasive. Understanding the nature and 
mechanisms of the sub-clonal populations known to harbor variants in genes important in polarity and 
invasion, which are critical attributes of cells undergoing EMT, may help us to better understand breast 
cancer progression and decipher better way of treating this disease.  
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Chapter 5 
Discussion 
Introduction 
Normal cellular homeostasis is dependent on a delicate balance between the expression of 
genes regulating growth, cell death, and polarity. Interruptions to the balance of these factors can lead to 
dysplasia and potentially the formation of a carcinoma. The importance of these factors are reflected in 
their inclusion as components of the hallmarks of cancer
52
. Combination of genetic alterations including 
deletions and/or loss of function mutations in genes that suppress tumor formation or amplifications 
and/or translocations in genes which promote oncogenesis can act as integral drivers of tumorigenesis. 
The cell has multiple mechanisms to inhibit the process of tumor formation. Broadly, genes important to 
maintaining critical pathways involved in inhibiting growth promotion and invasive capacity are called 
tumor suppressors.  
The classical method of tumor suppressor inactivation was first described by Alfred Knudson 
in 1971
30. Knudson’s two hit model based on Retinoblastoma inactivation describes the requirement of 
alteration to both alleles of a tumor suppressor gene in order to complete its full inactivation and the 
potentiation of tumorigenesis. Twenty-seven years after the description of the two hit model, the 
discovery of haploinsufficient genes, in which loss of only one allele of the tumor suppressor is required 
to inactivate the gene, was reported, changing the paradigm of how tumor suppressors are described
259, 
260
. Tumor suppressor genes can be disabled by multiple mechanisms including chromosomal deletion of 
one or both alleles or inactivating mutations like nonsense or frameshift alterations. Further, epigenetic 
alterations and overexpression of targeting microRNAs have also been described as mechanisms, beyond 
altering the genetic sequence, which can lead to the loss of expression of tumor suppressor genes. 
Besides altering expression of these critical tumor suppressors, another method to modify the regulatory 
nature of these genes is through the existence of single nucleotide changes inducing missense mutations, 
which may alter the ability of tumor suppressor genes to bind to the gene they regulate. No matter the 
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mechanism of inactivating the gene, alteration of tumor suppressors can lead to large cellular changes 
and may affect clinical outcome, as typified by germline mutations in tumor suppressors TAp53, PTEN, 
and BRCA1/2 which can greatly increase the lifetime risk of cancer for these individuals
261-263
. 
The TRIM family of annotated E3 ubiquitin ligases, though mostly known for their tumor 
promoting activities, contain noted tumor suppressors, like PML (TRIM19) which has been shown to be 
important for the promotion of DNA fidelity by its recruitment of vital DNA repair factors to nuclear 
bodies after DNA damage and cellular stress
264
. Examples of other members associated with tumor 
suppressive activities in cancer are TRIM13 in chronic lymphocytic leukemia, TRIM33 in chronic 
myelomonocytic leukemia, TRIM24 in hepatocellular carcinoma, and TRIM40 in colorectal cancer (see 
chapter 1 for further descriptions) 
72
. Our lab has previously implicated another important TRIM family 
protein, DEAR1 (TRIM62), as having strong tumor suppressive activities. In invasive breast cancer 
(IDC), DEAR1 expression was significantly associated with local recurrence free survival and was also 
found to be mutated and homozygously deleted
131
. Moreover, Dear1
-/-
 and Dear1
-/+
 mice exhibited late 
onset tumor formation in multiple tissues, including lung, mammary, and lymph, indicating the 
importance of bi-allelic expression of Dear1
2
. Our lab has further elucidate two of the significant 
molecular mechanisms behind DEAR1’s tumor suppressive activities including its role as a master 
regulator of acinar morphogenesis and negative regulator of TGFβ mediated migration in breast cancer2, 
131, 220
  
Discussion 
The work presented herein further implicates DEAR1 as a tumor suppressor through its 
characterization of the genetic mechanisms of DEAR1 inactivation. Our work has described the 
occurrence of chromosomal loss and mutation of the DEAR1 locus in multiple cancers including breast, 
lung, and colorectal adenocarcinomas
2
. Lending support for the clinical importance of chromosomal 
alterations involving the DEAR1 locus in these tumor types was the ability of the Dear1 mouse model to 
recapitulate the tumor spectrum associated with chromosome 1p loss in humans
2
. Loss of chromosome 
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arm 1p is a frequent event in epithelial tumors and has been shown to be clinically relevant, as 1p loss is 
associated with reduced overall survival in breast cancer
142, 143
. As cancer progression occurs by an 
accumulation of multiple genetic alterations, the ability for DEAR1 loss to cooperate with other 
alterations to affect survival was ascertained. Through database analysis, it was shown that the 
heterozygous deletion of the DEAR1 locus could cooperate with amplification of a known epithelial to 
mesenchymal transition (EMT) driver, SNAI2, to predict overall survival in Invasive Breast Cancer 
(IDC), further highlighting the clinical utility of DEAR1 chromosomal alterations
2
. As migration and 
invasion are important steps in late tumor progression, understanding the aberrant genetic changes which 
promote the movement of cells beyond the basement membrane can help unravel the underlying 
mechanisms regulating these processes. SLUG (SNAI2) has been identified as a prominent regulator of 
EMT, known to cooperate with other drivers of migration such as Twist to promote tumorigenesis
265
. 
SNAI2 is amplified and overexpressed in a variety of tumors and its expression has been shown to 
promote tumor formation in mice
266
.  Combination of alterations effecting different pathways but driving 
the same cellular process of migration can be powerful mechanisms in the progression of tumorigenesis. 
This is supported by the strong and significant synergistic effect of the chromosomal heterozygous loss 
of DEAR1 and the alteration of SNAI2 on predicting IDC survival rates. This association has leant to the 
possibility for future development of the use of chromosomal alterations of these two genes, DEAR1 and 
SNAI2, to act as a prognostic indicator for IDC to help in the stratification of patients for prognosis.  
As DEAR1 has been shown to be important for migration and invasion as well as a possible 
prognostic indicator in IDC, a better understanding of DEAR1’s role in the early in situ form of breast 
cancer is needed. To begin to understand if DEAR1 is genetically altered in in situ breast cancer, ultra-
deep targeted sequencing of a 48kb locus encompassing DEAR1 was completed in Pure Ductal 
Carcinoma in Situ (DCIS) and DCIS associated with invasive components. For this project, a custom 
targeted DEAR1 Ampliseq panel was generated, which exhibited strong precision capabilities, as well as 
a high degree of sensitivity and specificity. The DEAR1 Ampliseq panel showed a high degree of 
sensitivity and specificity in regards to single nucleotide variants. The sensitivity and specificity data 
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also showed our inability to be confident in Insertion/Deletions (INDEL) calls from the Ion Torrent 
platforms. The low sensitivity of Ion Torrent sequencing platforms to call INDELs has been shown in a 
variety of publications
212, 213
. This, however, did not affect our ability to understand the variation in 
DEAR1 in DCIS as previous analysis has shown that majority of variants seen in the DEAR1 locus, 
besides loss of the entire p arm of chromosome 1, are single base-pair substitutions(described in chapter 
2). Due to the high frequency to which chromosome 1p is lost in epithelial cancer as well as data 
showing that chromosomal alterations in DCIS are often conserved in its invasive counterpart, it was 
hypothesized that the vast majority of informative information concerning how DEAR1 variants evolve 
during breast cancer progression could be found in looking solely at nucleotide alterations
2, 142, 143, 233
. 
Further, the analytical performance of the custom sequencing panel generated was characterized by a 
novel spike in assay designed to assess the accuracy of the allele frequencies of the variants identified in 
the sequencing data. The novel spike-in assay showed a relatively high rate of recapitulation for the 
experimental variant allele frequencies in regards to the expected spiked-in allele frequencies. Moreover, 
our development of this method for determining the accuracy of variant allele frequencies for a 
sequencing panel can be utilized as an important analytical metric for any targeted sequencing approach. 
We hope that future research studies as well as potential clinical assays featuring targeted sequencing 
panels will employ this performance measurement to help researchers fully understand the capabilities of 
their sequencing panels.  
Ultra-deep targeted sequencing of DEAR1 revealed the high frequency (71%) to which the 
gene is altered in DCIS. Few noted genes have been shown to exhibit mutations at this degree in DCIS, 
such as Tp53, PIK3CA, and BRCA1 (as previously discussed in chapter 4). The high frequency of 
DEAR1 mutations in combination with the frequent loss of chromosomal 1p may cooperate to fully 
inactivate DEAR1 in these tumors. Variants discovered during sequencing contained notable exonic 
variants that were found during previous sequencing completed by our lab and other large sequencing 
efforts like The Cancer Genome Atlas (TCGA) in epithelial cancers, including breast cancer. Moreover, 
the presence of the first known nonsense alterations in DEAR1 in breast cancer was described as well as 
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a potential germline mutation. Potential functionality for many of these variants were suggested by 
deleterious prediction tools, SIFT and PolyPhen2, as well as by functional assays completed by our lab. 
It is important to note that particular factors, such as environmental cues, may modify the deleterious 
nature of some of the DEAR1 variants. For example, the D106V mutation, found both in DCIS and IDC, 
was shown to potentiate TGFβ signaling in the presence of the TGFβ ligand, in comparison to wild-type 
DEAR1
2
. Variants in DEAR1 that modulate DEAR1’s inhibitory nature regarding the TGFβ pathway may 
be able to intensify downstream phenotypic effects such as increasing motility and invasive capacity. 
Further, DEAR1 loss of function mutations may be able to synergize with other genetic defects in cancer 
to further promote tumorigenesis. For example, it has been shown that heterozygous loss of DEAR1 can 
cooperate with mutant Kras can promote tumorigenesis and metastasis in a Non-Small Cell Lung Cancer 
mouse model
138
. Moreover, the identification of nonsense and germline mutations in DEAR1 represent 
hallmarks of classical mechanisms for tumor suppressor inactivation and provide further evidence for the 
important role that DEAR1 plays in cancer. Additionally, the identification of germline mutations within 
DEAR1 hint at the potential for DEAR1 to act as a potential stratifier for inherited breast cancer cases. 
Future work in deciphering DEAR1’s roles in hereditary breast cancer need to be completed to better 
understand the frequency of DEAR1 alterations at the germline level. Sequencing for DEAR1 in large 
cohorts of breast cancer patients with strong family histories and whose genetic predisposition is 
currently unsolved may help in the molecular diagnosis of these patients. Altogether, this data indicates 
the significance of DEAR1 variants contributing to the loss of function of this important tumor 
suppressor in an early stage of breast disease. 
Currently, the American Cancer Society has identified a small number of genes known to 
increase the lifetime risk of breast cancer
221
. This list includes BRCA1, BRCA2, ATM, TP53, CHEK2, 
PTEN, CHD1, STK11, and PALB2. Most notable on this list are in BRCA1 and BRCA2 as defects in these 
genes are known to carry the highest risk of breast cancer estimated to be on average between 55-65%
221
. 
Despite the known increased risk of breast cancer associated with alterations in these genes, much 
discussion still exists in the field regarding how these variants should be used clinically. BRCA1 and 
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BRCA2 mutation catalogues, family case studies, and experimental in vitro testing have been able to 
identify over a 1000 variants within these genes that are classified as pathogenic and come with the 
recommendation of increased surveillance and/or potential prophylactic surgery. However, 10-15% of 
variants discovered during full gene sequencing of BRCA1 and BRCA2 are classified as variants of 
unknown significance (VUS)
267
. VUS variants are defined as a change in the DNA sequence with 
unknown effects on the gene product and disease risk
268
. These variants pose a challenge clinically as 
there is a possibility that these variants can be deleterious and alter disease risk but yet no clinical action 
can be recommended as there is no current substantiated evidence for their pathogenicity. 
Reclassification of these variants can occur as more information is gleaned from large population variant 
catalogues and as future additional family case studies, pathological profiles, and functional assays are 
completed
269
. Moreover, molecular studies have shown that the location of the variants within BRCA1 
and BRCA2 can inform on pathogenicity, with the highest levels of pathogenicity being associated with 
variants within the RING, BRCT, and DNA binding domains
269
. These domain structures are known to 
be important for BCRA1 and BRCA2’s functional roles in DNA repair and cell cycle regulation. These 
cases exemplify the use of molecular based knowledge to inform on the possible deleterious nature and 
clinical relevance of variants within cancer-related genes. As our study has identified variants in DEAR1 
in early stage breast cancer as well as a possible germline variant, understanding how these variants 
could be important clinically is critical. DEAR1 has been found previously to be a dominant regulator of 
polarity, acinar morphogenesis and EMT
2, 131
. Through these studies, the RING finger and the B-Box 
Coiled Coil (BBC) domains have been found to be integral to the regulation of these pathways. The 
RING finger has been shown to be necessary for DEAR1’s regulation of SMAD3 and TGFβ induced 
EMT
2
. Moreover, genetic complementation studies of a variant in the BBC domain have shown that this 
domain of DEAR1 can act in a dominant manner in the regulation of acinar morphogenesis
131
. Thus, 
variants within these domains may be more likely to be exert pathogenic effects. Sequencing of DEAR1 
in DCIS revealed multiple variants within these two domain structures. Mutations in codons 187 and 240 
not only occur in the BBC domain but are predicted to be deleterious by prediction tools PolyPhen2 and 
SIFT, which use amino acid conservation and structural analysis to predict the deleterious nature of 
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variants. These BBC domain variants have also been found in both IDC and DCIS samples of multiple 
breast cancer patients. Moreover, variants at codon 240 have been found to occur within the germline of 
2 breast cancer patients and molecular analysis has shown that variance at codon 187 can effect acinar 
morphogenesis, further giving credence to the pathogenicity of these variants. Another example of a 
variant with a high probability of pathogenicity is the occurrence of a nonsense variant at codon 19 in the 
RING domain. Nonsense variant are typically identified as loss of function variants as truncated 
transcripts which result from nonsense variants are often degraded through nonsense mediated decay. 
Variants in breast cancer patients occurring in DEAR1 at these codons or possibly within these domains 
may stratify patients for therapies targeting TGFβ or polarity pathways as well as designate the need for 
increased surveillance for patients who exhibit these variants within the germline. More research 
however is required to fully grasp the potential ability of DEAR1 variants in informing on clinical 
aspects, including therapy and breast cancer risk. As more knowledge is gained into how DEAR1 
regulates vital cellular processes and how these processes are abrogated in cancer, as well as a continued 
effort to catalogue variants in DEAR1, reclassification of these variants from VUS to clinically 
actionable may occur.  
Many of the somatic variants found in DEAR1 in DCIS were often sub-clonal yet private to 
either the matched in situ or invasive lesions within DCIS samples associated with invasive components. 
This was an unexpected finding as many studies have hinted at the similar profiles of DCIS and invasive 
lesions
223, 233, 236,235
. The sequencing of DCIS samples associated with invasive lesions indicated that 
DEAR1 mutations occur after both the major chromosomal alterations and the evolutionary split from the 
ancestral clone, thereby giving rise to both the DCIS and the IDC.  The private nature of these variants 
supports the less-heralded “parallel” model of DCIS progression, which described the independent yet 
parallel evolution of breast tumors that is supported by a few studies
237, 258
. The study of chromosomal 
alterations in DCIS and matched IDC has so far proven unfruitful in producing markers of DCIS 
progression. Recent evidence, including our work, has shown that the study of nucleotide variants may 
prove to be more beneficial in the search for progression biomarkers. More work, including whole 
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genome sequencing studies of many DCIS and IDC samples, as well as earlier lesions of breast 
hyperplasia, are need to fully elucidate the evolutionary nature of DCIS progression. However, if future 
studies give further support for an independent evolutionary model for DCIS and IDC, this can have 
large implications within the clinic. For example, lesions which have been thoroughly vetted to contain 
no evidence of histological invasiveness may be candidates for lumpectomy only or long-term 
surveillance as the risk of the development of an invasive lesion in pure DCIS, given the independent 
evolutionary model, is very low. Further, lesions in which any invasive component exists will require 
much more extensive treatment like lumpectomy plus radiation as there is a high possibility that the 
invasive component can develop into a full IDC. It is important to note that there exists a chance that 
small sub-clonal populations with invasive features may be missed during histological evaluation of the 
lesions as current practices only include the observation of a few representative histological slides, 
possibly leading to misdiagnosis of the lesions. If future practices stratify the intensiveness of the 
treatment options based on the presence or absence of diagnosed invasive components, misdiagnoses of 
DCIS/INV as pure DCIS in combination with positive surgical margins can increase the risk of 
recurrence in these patients. Therefore, better and more sensitive histological and molecular markers as 
well as more intensive histological practices are needed in order to fully vet DCIS lesions for the 
presence of invasiveness. In all, our work has provided demonstrated the presence of variants in DEAR1, 
a tumor suppressor integral in regulating polarity and migration, in the earliest form of breast cancer 
which may act as drivers in the progression of this disease as well as providing evidence for a “parallel” 
based evolution model for DCIS and IDC. 
Future Directions 
Further work to understand the comprehensive effects of DEAR1 variants in DCIS, however, is 
needed. RNAseq and immunohistochemistry on matched DNA sequencing samples will help to provide 
knowledge about the expression status of the variants, especially to determine if these variants induce a 
novel loss or gain of function. Dogma suggests that the nonsense variants found in our DCIS samples 
associated with invasive components induce a loss of function in DEAR1 as nonsense mutations are 
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typically thought to induce mRNA decay, leading to decreased gene expression and complete loss of 
function of the gene in those alleles. Further, evidence supporting the possibility that some of these 
variants are associated with a novel gain of function has been shown by previous studies completed by 
the TCGA in which some DEAR1 variants can coincide with chromosomal aberrations or increased gene 
expression of the variants
145, 146
. One possible advantage of missense mutations associated with moderate 
to high gene expression is the possibility that these variants fall in areas important for protein-protein 
interactions which can potentially disrupt DEAR1’s critical negative regulation of tumor promoting 
pathways, like the TGFβ pathway. Moreover, further sequencing analysis of important tumor suppressors 
and oncogenes can help to define new pathways that DEAR1 is associated with by delineating whether 
these genes exhibit a co-occurring or mutually exclusive nature with DEAR1 variants.  
Determining if DEAR1 variants have the ability to stratify populations at higher risk is also a 
critical undertaking. Most of the samples within the current study showed hormone receptor status 
associated with luminal breast cancer. Luminal type breast cancer is the most common subtype of breast 
cancer, accounting for 60% of all tumors, with luminal A subtype being more prevalent than luminal 
B
270
. A large sample population representing equal numbers of the breast cancer subtypes would be 
helpful in understanding if DEAR1 experiences differential mutation rate or spectrum in the different 
subtypes. This is especially important to understand if DEAR1 variants showed a different mutation 
pattern in the more aggressive breast cancer subtypes, like HER2 and basal, and therefore could be used 
to potentially further stratify these populations for prognosis 
271
. Further, racial disparity is a known 
epidemiological risk factor in breast cancer. African American women show a somewhat similar incident 
rates of breast cancer as Caucasians; however, breast cancer within the African American community 
tends to be more aggressive and incur higher mortality rates than Caucasians
272
. Determining the 
disparate molecular and genetic drivers unique to breast cancer in African American women will be very 
important to understanding what factors lead to a more aggressive behavior of these tumors. The current 
study is limited in this scope due to its inclusion of mostly Caucasians. As mutation or loss of DEAR1 
expression has been shown to allow for an increased propensity for migration and invasion, describing 
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DEAR1’s potential role in the more aggressive phenotype of African American breast cancer will be 
important. Defining new molecular markers for sub-groups of breast cancer can be vital for future 
therapeutic and prognosis stratification efforts. 
The interplay between the tumor and the microenvironment surrounding it may also be 
important to understanding why invasive lesions associated with a DCIS counterpart tend to be less 
aggressive than pure IDC lesions. Wong et al. 2010 has shown that the nuclear grade and degree of 
proliferation is significantly reduced in IDC associated with DCIS in comparison to pure IDC
273
. Further, 
the same group found an inverse relationship between the size of the DCIS component and 
aggressiveness of its matched adjacent IDC. Pure IDC has also been associated with larger tumors and 
earlier onset of metastasis than DCIS-IDC
274
. These studies suggest a large degree of interaction between 
the DCIS and IDC components and their potential to regulate each other. Understanding how the DCIS 
component can limit the aggressiveness of the invasive lesion may help us to uncover new, targetable 
areas important to inhibiting the aggressive phenotype.   
The field as a whole has much to learn in order for us to fully grasp the mechanism of 
progression of breast cancer, as fully comprehending the pathway taken by these lesions can have large 
effects on how these tumors are clinically treated. A study conducted by Newburger et al. 2013 
suggested that some invasive breast cancers have more in common with their very early neoplastic lesion 
counterpart than with a matched DCIS lesion
258
. Though the sequencing efforts within this study focused 
on a single gene, DEAR1, in matched DCIS and invasive tumors, the limited number of shared variants 
between the lesions may give some credence to the independent “parallel” progression model. If a 
“parallel” model of breast cancer progression exists, with atypical ductal hyperplasia or even earlier 
lesions hosting the common cells of origins for both DCIS and IDC, this may indicate the need to 
identify factors within these very early, benign states of breast disease that may predispose the lesions to 
spurring off independent DCIS and/or invasive lesions.  Moreover, Newburger et al 2013 also identified 
a subset of invasive lesions which showed a high degree of commonality with their matched DCIS 
neoplasia. This idea is supported by other molecular and cytogenetic based studies which have indicated 
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a preservation of chromosomal aberrations, degree of nuclear atypia, and immunohistochemical 
expression of hormone receptor status between the DCIS and IDC tumors
233, 275
. Understanding what 
intrinsic features are differentially associated with clonal or independent, parallel evolution are important 
to comprehend the underlying mechanisms of breast tumor progression as well as for stratifying patients 
for differential treatment strategies. Recently, it has been suggested that the tumor microenvironment can 
play a role in DCIS progression
276, 277
 Further work in this area to delineate the potential ability of 
stromal and immunological factors to influence breast cancer progression, and how these pathways 
interplay with inherent genetic alterations within these lesions, is greatly needed.  
It is obvious that multiple factors are critical in breast cancer progression and our knowledge 
of this area is still in its infancy. How genetic and immune factors, along with tumor microenvironment 
signals, integrate to drive the mechanisms behind distinct evolutionary patterns seen in breast cancer is a 
major question in this field which can have huge clinical implications. Much more work is needed in this 
area in order to fully comprehend the molecular mechanisms driving tumor progression in breast cancer. 
Defining these pathways can potentially lead to better prognostic methods and new strategies for treating 
this disease. Our work has discovered novel variants in DCIS in the DEAR1 tumor suppressor which is 
important in the regulation of polarity and migration, early essential steps in EMT. The pattern of these 
variants have also revealed the distinct independent evolution of DCIS and their adjacent invasive 
components. Future larger studies are needed to fully comprehend the ability of DEAR1 to act as a 
predictive marker for breast cancer progression as well as to understand the factors important to 
determining the evolutionary pathway central to DCIS and IDC progression. Despite this, the current 
study described herein provides the first step to understanding the possible effects of DEAR1 genetic 
alterations in breast cancer and how these variants potentially evolve during the progression of DCIS.  
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Appendix 1. Spike-In Plasmid Sequence 
FASTA sequenced of the plasmid spiked into NA12878 for determination of allele frequency sensitivity. 
Substitutions and insertions deviant from the reference sequence are bolded/underlined while deletions 
are highlighted by underlined spaces. Original plasmid design created by Dr. Steven Lott. 
 
>13AAT37P_1351815 
CACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCCGCATTTTTAGGCTAATGGGCTCTGC
ATCTAAGGTAACGATCAGCTTTGGGTATACCCTCACCCTGTCCCCCAGCCTGTGGGCAGGA
AGGTGGTGGCACATGACTATAATGTGTGGACTCACCGACTACCAGGTGCCTTCCACAGGCT
CCAGCATCATCACTGACCAGATCGTTACCTTAGCAGATCAGTGGGAGAAGTAGGAACAGGA
GCCAGACTGACTTCACACTAAGGTAACGATGGCCCCACAGACAAAAAAAGGGGCCCAGCC
AACCAGGCTGCTGCTCTCTGAACTCCCCAGGGG_CTCTGCTCTGGGCAGGACGTTGGAGCAC
AGTCTGTTCCTCCCGCAGCTCCTCTCTGGCATCGTTACCTTAGAGGCAGCTTTCTCTAGAGC
AGGGGTTTCAGGAAGTCTTGGAGATAACTAAGGTAACGATTCATTATACCATCTGC_ 
_GGTGAAGAAGACAGGGAGCTTTTCCAATGTGTCTGCGGATG 
CACAGCACTCAGCACACAGTAAAGGTGTGTAGCTGAATAACGCGCATCAACGCCCTGGATC
GTTACCTTAGGTTGCAGGAGGAAGGAAAGACTCCAGGCTCACCTTGGTCTCTAAGGTAACG
ATCCGCCAGTTGTCGCTTGAGCAGCTGCAGCGC_ _ _ 
GGTGTGTTCCCGCTCGCTGTCTTGAAGGGCCTGTAGTTGGTCCTTCAGCTCCCTCTATCGTTA
CCTTAG 
GAAACACACACAGGGCCGCTGGGCCTCATGGGCCTTCCGCTCACTGCCCGCTTTCCAG 
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Appendix II. R Code to Extract Barcoded Reads from Unmapped BAM Files 
Novel spike-in assay for determination of the accuracy of variant allele frequencies required the 
extraction of barcoded reads representing the presence of the artificial variants spiked into normal control 
DNA NA12878. R programming code represents the method used to extract these barcoded reads from 
unmapped BAM files. R programming code originally written by Dr. Steven Lott.  
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Appendix III- Differential Testing of Various Variant Filtering Stringencies. Table details the reduction 
of variant counts through various variant filtering strategies. Variant filtering occurred after the use of the 
automated variant calling by the Torrent Variant Caller using parameters listed in the methods in chapter 
3. Multiple strategies were tested in order to reduce spurious variants with low levels of evidence per 
variant. Ultimately, coverage depth of at least 1000x with greater or equal to 60 reads representing the 
variant with at least 30 supporting reads on each forward and reverse strands. Acronyms: DP=Coverage 
Depth; AO=Alternative allele observations; SAF/SAR=alternative allele observations on the Forward 
and Reverse strands, respectively; FDP= Flow evaluator Coverage Depth; FAO= Flow evaluator 
Alternative allele observations; FSAF/FSAR= flow evaluator alternative allele observations on the 
Forward and Reverse strands 
 
Sample PD3 
Pure DCIS 
D05 
INV 
PD9 
Pure DCIS 
D11 
INV 
DP>200, AO>20, 
SAF/SAR>5 
32 303 33 229 
FDP>1000, 
FAO>20, 
FSAF/FSAR>10 
16 262 30 204 
FDP>1000, 
FAO>40, 
FSAF/FSAR>10 
16 262 27 204 
FDP>1000, 
FAO>50, 
FSAF/FSAR>10 
14 262 26 202 
FDP>1000, 
FAO>40, 
FSAF/FSAR>20 
12 256 21 199 
FDP>1000, 
FAO>80, 
FSAF/FSAR>20 
10 254 18 197 
FDP>1000, 
FAO>60, 
FSAF/FSAR>30 
11 
66% reduction 
249 
18% reduction 
18 
46% reduction 
197 
14% reduction 
FDP>1000, 
FAO>130, 
FSAF/FSAR>30 
9 238 14 189 
FDP>1000, 
FAO>100, 
FSAF/FSAR>50 
8 235 15 182 
FDP>1000, 
FAO>200, 
FSAF/FSAR>50 
6 212 10 162 
        71% reduction           30% reduction        70% reduction         29% reduction  
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Appendix IV. R Code to Calculate Coverage By Amplicon. 
As designed sequencing amplicons often produced slightly overlapping fragments, calculation of 
sequencing coverage by amplicon required manual determination via R programming code. R 
programming code originally written by Dr. Steven Lott. 
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Appendix V. R Code to Graph Digital PCR Data. 
Variants found by sequencing for both control and clinical samples on the Ion Torrent Sequencing 
platforms were verified by digital PCR for the presence and allele frequencies. Figure shows the R 
programming code written for the creation of scatter plot plotting sequencing allele frequencies versus 
digital PCR allele frequencies of the same sample. 95% confidence interval as well as Pearson’s 
correlation coefficient was calculated.  
 
 
 148 
 
Appendix VI. R Code for Determination of Sensitivity and Specificity. 
Sensitivity and specificity of the DEAR1 Ampiseq panel was determined by the R program epiR using 
the following R programming code. A 95% confidence interval was determined for the performance 
measures using epiR as well.  
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Appendix VII –Catalogue of Clinical Samples Sequenced. Table contains a detailed list of sample and 
sample type/components sequenced for each patient. 
 Sample Path. Normal 
Lymph or 
Adjacent 
DCIS Invasive 
1 PD1 Pure DCIS  X n/a 
2 PD2 Pure DCIS  X n/a 
3 PD3 Pure DCIS  X n/a 
4 PD4 Pure DCIS X-Lymph X n/a 
5 PD5 Pure DCIS X-Lymph X n/a 
6 PD6 Pure DCIS  X n/a 
7 PD7 Pure DCIS  X n/a 
8 PD8 Pure DCIS X-Lymph X n/a 
9 PD9 Pure DCIS  X n/a 
10 PD10 Pure DCIS  X n/a 
11 PD11 Pure DCIS  X n/a 
12 PD12 Pure DCIS  X n/a 
13 PD13 Pure DCIS  X n/a 
14 PD14 Pure DCIS  X n/a 
15 PD15 Pure DCIS X- -Lymph X n/a 
16 
PD16 
Pure DCIS X-Adjacent 
Breast 
X n/a 
17 PD17 Pure DCIS X-Lymph X n/a 
1 D01 DCIS/ INV X-Lymph X X 
2 D02 DCIS/ INV X-Lymph X X 
3 D03 DCIS/ INV X-Lymph X X 
4 D04 DCIS/ INV X-Lymph X X 
5 D05 DCIS/ INV X-Lymph X X 
6 D06 DCIS/ INV X-Lymph X X 
7 D07 DCIS/ INV X-Lymph X X 
8 D08 DCIS/ INV X-Lymph X X 
9 D09 DCIS/ INV  X X 
10 D10 DCIS/ INV X-Lymph X X 
11 D11 DCIS/ INV  X X 
12 D12 DCIS/ INV  X X 
13 D13  DCIS/ INV  X X 
14 D14 DCIS/ INV  X X 
15 D15 DCIS/ INV  X X 
16 D16 DCIS/ INV X-Lymph X X 
17 D17 DCIS/ INV X-Lymph X X 
18 D18 DCIS/ INV  Unable to 
complete 
Variant Calling 
X 
19 D19 DCIS/ INV  Unable to 
complete 
Variant Calling 
X 
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Appendix IIX. R Code for Creation of Venn Diagram Using the VennDiagram R Program 
A Venn diagram was created with R package VennDiagram to visualize the degree of shared 
variants between the adjacent DCIS and invasive components of matched samples. The following 
R code was used within the VennDiagram package to complete the graph. 
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Appendix IX. R Code for Variant Count Per Sample Boxplots. 
Visualization of variant counts per sample were created using ggplot2 R package. R programming code 
used to create the box-plots are shown below as well as the code to determine the mean of each value set.  
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Appendix 10 - Detailed List of All Variants Harbored Within the 48kb Locus Involving DEAR1 Found in Ductal Carcinoma In Situ. This table contains 
all variants that were found via sequencing within the 48kb locus harboring DEAR1 and regulatory regions upstream of the gene. Variants that may be 
associated with formalin fixation are in bold. The criteria for possible fixation induced variants were that the nucleotide change was associated with 
C>T/G>A nucleotide changes and variant allele frequencies were shown to be at 0.04 or less. C>T/G>A variants have been previously reported to be 
enriched in formalin fixed samples due to the process causing cytosine deamination. The chosen variant frequency of 0.04 or less for the possible 
formalin induced changes was used due to the very low possibility that a particular nucleotide would undergo cytosine deamination and having shown 
that variants at 0.05 variant frequencies were able to be verified by orthogonal methods. Potential germline variants not excluded due to lack of 
sequenced matched normal sample are italicized.  
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
PD1 Pure DCIS 33629668 TC> CA c.504+1404 GA>TG 0.93  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 0.56  Intronic 
  33645665 AA> CT c.408+961 TT>AG 0.56  Intronic 
  33648859 T> C Upstream 0.08  Upstream 
PD2 Pure DCIS 33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33645665 AA> CT c.408+961 TT>AG 1.00  Intronic 
PD3 Pure DCIS 33612040 C> G c.*738 G>C 0.16  3’UTR 
  33612944 T> C p.Asp421Gly c.1262A>G 0.04  Exonic 
  33613286 C> T p.Arg307His  
c.920G>A 
0.03 Failed to 
validate 
Exonic 
  33613337 G> C c.878-9 C>G 0.03  Intronic 
  33614654 C> T c.878-1326 G>A 0.13  Intronic 
  33626451 A> T c.505-906 T>A 0.05  Intronic 
  33629610 A> G c.504+1462 T>C 0.06  Intronic 
  33630031 A> G c.504+1041 T>C 0.05  Intronic 
  33633168 A> T c.409-2001 T>A 0.06  Intronic 
  33634506 C> T c.409-3339 G>A 0.04  Intronic 
  33638079 A> T c.409-6912 T>A 0.14  Intronic 
PD4 Pure DCIS 33625332 C> T p.Asp240Asn  
c.718G>A 
0.07  Exonic 
  33633168 A> T c.409-2001 T>A 0.07  Intronic 
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Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
PD5 Pure DCIS 33636180 G> A c.409-5013 C>T 0.05  Intronic 
  33638079 A> T c.409-6912 T>A 0.25  Intronic 
  33611279 C> T c.*1499 G>A 0.05  3’UTR 
  33612510 A> G c.*268 T>C 0.05  3’UTR 
  33612944 T> C p.Asp421Gly c.1262A>G 0.68 Yes Exonic 
  33623802 T> G c.877+52 A>C 0.03  Intronic 
  33638079 A> T c.409-6912 T>A 0.06  Intronic 
  33641976 C> T c.408+4650 G>A 0.04  Intronic 
  33642042 C> T c.408+4584 G>A 0.04  Intronic 
  33645209 C> T c.408+1417 G>A 0.03  Intronic 
  33646717 T> A p.Asp106Val c.317A>T 0.04  Exonic 
  33648831 A> T Upstream 0.04  Upstream 
PD6 Pure DCIS 33612040 C> G c.*738 G>C 0.10  3'UTR 
  33612944 T> C p.Asp421Gly 
c.1262A>G 
0.06 Yes Exonic 
  33625571 A> G c.505-26 T>C 0.06  Intronic 
  33625581 G> C c.505-36 C>G 0.04  Intronic 
  33633168 A> T c.409-2001 T>A 0.08  Intronic 
  33638074 A> G c.409-6907 T>C 0.03  Intronic 
  33638079 A> T c.409-6912 T>A 0.19  Intronic 
  33641731 C> G c.408+4895 G>C 0.08  Intronic 
  33651167 A> G Upstream 0.03  Upstream 
PD7 Pure DCIS 33611279 C> T c.*1499 G>A 0.05  3'UTR 
  33641485 G> A c.408+5141 C>T 0.03  Intronic 
  33641976 C> T c.408+4650 G>A 0.03  Intronic 
  33646717 T> A p.Asp106Val 
c.317A>T 
0.04  Exonic 
  33648235 G> A Upstream 0.05  Upstream 
PD8 Pure DCIS 33611279 C> T c.*1499 G>A 0.03  3'UTR 
  33611936 C> T c.*842 G>A 0.03  3'UTR 
  33614654 C> T c.878-1326 G>A 0.07  Intronic 
  33616024 C> T c.878-2696 G>A 0.03  Intronic 
  33617588 G> A c.878-4260 C>T 0.03  Intronic 
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Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
PD8 Pure DCIS 33623802 T> G c.877+52 A>C 0.07  Intronic 
  33625332 C> T p.Asp240Asn 
c.718G>A 
0.04 Failed to 
validate 
Exonic 
  33626876 G> T c.505-1331 C>A 0.06  Intronic 
  33627151 G> A  c.505-1606 C>T 0.03  Intronic 
  33627310 C> T c.505-1765 G>A 0.04  Intronic 
  33633167 C> T c.409-2000 G>A 0.03  Intronic 
  33634758 G> A c.409-3591 C>T 0.03  Intronic 
  33634770 G> A c.409-3603 C>T 0.05  Intronic 
  33639129 T> A c.408+7497 A>T 0.04  Intronic 
  33642042 C> T c.408+4584 G>A 0.05  Intronic 
  33644997 G> T c.408+1629 C>A 0.04  Intronic 
  33645290 G> A c.408+1336 C>T 0.04  Intronic 
  33645659 A> T c.408+967 T>A 0.03  Intronic 
  33645665 AA> CT c.408+961 TT>AG 1.00  Intronic 
  33646717 T> A p.Asp106Val c.317A>T 0.04 Yes Exonic 
  33647348 G> A Upstream 0.05  Upstream 
  33648831 A> T Upstream 0.14  Upstream 
PD9 Pure DCIS 33612520 C> T c.*258 G>A 0.04  3'UTR 
  33621086 T> C c.877+2768 A>G 0.05  Intronic 
  33623802 T> G c.877+52 A>C 0.05  Intronic 
  33626876 G> T c.505-1331 C>A 0.09  Intronic 
  33626913 A> G c.505-1368 T>C 0.05  Intronic 
  33638079 A> T c.409-6912 T>A 0.17  Intronic 
  33639129 T> A c.408+7497 A>T 0.05  Intronic 
  33639131 C> T c.408+7495 G>A 0.05  Intronic 
  33642042 C> T c.408+4584 G>A 0.05  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645659 A> T c.408+967 T>A 0.04  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33645665 AA> CT c.408+961 TT>AG 1.00  Intronic 
  33645916 C> T c.408+710 G>A 0.03  Intronic 
155 
 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
PD9 Pure DCIS 33645918 C> G c.408+708 G>C 0.08  Intronic 
  33646083 C> T c.408+543 G>A 0.04  Intronic 
  33648831 A> T Upstream 0.12  Upstream 
  33649303 A> C Upstream 0.04  Upstream 
PD10 Pure DCIS 33618680 G> T c.877+5174C>A 0.07  Intronic 
  33629668 TC> CA c.504+1404GA>TG 0.36  Intronic 
  33636199 C> A c.409-5032G>T 0.09  Intronic 
PD11 Pure DCIS 33612419 G> A c.*359 C>T 0.03  3’ UTR 
  33618738 G> A c.877+5116 C>T 0.04  Intronic 
  33623802 T> G c.877+52 A>C 0.05  Intronic 
  33629668 TC>CA c.504+1404 GA>TG 0.06  Intronic 
  33639129 T> A c.408+7497 A>T 0.05  Intronic 
  33642042 C> T c.408+4584 G>A 0.04  Intronic 
  33642082 G> A c.408+4544 C>T 0.07  Intronic 
  33648831 A> T Upstream 0.15  Upstream 
PD12 Pure DCIS 33618680 G> T c.877+5174 C>A 0.09  Intronic 
  33618799 A> T c.877+5055 T>A 0.04  Intronic 
  33625332 C> T p.Asp240Asn 
c.718G>A 
0.81 Yes (germline) Exonic 
  33625491 G> A p.Arg187Trp 
c.559C>T 
0.13 Yes Exonic 
PD13 Pure DCIS 33644798 AA>GC c.408+1828  
TT>GC 
1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 
delAG 
1.00  Intronic 
  33645665 AA>CT c.408+961 TT>AG 1.00  Intronic 
  33648859 T> C Upstream 0.05  Upstream 
PD14 Pure DCIS 33621086 T> C c.877+2768 A>G 0.04  Intronic 
  33623802 T> G c.877+52 A>C 0.04  Intronic 
  33626876 G> T c.505-1331 C>A 0.11  Intronic 
  33628265 T> C c.505-2720 A>G 0.03  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 0.97  Intronic 
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Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
PD14 Pure DCIS 33645120 A> G c.408+1506 T>C 0.05  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 0.48  Intronic 
  33645665 AA> CT c.408+961 TT>AG 0.48  Intronic 
PD15 Pure DCIS 33611941 G>A c.*837C>T 0.99  3’ UTR 
  33645278 G>A c.408+1348C>T 0.98  Intronic 
PD16 Pure DCIS 33612362 A> G c.*416 T>C 0.05  3’ UTR 
  33625581 G> C c.505-36 C>G 0.04  Intronic 
  33633168 A> T c.409-2001 T>A 0.04  Intronic 
PD17 Pure DCIS 33611279 C> T c.*1499 G>A 0.10  3’ UTR 
  33612132 G> A c.*646 C>T 0.03  3’ UTR 
  33612419 G> A c.*359 C>T 0.04  3’ UTR 
  33612422 C> T c.*356 G>A 0.05  3’ UTR 
  33613346 G> A c.878-18 C>T 0.03  Intronic 
  33616298 G> C c.878-2970 C>G 0.03  Intronic 
  33616750 G> A c.878-3422 C>T 0.03  Intronic 
  33617411 G> T c.878-4083 C>A 0.03  Intronic 
  33627170 C> T c.505-1625 G>A 0.03  Intronic 
  33627359 C> T c.505-1814 G>A 0.03  Intronic 
  33629796 G> A c.504+1276 C>T 0.03  Intronic 
  33631379 C> T c.409-212 G>A 0.05  Intronic 
  33636180 G> A c.409-5013 C>T 0.08  Intronic 
  33638079 A> T c.409-6912 T>A 0.14  Intronic 
  33638577 G> A c.409-7410 C>T 0.06  Intronic 
  33638745 C> T c.409-7578 G>A 0.04  Intronic 
  33638780 T> C c.409-7613 A>G 0.06  Intronic 
  33641731 C> G c.408+4895 G>C 0.05  Intronic 
  33641905 C> T c.408+4721 G>A 0.03  Intronic 
D01 DCIS 33611230 A> G c.*1548 T>C 0.09  3'UTR 
  33612117 G> A c.*661 C>T 0.03  3'UTR 
  33613159 G> A p.Gly349Gly 
c.1047C>T 
0.04  Exonic 
  33629577 G> A c.505-1682 C>T 0.03  Intronic 
  33630773 G> A c.504+1495 C>T 0.04  Intronic 
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Chromosome 1  
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Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D01 DCIS 33630780 G> A c.504+299 C>T 0.05  Intronic 
  33630813 G> A c.504+259 C>T 0.03  Intronic 
  33631291 C> T c.409-124 G>A 0.04  Intronic 
  33633418 C> T c.409-2251 G>A 0.04  Intronic 
  33638005 G> A c.409-6838 C>T 0.05  Intronic 
  33638013 G> A c.409-6846 C>T 0.04  Intronic 
  33638085 G> A c.409-6918 C>T 0.03  Intronic 
  33638937 C> T c.408+7689 G>A 0.03  Intronic 
  33639060 G> A c.408+7566 C>T 0.06  Intronic 
  33639129 T> A c.408+7497A>T 0.03  Intronic 
  33641447 C> T c.408+5179 G>A 0.04  Intronic 
  33645853 C> T c.408+773 G>A 0.03  Intronic 
  33646036 T> C c.408+590 A>G 0.05  Intronic 
  33647588 C> T Upstream 0.03  Upstream 
  33649491 C> T Upstream 0.04  Upstream 
  33649569 G> A Upstream 0.04  Upstream 
  33649571 G> A Upstream 0.04  Upstream 
  33653042 G> A Upstream 0.03  Upstream 
  33681449 G> A Upstream 0.03  Upstream 
 INV 33639129 T> A c.408+7497 A>T 0.07  Intronic 
  33648206 T> C Upstream 0.16  Upstream 
  33648250 G> A Upstream 0.04  Upstream 
D02 DCIS 33639129  T >A c.408+7497 A>T 0.04  Intronic 
  33648237 
 
A> G Upstream 0.05  Upstream 
 INV  33639129  T >A c.408+7497 A>T 0.04  Intronic 
D03 INV 33638085 G> A c.409-6918 C>T 0.04  Intronic 
  33639129 T> A c.408+7497 A>T 0.03  Intronic 
  33646036 T> C c.408+590 A>G 0.03  Intronic 
D04 DCIS 33611114 G> A c.*1664 C>T 0.03  3'UTR 
  33630779 G >A c.504+293 C>T 0.03  Intronic 
  33630928 C> T c.504+144 G>A 0.03  Intronic 
  33638086 G> A c.409-6919 C>T 0.04  Intronic 
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Hg19 location 
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Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D04 DCIS 33638087 G> A c.409-6920 C>T 0.04  Intronic 
  33641958 C> T c.408+4668 G>A 0.02  Intronic 
  33648250 G> A Upstream 0.10  Upstream 
  33648859 T> C Upstream 0.04  Upstream 
  33658110 G> A Upstream 0.05  Upstream 
 INV 33611115 G> A c.*1663 C>T 0.03  3'UTR 
  33612419 G> A c.*359 C>T 0.04  3'UTR 
  33613056 G> A p.Arg384Cys 
c.1150C>T 
0.03  Exonic 
  33616887 G> A c.878-3559 C>T 0.03  Intronic 
  33619885 C> T c.877+3969 G>A 0.03  Intronic 
  33630779 G >A c.504+293 C>T 0.03  Intronic 
  33648250 G> A Upstream 0.05  Upstream 
  33658110 G> A Upstream 0.04  Upstream 
D05 DCIS 33612172 T> A c.*606 A>T 0.04  3'UTR 
  33612419 G> A c.*359 C>T 0.04  3'UTR 
  33616711 G> A c.878-3383 C>T 0.03  Intronic 
  33616870 G> A c.878-3542 C>T 0.04  Intronic 
  33616875 G> A c.878-3547 C>T 0.04  Intronic 
  33617291 C> T c.878-3963 G>A 0.04  Intronic 
  33618447 G> A c.878-5119 C>T 0.03  Intronic 
  33618473 G> A c.878-5145 C>T 0.04  Intronic 
  33618913 G> A c.877+4941 C>T 0.03  Intronic 
  33628228 G> A c.505-2683 C>T 0.03  Intronic 
  33629192 C> T c.504+1880 G>A 0.04  Intronic 
  33629215 C> T c.504+1857 G>A 0.03  Intronic 
  33629313 G> A c.504+1759 C>T 0.04  Intronic 
  33630776 C> T c.504+296 G>A 0.03  Intronic 
  33630850 C> T c.504+222 G>A 0.04  Intronic 
  33630908 C> T c.504+164 G>A 0.03  Intronic 
  33630924 C> T c.504+148 G>A 0.05  Intronic 
  33630930 C> T c.504+142 G>A 0.06  Intronic 
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Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 DCIS 33633418 C> T c.409-2251 G>A 0.05  Intronic 
  33634348 C> T c.409-3181 G>A 0.03  Intronic 
  33634759 G> A c.409-3592 C>T 0.03  Intronic 
  33636288 G> A c.409-5121 C>T 0.03  Intronic 
  33637967 G> A c.409-6800 C>T 0.03  Intronic 
  33638016 G> A c.409-6849 C>T 0.05  Intronic 
  33638082 G> A c.409-6915 C>T 0.04  Intronic 
  33638391 G> A c.409-7224 C>T 0.05  Intronic 
  33638864 C> T c.409-7697 G>A 0.06  Intronic 
  33638955 C> T c.408+7671 G>A 0.05  Intronic 
  33640229 C> T c.408+6397 G>A 0.03  Intronic 
  33641723 C> T c.408+4903 G>A 0.03  Intronic 
  33641954 C> T c.408+4672 G>A 0.05  Intronic 
  33643863 G> A c.408+2763 C>T 0.04  Intronic 
  33644807 C> T c.408+1819 G>A 0.03  Intronic 
  33645245 G> A c.408+1381 C>T 0.04  Intronic 
  33645855 C> T c.408+771 G>A 0.02  Intronic 
  33645870 C> T c.408+756 G>A 0.04  Intronic 
  33645977 T> C c.408+649 A>G 0.03  Intronic 
  33646036 T> C c.408+590 A>G 0.09  Intronic 
  33647350 G> A Upstream 0.05  Upstream 
  33648206 T> C Upstream 0.03  Upstream 
  33648250 G> A Upstream 0.09  Upstream 
  33649483 G> A Upstream 0.03  Upstream 
  33653025 G> A Upstream 0.03  Upstream 
  33653135 G> A Upstream 0.03  Upstream 
 INV 33611942 G> A c.*836 C>T 0.03  3'UTR 
  33612099 CCCT>GGGA  c.*676 AGGG>TCCC 0.43  3'UTR 
  33612922 G> A p.Ile428Ile 
c.1284C>T 
0.04  Exonic 
  33612977 C> T p.Arg410Gln 
c.1229G>A 
 
0.03  Exonic 
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Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33612994 C> T p.Trp404* 
c.1212G>A 
0.03  Exonic 
  33613048 G> A p.Phe386Phe 
c.1158C>T 
 
0.07  Exonic 
  33613079 C> T p.Gly376Asp 
c.1127G>A 
0.04  Exonic 
  33613086 G> A p.Arg374Cys 
c.1120C>T 
0.05  Exonic 
  33613124 G> C p.Thr361Ser 
c.1082C>G 
0.09  Exonic 
  33613140 C> T p.Val356Met 
c.1066G>A 
0.06  Exonic 
  33615544 C> T c.878-2216 G>A 0.03  Intronic 
  33615553 C> T c.878-2225 G>A 0.03  Intronic 
  33615721 C> T c.878-2393 G>A 0.04  Intronic 
  33615741 C> T c.878-2413 G>A 0.03  Intronic 
  33616139 C> G c.878-2811 G>C 0.08  Intronic 
  33616143 G> A c.878-2815 C>T 0.16  Intronic 
  33616177 G> A c.878-2849 C>T 0.09  Intronic 
  33616199 G> A c.878-2871 C>T 0.04  Intronic 
  33616214 G> A c.878-2886 C>T 0.09  Intronic 
  33616247 G> A c.878-2919 C>T 0.07  Intronic 
  33616252 C> T c.878-2924 G>A 0.03  Intronic 
  33616495 C> G c.878-3167 G>C 0.03  Intronic 
  33616610 G> A c.878-3282 C>T 0.03  Intronic 
  33616615 G> A c.878-3287 C>T 0.05  Intronic 
  33616667 C> T c.878-3339 G>A 0.05  Intronic 
  33616672 G> A c.878-3344 C>T 0.05  Intronic 
  33616704 G> A c.878-3376 C>T 0.03  Intronic 
  33616712 G> A c.878-3384 C>T 0.05  Intronic 
  33616739 G> A c.878-3411 C>T 0.04  Intronic 
  33616752 G> A c.878-3424 C>T 0.06  Intronic 
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Variant  Variant 
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Validated Area within DEAR1 
D05 INV 33616805 A> G c.878-3477 T>C 0.04  Intronic 
  33616808 G> A c.878-3480 C>T 0.03  Intronic 
  33616822 G> A c.878-3494 C>T 0.03  Intronic 
  33616829 G> A c.878-3501 C>T 0.07  Intronic 
  33616871 G> A c.878-3543 C>T 0.06  Intronic 
  33616890 G> A c.878-3562 C>T 0.07  Intronic 
  33616897 G> A c.878-3569 C>T 0.06  Intronic 
  33616903 G> A c.878-3575 C>T 0.06  Intronic 
  33616908 G> A c.878-3580 C>T 0.06  Intronic 
  33616994 G> A c.878-3666 C>T 0.03  Intronic 
  33617168 C> T c.878-3840 G>A 0.04  Intronic 
  33617287 G> A c.878-3959 C>T 0.04  Intronic 
  33617289 C> T  c.878-3961 G>A 0.03  Intronic 
  33617296 G> A c.878-3968 C>T 0.04  Intronic 
  33617325 C> G c.878-3997 G>C 0.03  Intronic 
  33617378 C> T c.878-4050 G>A 0.06  Intronic 
  33617393 T> C c.878-4065 A>G 0.03  Intronic 
  33617396 C> T c.878-4068 G>A 0.06  Intronic 
  33617416 C> T c.878-4088 G>A 0.05  Intronic 
  33617428 C> G c.878-4100 G>C 0.09  Intronic 
  33617605 C> T c.878-4277 G>A 0.03  Intronic 
  33617613 C> T c.878-4285 G>A 0.04  Intronic 
  33617617 G> A c.878-4289 C>T 0.03  Intronic 
  33618734 G> A c.877+5120 C>T 0.04  Intronic 
  33618849 C> T c.877+5005 G>A 0.04  Intronic 
  33618852 G> A c.877+5002 C>T 0.07  Intronic 
  33618876 C> T  c.877+4978 G>A 0.06  Intronic 
  33618907 C> T c.877+4947 G>A 0.06  Intronic 
  33618961 C> T c.877+4893 G>A 0.05  Intronic 
  33618964 C> T c.877+4890 G>A 0.05  Intronic 
  33618968 C> T c.877+4886 G>A 0.07  Intronic 
  33621043 G> A c.877+2811 C>T 0.04  Intronic 
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  33621066 G> A c.877+2788 C>T 0.04  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33621087 C> T c.877+2767 G>A 0.03  Intronic 
  33621105 C> T c.877+2749 G>A 0.05  Intronic 
  33623968 G> A p.Leu255Phe 
c.763C>T 
0.04  Exonic 
  33623984 G> A c.762-15 C>T 0.04  Intronic 
  33624019 C> T c.762-50 G>A 0.05  Intronic 
  33625353 G> T p.Gln233Lys 
c.697C>A 
0.03  Exonic 
  33625444 C> T p.Ala202Ala 
c.606G>A 
0.04  Exonic 
  33625495 C> T p.Leu185Leu 
c.555G>A 
0.03  Exonic 
  33625503 C> T p.Glu183Lys 
c.547G>A 
0.04  Exonic 
  33626859 G> A c.505-1314 C>T 0.04  Intronic 
  33627078 G> A c.505-1533 C>T 0.03  Intronic 
  33627136 G> A c.505-1591 C>T 0.04  Intronic 
  33627170 C> T  c.505-1625 G>A 0.03  Intronic 
  33627283 G> A c.505-1738 C>T 0.04  Intronic 
  33627339 C> T c.505-1794 G>A 0.03  Intronic 
  33627370 C> T c.505-1825 G>A 0.03  Intronic 
  33627375 G> A c.505-1830 C>T 0.04  Intronic 
  33627387 C> A c.505-1842 G>T 0.03  Intronic 
  33627405 C> T c.505-1860 G>A 0.03  Intronic 
  33627445 C> T c.505-1900 G>A 0.03  Intronic 
  33628205 G> A c.505-2660 C>T 0.06  Intronic 
  33628224 G> A c.505-2679 C>T 0.03  Intronic 
  33628238 G> A c.505-2693 C>T 0.05  Intronic 
  33629313 G> A c.504+1759C>T 0.05  Intronic 
  33629340 G> T c.504+1732 C>A 0.07  Intronic 
  33629363 G> A c.504+1709 C>T 0.06  Intronic 
  33629494 G> A c.504+1578 C>T 0.04  Intronic 
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  33629572 G> A c.504+1500 C>T 0.05  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33629715 G> A c.504+1357 C>T 0.04  Intronic 
  33629773 C> T c.504+1299 G>A 0.04  Intronic 
  33629776 G> A c.504+1296 C>T 0.04  Intronic 
  33629777 C> T c.504+1295 G>A 0.05  Intronic 
  33629778 C> T c.504+1294 G>A 0.04  Intronic 
  33629801 G> A c.504+1271 C>T 0.04  Intronic 
  33629843 G> A c.504+1229 C>T 0.03  Intronic 
  33629844 G> A c.504+1228 C>T 0.05  Intronic 
  33629857 C> T c.504+1215 G>A 0.04  Intronic 
  33629872 GG>AA c.504+1200 CC>TT 0.03  Intronic 
  33629897 C> T c.504+1175 G>A 0.04  Intronic 
  33630292 G> A c.504+780 C>T 0.03  Intronic 
  33630716 G> A c.504+356 C>T 0.04  Intronic 
  33630759 G> A c.504+313 C>T 0.04  Intronic 
  33630775 C> T c.504+297 G>A 0.1  Intronic 
  33630778 G> A c.504+294 C>T 0.09  Intronic 
  33630843 C> T c.504+229 G>A 0.05  Intronic 
  33630850 C> T c.504+222 G>A 0.04  Intronic 
  33630881 G> A c.504+191 C>T 0.05  Intronic 
  33630900 C> T c.504+172 G>A 0.06  Intronic 
  33630906 C> T c.504+166 G>A 0.06  Intronic 
  33630913 C> T c.504+159 G>A 0.03  Intronic 
  33631195 G> A c.409-28 C>T 0.03  Intronic 
  33631232 C> T c.409-65 G>A 0.04  Intronic 
  33631277 C> T c.409-110 G>A 0.05  Intronic 
  33631302 C> T c.409-135 G>A 0.05  Intronic 
  33631305 C> T c.409-1897 G>A 0.06  Intronic 
  33633064 C> T c.409-2116 C>T 0.03  Intronic 
  33633283 G> A c.409-2138 G>A 0.06  Intronic 
  33633305 C> T c.409-3128 C>T 0.09  Intronic 
  33634295 G> A c.409-3191 G>A 0.05  Intronic 
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  33634358 C> T c.409-3128 C>T 0.05  Intronic 
  33634373 C> G c.409-3206 G>C 0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33634375 G> A c.409-3208 C>T 0.05  Intronic 
  33634646 C> T  c.409-3479 G>A 0.04  Intronic 
  33634651 C> T c.409-3484 G>A 0.05  Intronic 
  33634691 G> A c.409-3524 C>T 0.03  Intronic 
  33634693 G> A c.409-3526 C>T 0.04  Intronic 
  33634756 G> A c.409-3589 C>T 0.06  Intronic 
  33634793 G> A c.409-3626 C>T 0.03  Intronic 
  33634798 G> A c.409-3631 C>T 0.03  Intronic 
  33636146 G> A c.409-4979 C>T 0.03  Intronic 
  33636276 G> A c.409-5109 C>T 0.05  Intronic 
  33636287 A> G c.409-5120 T>C 0.05  Intronic 
  33636289 G> A c.409-5122 C>T 0.05  Intronic 
  33636668 C> T  c.409-5501 G>A 0.03  Intronic 
  33636691 G> A c.409-5524 C>T 0.04  Intronic 
  33636713 C> T c.409-5546 G>A 0.03  Intronic 
  33636721 G> C c.409-5554 C>G 0.03  Intronic 
  33636725 C> T c.409-5558 G>A 0.03  Intronic 
  33636738 G> A c.409-5571 C>T 0.03  Intronic 
  33637943 G> A c.409-6776 C>T 0.05  Intronic 
  33637946 G> A c.409-6779 C>T 0.05  Intronic 
  33638005 G> A c.409-6838 C>T 0.03  Intronic 
  33638086 G> A c.409-6919 C>T 0.05  Intronic 
  33638194 C> G c.409-7027 G>C 0.06  Intronic 
  33638199 G> A c.409-7032 C>T 0.06  Intronic 
  33638242 C> T c.409-7075 G>A 0.08  Intronic 
  33638251 C> T c.409-7084 G>A 0.03  Intronic 
  33638258 G> A c.409-7091 C>T 0.06  Intronic 
  33638290 G> A c.409-7123 C>T 0.06  Intronic 
  33638302 G> T c.409-7135 C>A 0.04  Intronic 
  33638370 G> A c.409-7203 C>T 0.04  Intronic 
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  33638393 C> T  c.409-7226 G>A 0.04  Intronic 
  33638472 C> T c.409-7305 G>A 0.05  Intronic 
  33638475 G> A c.409-7308 C>T 0.04  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33638518 C> T c.409-7351 G>A 0.08  Intronic 
  33638547 G> A c.409-7380 C>T 0.07  Intronic 
  33638551 CC> TT c.409-7384 GG>AA 0.07  Intronic 
  33638558 C> T c.409-7391 G>A 0.07  Intronic 
  33638608 C> T c.409-7441 G>A 0.08  Intronic 
  33638611 C> T c.409-7444 G>A 0.04  Intronic 
  33638647 C> T c.409-7480 G>A 0.04  Intronic 
  33638744 C> T c.409-7577 G>A 0.04  Intronic 
  33638757 A> C c.409-7590 T>G 0.05  Intronic 
  33638758 C> T   c.409-7591 G>A 0.04  Intronic 
  33638762 C> T c.409-7595 G>A 0.04  Intronic 
  33638860 C> T c.409-7693 G>A 0.05  Intronic 
  33638864 C> T c.409-7697G>A 0.05  Intronic 
  33638875 G> A c.409-7708 C>T 0.04  Intronic 
  33638918 C> T  c.408+7708 G>A 0.04  Intronic 
  33638982 C> T c.408+7644 G>A 0.08  Intronic 
  33638990 G> C c.408+7636 C>G 0.08  Intronic 
  33639069 C> T  c.408+7557 G>A 0.09  Intronic 
  33639083 C> A c.408+7543 G>T 0.09  Intronic 
  33640324 C> T c.408+6302 G>A 0.04  Intronic 
  33640342 G> A c.408+6284 C>T 0.04  Intronic 
  33641453 C> T c.408+5173 G>A 0.03  Intronic 
  33641656 C> G c.408+4970 G>C 0.03  Intronic 
  33641668 C> T c.408+4958 G>A 0.04  Intronic 
  33641874 C> T c.408+4752 G>A 0.04  Intronic 
  33641909 C> T c.408+4717 G>A 0.04  Intronic 
  33641923 C> T c.408+4703 G>A 0.05  Intronic 
  33641994 C> T c.408+4632 G>A 0.04  Intronic 
  33642018 C> T c.408+4608 G>A 0.04  Intronic 
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  33642063 C> T c.408+4563 G>A 0.03  Intronic 
  33642109 G> A c.408+4517 C>T 0.04  Intronic 
  33643885 G> A c.408+2741 C>T 0.04  Intronic 
  33643944 G> A c.408+2682 C>T 0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33644402 C> T  c.408+2224 G>A 0.04  Intronic 
  33644432 G> A c.408+2194 C>T 0.04  Intronic 
  33644439 C> T c.408+2187 G>A 0.05  Intronic 
  33644451 C> T c.408+2175 G>A 0.03  Intronic 
  33644474 G> A c.408+2152 C>T 0.04  Intronic 
  33644863 C> T c.408+1763 G>A 0.04  Intronic 
  33644894 G> A c.408+1732 C>T 0.04  Intronic 
  33645020 G> A c.408+1606 C>T 0.04  Intronic 
  33645027 G> A c.408+1599 C>T 0.04  Intronic 
  33645040 C> A c.408+1586 G>T 0.04  Intronic 
  33645090 G> A c.408+1536 C>T 0.03  Intronic 
  33645128 C> T  c.408+1498 G>A 0.07  Intronic 
  33645151 C> T c.408+1475 G>A 0.03  Intronic 
  33645183 G> A c.408+1443 C>T 0.06  Intronic 
  33645290 G> A c.408+1336 C>T 0.04  Intronic 
  33645303 C> T  c.408+1323 G>A 0.04  Intronic 
  33645307 C> T c.408+1319 G>A 0.04  Intronic 
  33645675 G> A c.408+951 C>T 0.03  Intronic 
  33645696 G> A c.408+930 C>T 0.04  Intronic 
  33645855 C> T c.408+771G>A 0.04  Intronic 
  33645856 C> T  c.408+770 G>A 0.05  Intronic 
  33645912 C> T  c.408+714 G>A 0.04  Intronic 
  33645932 C> T c.408+694 G>A 0.04  Intronic 
  33645955 C> T c.408+671 G>A 0.04  Intronic 
  33645964 G> C c.408+662 C>G 0.04  Intronic 
  33646035 C> T  c.408+591 G>A 0.03  Intronic 
  33646036 T> C c.408+590A>G 0.06  Intronic 
  33646094 C> T  c.408+532 G>A 0.04  Intronic 
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  33646110 C> T c.408+516 G>A 0.07  Intronic 
  33646271 C> T c.408+355 G>A 0.03  Intronic 
  33647517 G> A Upstream 0.04  Upstream 
  33647526 G> A Upstream 0.04  Upstream 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D05 INV 33647595 C> T  Upstream 0.04  Upstream 
  33647631 C> A  Upstream 0.06  Upstream 
  33648206 T> C Upstream 0.15  Upstream 
  33648250 G> A Upstream 0.09  Upstream 
  33648829 G> A Upstream 0.04  Upstream 
  33649473 C> T  Upstream 0.06  Upstream 
  33649476 G> A Upstream 0.06  Upstream 
  33649564 C> T  Upstream 0.05  Upstream 
  33649574 C> G Upstream 0.07  Upstream 
  33651320 C> T Upstream 0.05  Upstream 
  33651330 C> T Upstream 0.07  Upstream 
  33651397 G> T Upstream 0.04  Upstream 
  33651410 G> A Upstream 0.06  Upstream 
  33653008 C> G Upstream 0.05  Upstream 
  33653022 G> A Upstream 0.06  Upstream 
  33653028 G> A Upstream 0.07  Upstream 
  33653059 G> A Upstream 0.04  Upstream 
  33657843 C> T Upstream 0.04  Upstream 
  33657845 C> T Upstream 0.06  Upstream 
  33657853 C> T Upstream 0.06  Upstream 
  33657922 C> T Upstream 0.07  Upstream 
  33658110 G> A Upstream 0.03  Upstream 
  33658670 G> A Upstream 0.05  Upstream 
  33658796 G> A Upstream 0.04  Upstream 
  33681361 C> T  Upstream 0.04  Upstream 
  33681404 C> T  Upstream 0.04  Upstream 
  33681418 G> A Upstream 0.03  Upstream 
  33681433 C> T Upstream 0.04  Upstream 
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D06 DCIS 33613098 C> T p.Glu370Lys      
 c.1108G>A 
0.04  Exonic 
  33625498 C> T p.Arg184Arg 
c.552G>A 
0.03  Exonic 
  33616812 G> A c.878-3484 C>T 0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D06 DCIS 33638087 G> A c.409-6920 C>T 0.03  Intronic 
  33638582 C> T c.409-7415 G>A 0.03  Intronic 
  33644801 C> T c.408+1825 G>A 0.04  Intronic 
 INV 33611108 G> A c.*1670 C>T 0.06  3'UTR 
  33611283 G> A c.*1495 C>T 0.05  3'UTR 
  33611323 C> T c.*1455 G>A 0.03  3'UTR 
  33612181 C> T c.*597 G>A 0.03  3'UTR 
  33612370 G> A c.*408 C>T 0.04  3'UTR 
  33612419 G> A c.*359 C>T 0.03  3'UTR 
  33613072 G> C p.Ile378Met 
c.1134C>G 
0.03  Exonic 
  33613080 C> T p.Gly376Ser 
c.1126G>A 
0.03  Exonic 
  33613116 C> T p.Val364Met 
c.1090G>A 
0.03  Exonic 
  33616206 G> A c.878-2878 C>T 0.03  Intronic 
  33616478 G> A c.878-3150 C>T 0.03  Intronic 
  33616729 G> A c.878-3401 C>T 0.04  Intronic 
  33616839 G> A c.878-3511 C>T 0.03  Intronic 
  33616870 G> A c.878-3542 C>T 0.03  Intronic 
  33616875 G> A c.878-3547 C>T 0.03  Intronic 
  33616890 G> A c.878-3562 C>T 0.03  Intronic 
  33616898 G> A c.878-3570 C>T 0.06  Intronic 
  33616902 G> A c.878-3574 C>T 0.04  Intronic 
  33619899 C> T c.877+3955 G>A 0.03  Intronic 
  33623976 G> A c.762-7 C>T 0.03  Intronic 
  33625263 G> A c.761+26 C>T 0.03  Intronic 
  33625514 C> T p.Gly179Asp 0.04  Exonic 
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c.536G>A 
  33629315 G> A c.504+1757 C>T 0.07  Intronic 
  33629321 G> A c.504+1751 C>T 0.04  Intronic 
  33629360 G> A c.504+1712 C>T 
 
0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D06 INV 33630778 G> A c.504+294 C>T 0.09  Intronic 
  33630913 C> T c.504+159 G>A 0.03  Intronic 
  33630919 C> T c.504+153 G>A 0.06  Intronic 
  33630920 C> T c.504+152 G>A 0.05  Intronic 
  33630930 C> G c.504+142 G>C 0.03  Intronic 
  33633308 C> G c.409-2141 G>C 0.05  Intronic 
  33634282 G> A c.409-3115 C>T 0.04  Intronic 
  33634288 G> A c.409-3121 C>T 0.04  Intronic 
  33634294 G> A c.409-3127 C>T 0.04  Intronic 
  33636640 G> A c.409-5473 C>T 0.07  Intronic 
  33636663 G> A c.409-5496 C>T 0.03  Intronic 
  33638086 G> A c.409-6919 C>T 0.03  Intronic 
  33638217 G> A c.409-7050 C>T 0.03  Intronic 
  33638393 C> T c.409-7226 G>A 0.03  Intronic 
  33638506 C> T c.409-7339 G>A 0.05  Intronic 
  33638844 C> T c.409-7677 G>A 0.03  Intronic 
  33638868 C> T c.409-7701 G>A 0.03  Intronic 
  33638932 C> T c.408+7694 G>A 0.03  Intronic 
  33639142 C> T c.408+7484 G>A 0.04  Intronic 
  33641558 C> T c.408+5068 G>A 0.04  Intronic 
  33641940 C> T c.408+4686 G>A 0.03  Intronic 
  33642164 C> G c.408+4462 G>C 0.02  Intronic 
  33645318 G> A c.408+1308 C>T 0.03  Intronic 
  33645919 C> T c.408+707 G>A 0.03  Intronic 
  33646965 G> A p.Ser23Ser 
c.69C>T 
0.04  Exonic 
  33648722 G> A Upstream 0.04  Upstream 
  33649476 G> A Upstream 0.04  Upstream 
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  33649511 G> A Upstream 0.04  Upstream 
  33657845 C> T Upstream 0.03  Upstream 
  33657889 C> T Upstream 0.03  Upstream 
D07 DCIS 33639129 T> A c.408+7497 A>T 
 
0.04  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D07 INV 33648237 A> G Upstream 0.05  Upstream 
D08 DCIS 33639129 T> A Upstream 0.05  Upstream 
  33648250 G> A Upstream 0.15  Upstream 
 INV 33611230 A> G c.*1548 T>C 0.04  3'UTR 
  33616852 G> A c.878-3524 C>T 0.04  Intronic 
  33629318 C> T c.504+1754 G>A 0.03  Intronic 
  33638876 G> C c.409-7709 C>G 0.03  Intronic 
  33639129 T> A Upstream 0.05  Upstream 
  33657915 A> G Upstream 0.03  Upstream 
D09 DCIS 33612473 T> C c.*305 A>G 0.14  3'UTR 
  33629668 TC> CA c.504+1404 GA>TG 0.46  Intronic 
  33644798 AA> GC  c.408+1828 TT>GC 1  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 0.51  Intronic 
 INV 33629668 TC> CA c.504+1404 GA>TG 0.49  Intronic 
  33639129 T> A c.408+7497 A>T 0.05  Intronic 
  33644798 AA> GC  c.408+1828  TT>GC 1  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 0.52  Intronic 
  33648859 T> C Upstream 0.05  Upstream 
D10 DCIS 33639129 T> A c.408+7497 A>T 0.04  Intronic 
 INV 33644798 AA> GC c.408+1828 TT>GC 1  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1  Intronic 
D11 DCIS 33612419 G> A c.*359 C>T 0.04  3'UTR 
  33612452 G> A c.*326 C>T 0.03  3'UTR 
  33613021 G> A p.Asn395Asn 
c.1185C>T 
0.03  Exonic 
  33613415 G> A c.878-87 C>T 0.04  Intronic 
  33616060 C> T c.878-2732 G>A 0.03  Intronic 
  33616104 C> T c.878-2732 G>A 0.03  Intronic 
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  33616166 C> T c.878-2776 G>A 0.03  Intronic 
  33616221 G> A c.878-2838 G>A 
 
0.03  Intronic 
  33616233 G> A c.878-2893 C>T 0.03  Intronic 
  33616342 G> A c.878-2905 C>T 0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 DCIS 33616344 G> A c.878-3016 C>T 0.04  Intronic 
  33616397 G> A c.878-3069 C>T 0.03  Intronic 
  33616513 G> A c.878-3185 C>T 0.03  Intronic 
  33616666 G> A c.878-3338 C>T 0.05  Intronic 
  33616684 G> A c.878-3356 C>T 0.03  Intronic 
  33616712 G> A c.878-3384 C>T 0.04  Intronic 
  33616808 G> A c.878-3480 C>T 0.04  Intronic 
  33616864 G> A c.878-3536 C>T 0.03  Intronic 
  33616887 G> A c.878-3559 C>T 0.04  Intronic 
  33616891 G> A c.878-3563 C>T 0.04  Intronic 
  33618646 G> A c.877+5208 C>T 0.11  Intronic 
  33618721 G> A c.877+5133 C>T 0.03  Intronic 
  33618922 C> T c.877+4932 G>A 0.03  Intronic 
  33621020 C> T c.877+2834 G>A 0.03  Intronic 
  33623961 C> T p.Gly257Glu 
c.770G>A 
0.03  Exonic 
  33623985 G> A c.762-16 C>T 0.03  Intronic 
  33625122 C> T c.761+167 G>A 0.03  Intronic 
  33625142 C> T c.761+147 G>A 0.04  Intronic 
  33625456 C> T p.Glu77Glu 
c.231G>A 
0.03  Exonic 
  33625665 G> A c.505-120 C>T 0.04  Intronic 
  33627101 C> T c.142-1556 G>A 0.02  Intronic 
  33627241 C> T c.505-1696 G>A 0.04  Intronic 
  33627263 G> A c.505-1718 C>T 0.04  Intronic 
  33627291 C> T c.505-1746 G>A 0.03  Intronic 
  33628207 G> A c.505-2662 C>T 0.04  Intronic 
  33629578 G> A c.504+1494 C>T 0.03  Intronic 
172 
 
  33630772 G> A c.504+300 C>T 0.08  Intronic 
  33630775 C> T c.504+297 G>A 0.05  Intronic 
  33630908 C> T c.504+164 G>A 0.04  Intronic 
  33630925 C> T c.504+147 G>A 0.05  Intronic 
  33633303 C> T c.409-2136 G>A 0.05  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 DCIS 33633416 G> A c.409-2249 C>T 0.03  Intronic 
  33634282 G> A c.409-3115 C>T 0.03  Intronic 
  33634785 C> T c.409-3618 G>A 0.03  Intronic 
  33636295 G> A c.409-5128 C>T 0.05  Intronic 
  33637997 G> A c.409-6830 C>T 0.03  Intronic 
  33638004 G> A c.409-6837 C>T 0.09  Intronic 
  33638021 G> A c.409-6854 C>T 0.04  Intronic 
  33638048 G> A c.409-6881 C>T 0.03  Intronic 
  33638086 G> A c.409-6919 C>T 0.05  Intronic 
  33638087 G> A c.409-6920 C>T 0.04  Intronic 
  33638181 G> A c.409-7014 C>T 0.03  Intronic 
  33638182 G> A c.409-7015 C>T 0.03  Intronic 
  33638210 G> A c.409-7043 C>T 0.03  Intronic 
  33638360 C> T c.409-7193 G>A 0.04  Intronic 
  33638535 C> T c.409-7368 G>A 0.03  Intronic 
  33639014 G> A c.408+7612 C>T 0.05  Intronic 
  33641603 C> T c.408+5023 G>A 0.03  Intronic 
  33641922 C> T c.408+4704 G>A 0.04  Intronic 
  33641929 C> T c.408+4697 G>A 0.03  Intronic 
  33641956 C> T c.408+4670 G>A 0.05  Intronic 
  33641976 C> T c.408+4650 G>A 0.03  Intronic 
  33643945 G> A c.408+2681 C>T 0.05  Intronic 
  33644794 C> T c.408+1832 G>A 0.04  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33644941 G> A c.408+1685 C>T 0.03  Intronic 
  33645037 G> A c.408+1589 C>T 0.03  Intronic 
  33645055 G> A c.408+1571 C>T 0.04  Intronic 
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  33645109 C> T c.408+1517 G>A 0.03  Intronic 
  33645179 C> T c.408+1447 G>A 0.03  Intronic 
  33645185 G> A c.408+1441 C>T 0.04  Intronic 
  33645644 G> A c.408+982 C>T 0.03  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33645856 C> T c.408+770 G>A 0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 DCIS 33645897 C> T c.408+729 G>A 0.04  Intronic 
  33645931 C> T c.408+695 G>A 0.04  Intronic 
  33645937 C> T c.408+689 G>A 0.04  Intronic 
  33645997 C> T c.408+629 G>A 0.03  Intronic 
  33646001 C> T c.408+625 G>A 0.04  Intronic 
  33646103 C> T c.408+523 G>A 0.04  Intronic 
  33646143 C> T c.408+483 G>A 0.03  Intronic 
  33646165 C> T c.408+461 G>A 0.03  Intronic 
  33646181 C> T c.408+445 G>A 0.04  Intronic 
  33646186 C> T c.408+440 G>A 0.04  Intronic 
  33646330 C> T c.408+296 G>A 0.03  Intronic 
  33646333 C> T c.408+293 G>A 0.04  Intronic 
  33646347 C> T c.408+279 G>A 0.03  Intronic 
  33647195 G> A c.-162 C>T 0.03  5'UTR 
  33648206 T> C Upstream 0.14  Upstream 
  33649525 C> T Upstream 0.04  Upstream 
  33649543 C> T Upstream 0.04  Upstream 
  33649577 C> T Upstream 0.03  Upstream 
  33651364 C> T Upstream 0.04  Upstream 
  33651366 G> A Upstream 0.04  Upstream 
  33653032 G> A Upstream 0.05  Upstream 
  33656997 C> T Upstream 0.03  Upstream 
  33657853 C> T Upstream 0.03  Upstream 
  33657888 C> T Upstream 0.04  Upstream 
  33657910 C> T Upstream 0.04  Upstream 
  33657918 C> T Upstream 0.03  Upstream 
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 INV 33611118 G> A c.*1660 C>T 0.03  3'UTR 
  33611332 G> A c.*1446 C>T 0.03  3'UTR 
  33611892 G> A c.*886 C>T 0.03  3'UTR 
  33612122 G> A c.*656 C>T 0.03  3'UTR 
  33612384 G> A c.*394 C>T 0.05  3'UTR 
  33612468 GGTA> CCAT c.*307 TACC>ATGG 0.06  3'UTR 
  33612547 G> A c.*231 C>T 0.03  3'UTR 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 INV 33612978 G> A p.Arg410Trp 
c.1228C>T 
0.03  Exonic 
  33613058 C> T p.Ser383Asn 
c.1148G>A 
0.03  Exonic 
  33613079 C> T p.Gly376Asp 
c.1127G>A 
0.04  Exonic 
  33613085 C> T p.Arg374His 
c.1121G>A 
0.05  Exonic 
  33613200 C> T p.Val336Met 
c.1006G>A 
0.03  Exonic 
  33613362 G> A c.878-34 C>T 0.04  Intronic 
  33615571 G> A c.878-2243 C>T 0.04  Intronic 
  33615678 C> T c.878-2350 G>A 0.03  Intronic 
  33616092 C> T c.878-2764 G>A 0.05  Intronic 
  33616105 C> T c.878-2777 G>A 0.04  Intronic 
  33616197 G> A c.878-2869 C>T 0.05  Intronic 
  33616324 G> A c.878-2996 C>T 0.05  Intronic 
  33616726 G> A c.878-3398 C>T 0.04  Intronic 
  33616740 G> A c.878-3412 C>T 0.04  Intronic 
  33616897 G> A c.878-3569 C>T 0.03  Intronic 
  33617358 C> T c.878-4030 G>A 0.04  Intronic 
  33618710 G> A c.877+5144 C>T 0.05  Intronic 
  33618712 G> A c.877+5142 C>T 0.05  Intronic 
  33618734 G> A c.877+5120 C>T 0.04  Intronic 
  33619828 G> A c.877+4026 C>T 0.05  Intronic 
  33623981 G> A c.762-12 C>T 0.04  Intronic 
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  33623997 C> T c.762-28 G>A 0.03  Intronic 
  33624003 G> A c.762-34 C>T 0.04  Intronic 
  33624016 G> A c.762-47 C>T 0.03  Intronic 
  33624033 C> T c.762-64 G>A 0.05  Intronic 
  33624036 G> A c.762-67 C>T 0.03  Intronic 
  33624050 G> A c.762-81 C>T 0.03  Intronic 
  33625077 C> T c.761+212 G>A 0.04  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 INV 33625655 G> A c.505-110 C>T 0.03  Intronic 
  33625663 G> A c.505-118 C>T 0.04  Intronic 
  33626868 G> A c.505-1323 C>T 0.03  Intronic 
  33626885 G> A c.505-1340 C>T 0.04  Intronic 
  33626928 G> A c.505-1383 C>T 0.04  Intronic 
  33627271 G> A c.505-1726 C>T 0.07  Intronic 
  33627411 C> T c.505-1866 G>A 0.03  Intronic 
  33627448 C> T c.505-1903 G>A 0.03  Intronic 
  33628224 G> A c.142-2679 C>T 0.03  Intronic 
  33628228 G> A c.505-2683 C>T 0.03  Intronic 
  33628249 G> A c.505-2704 C>T 0.03  Intronic 
  33628254 G> A c.505-2709 C>T 0.03  Intronic 
  33628264 G> A c.505-2719 C>T 0.07  Intronic 
  33629174 C> T c.504+1898 G>A 0.04  Intronic 
  33629225 C> T c.504+1847 G>A 0.05  Intronic 
  33629389 C> T c.504+1683 G>A 0.03  Intronic 
  33629399 G> A c.504+1673 C>T 0.04  Intronic 
  33629408 G> A c.504+1664 C>T 0.03  Intronic 
  33629429 C> T c.504+1643 G>A 0.03  Intronic 
  33629544 G> A c.504+1528 C>T 0.03  Intronic 
  33629741 G> A c.504+1331 C>T 0.04  Intronic 
  33629784 G> A c.504+1288 C>T 0.03  Intronic 
  33629829 G> A c.504+1243 C>T 0.04  Intronic 
  33629870 C> T c.504+1202 G>A 0.03  Intronic 
  33630756 C> T c.504+316 G>A 0.03  Intronic 
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  33630782 C> T c.504+290 G>A 0.04  Intronic 
  33630846 C> T c.504+226 G>A 0.03  Intronic 
  33630900 C> T c.504+172 G>A 0.04  Intronic 
  33630928 C> T c.504+144 G>A 0.09  Intronic 
  33630929 C> T c.504+143 G>A 0.06  Intronic 
  33631385 C> T c.409-218 G>A 0.04  Intronic 
  33633128 C> T c.409-1961 G>A 0.04  Intronic 
  33633231 C> T c.409-2064 G>A 0.05  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 INV 33633241 C> T c.409-2074 G>A 0.04  Intronic 
  33634280 C> T c.409-3113 G>A 0.03  Intronic 
  33634288 G> A c.409-3121 C>T 0.03  Intronic 
  33634320 G> A c.409-3153 C>T 0.04  Intronic 
  33634322 G> A c.409-3155 C>T 0.06  Intronic 
  33634343 G> A c.409-3176  C>T 0.04  Intronic 
  33634391 G> A c.409-3224 C>T 0.04  Intronic 
  33634592 C> T c.409-3425 G>A 0.03  Intronic 
  33634609 C> T c.409-3442 G>A 0.04  Intronic 
  33634699 G> A c.409-3532 C>T 0.03  Intronic 
  33634705 G> A c.409-3538 C>T 0.05  Intronic 
  33636128 G> A c.409-4961 C>T 0.04  Intronic 
  33636180 G> A c.409-5013 C>T 0.03  Intronic 
  33636640 G> A c.409-5473 C>T 0.03  Intronic 
  33636654 G> A c.409-5487 C>T 0.04  Intronic 
  33636661 C> T c.409-5494 G>A 0.03  Intronic 
  33637967 G> A c.409-6800 C>T 0.03  Intronic 
  33638000 G> A c.409-6833 C>T 0.06  Intronic 
  33638005 G> A c.409-6838 C>T 0.08  Intronic 
  33638065 G> A c.409-6898 C>T 0.04  Intronic 
  33638081 G> A c.409-6914 C>T 0.07  Intronic 
  33638180 G> A c.409-7013 C>T 0.03  Intronic 
  33638199 G> A c.409-7032 C>T 0.05  Intronic 
  33638200 G> A c.409-7033 C>T 0.03  Intronic 
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  33638349 C> T c.409-7182 G>A 0.04  Intronic 
  33638384 C> T c.409-7217 G>A 0.03  Intronic 
  33638462 G> A c.409-7295 C>T 0.04  Intronic 
  33638480 C> T c.409-7313 G>A 0.04  Intronic 
  33638575 C> T c.409-7408 G>A 0.04  Intronic 
  33638591 C> T c.409-7424 G>A 0.05  Intronic 
  33638623 C> T c.409-7456 G>A 0.03  Intronic 
  33638637 C> T c.409-7470 G>A 0.03  Intronic 
  33638753 C> T c.409-7586 G>A 0.04  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 INV 33638762 C> T c.409-7595 G>A 0.04  Intronic 
  33638803 C> T c.409-7636 G>A 0.03  Intronic 
  33638808 C> T c.409-7641 G>A 0.06  Intronic 
  33638828 C> T c.409-7661 G>A 0.04  Intronic 
  33638848 C> T c.409-7681 G>A 0.03  Intronic 
  33638864 C> T c.409-7697 G>A 0.03  Intronic 
  33638872 C> T c.409-7705 G>A 0.03  Intronic 
  33638884 C> T c.409-7717 G>A 0.07  Intronic 
  33638889 C> T c.409-7722 G>A 0.03  Intronic 
  33639002 G> A c.408+7624 C>T 0.03  Intronic 
  33639010 G> A c.408+7616 C>T 0.06  Intronic 
  33639044 G> A c.408+7582 C>T 0.03  Intronic 
  33639046 G> A c.408+7580 C>T 0.04  Intronic 
  33639056 G> A c.408+7570 C>T 0.03  Intronic 
  33640222 C> T c.408+6404 G>A 0.04  Intronic 
  33640229 C> T c.408+6397 G>A 0.04  Intronic 
  33640366 C> T c.408+6260 G>A 0.03  Intronic 
  33641447 C> T c.408+5179 G>A 0.03  Intronic 
  33641481 C> T c.408+5145 G>A 0.04  Intronic 
  33641528 C> T c.408+5098 G>A 0.05  Intronic 
  33641543 G> A c.408+5083 C>T 0.04  Intronic 
  33641565 G> A c.408+5061 C>T 0.04  Intronic 
  33641599 C> T c.408+5027 G>A 0.04  Intronic 
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  33641650 G> A c.408+4976 C>T 0.04  Intronic 
  33641707 C> T c.408+4919 G>A 0.04  Intronic 
  33641767 C> T c.408+4859 G>A 0.03  Intronic 
  33641874 C> T c.408+4752 G>A 0.07  Intronic 
  33641923 C> T c.408+4703 G>A 0.04  Intronic 
  33641959 C> T c.408+4667 G>A 0.06  Intronic 
  33641962 C> T c.408+4664 G>A 0.05  Intronic 
  33643862 G> A c.408+2764 C>T 0.03  Intronic 
  33643874 G> A c.408+2752 C>T 0.04  Intronic 
  33643882 G> A c.408+2744 C>T 0.03  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 INV 33643887 G> A c.408+2739 C>T 0.03  Intronic 
  33644006 G> A c.408+2620 C>T 0.03  Intronic 
  33644084 G> A c.408+2542 C>T 0.03  Intronic 
  33644433 G> A c.408+2193 C>T 0.04  Intronic 
  33644439 C> T c.408+2187 G>A 0.03  Intronic 
  33644442 G> A c.408+2184 C>T 0.05  Intronic 
  33644467 G> A c.408+2159 C>T 0.06  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33644908 G> A c.408+1718 C>T 0.04  Intronic 
  33644917 G> A c.408+1709 C>T 0.04  Intronic 
  33645017 C> T c.408+1609 G>A 0.06  Intronic 
  33645020 G> A c.408+1606 C>T 0.05  Intronic 
  33645036 G> A c.408+1590 C>T 0.03  Intronic 
  33645110 C> T c.408+1516 G>A 0.03  Intronic 
  33645161 C> T c.408+1465 G>A 0.05  Intronic 
  33645176 C> T c.408+1450 G>A 0.03  Intronic 
  33645203 G> A c.408+1423 C>T 0.04  Intronic 
  33645207 G> A c.408+1419 C>T 0.04  Intronic 
  33645240 G> A c.408+1386 C>T 0.03  Intronic 
  33645285 G> A c.408+1341 C>T 0.09  Intronic 
  33645318 G> A c.408+1308 C>T 0.03  Intronic 
  33645597 G> A c.408+1029 C>T 0.05  Intronic 
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  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33645771 C> T c.408+855 G>A 0.03  Intronic 
  33645897 C> T c.408+729 G>A 0.03  Intronic 
  33645934 C> T c.408+692 G>A 0.03  Intronic 
  33646036 T> C c.408+590 A>G 0.06  Intronic 
  33646277 C> T c.408+349 G>A 0.03  Intronic 
  33646304 C> T c.408+322 G>A 0.04  Intronic 
  33646644 G> A p.Asp130Asp 
c.390C>T 
0.16  Exonic 
  33646650 G> A p.Ile128Ile 
c.384C>T 
0.03  Exonic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D11 INV 33647177 G> A c.-144 C>T 0.03  5'UTR 
  33647232 G> A c.-199 C>T 0.03  5'UTR 
  33647319 G> A Upstream 0.04  Upstream 
  33647348 G> A Upstream 0.05  Upstream 
  33647350 G> A Upstream 0.06  Upstream 
  33647588 C> T Upstream 0.04  Upstream 
  33648237 A> G Upstream 0.03  Upstream 
  33648765 G> A Upstream 0.03  Upstream 
  33649376 G> A Upstream 0.03  Upstream 
  33649414 G> A Upstream 0.03  Upstream 
  33649463 G> A Upstream 0.04  Upstream 
  33649470 C> T Upstream 0.04  Upstream 
  33649489 G> A Upstream 0.03  Upstream 
  33649491 C> T Upstream 0.04  Upstream 
  33649492 C> T Upstream 0.07  Upstream 
  33649495 C> T Upstream 0.04  Upstream 
  33649529 G> A Upstream 0.03  Upstream 
  33649588 G> A Upstream 0.04  Upstream 
  33651192 C> T Upstream 0.05  Upstream 
  33651312 C> T Upstream 0.03  Upstream 
  33651315 G> A Upstream 0.05  Upstream 
  33651406 G> A Upstream 0.05  Upstream 
180 
 
  33651475 C> T Upstream 0.03  Upstream 
  33653001 G> A Upstream 0.05  Upstream 
  33653032 G> A Upstream 0.05  Upstream 
  33653057 G> A Upstream 0.05  Upstream 
  33653093 G> A Upstream 0.04  Upstream 
  33657851 C> T Upstream 0.04  Upstream 
  33657912 C> T Upstream 0.03  Upstream 
  33657981 C> T Upstream 0.04  Upstream 
  33657990 C> T Upstream 0.03  Upstream 
  33658118 G> A Upstream 0.03  Upstream 
D12 DCIS 33612422 C> T c.*356 G>A 0.04  3'UTR 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D12 DCIS 33612446 G> A c.*332 C>T 0.04  3'UTR 
  33628228 G> A c.505-2683 C>T 0.03  Intronic 
  33629305 G> A c.504+1767 C>T 0.02  Intronic 
  33629323 G> A c.504+1749 C>T 0.04  Intronic 
  33629668 TC> CA c.504+1404 GA>TG 0.50  Intronic 
  33630843 C> T c.504+229 G>A 0.04  Intronic 
  33638065 G> A c.409-6898 C>T 0.03  Intronic 
  33638085 G> A c.409-6918 C>T 0.04  Intronic 
  33638086 G> A c.409-6919 C>T 0.05  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 0.50  Intronic 
  33645855 C> T c.408+771 G>A 0.03  Intronic 
  33646979 G> A p.Gln19* 
c.55C>T 
0.04  Exonic 
  33647350 G> A Upstream 0.04  Upstream 
  33648250 G> A Upstream 0.80  Upstream 
  33648859 T> C Upstream 0.06  Upstream 
  33658110 G> A Upstream 0.06  Upstream 
  33612448 G> A c.*330 C>T 0.04  3'UTR 
  33612452 G> A c.*326 C>T 0.03  3'UTR 
  33612948 G> A p.Leu420Leu 
c.1258C>T 
0.03  Exonic 
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 INV 33616704 G> A c.878-3376 C>T 0.03  Intronic 
  33616716 G> A c.878-3376 C>T 0.03  Intronic 
  33616791 G> A c.878-3463 C>T 0.04  Intronic 
  33616897 G> A c.878-3569 C>T 0.08  Intronic 
  33625426 C> T p.Leu208Leu 
c.624G>A 
0.05  Exonic 
  33627317 C> T c.505-1772 G>A 0.04  Intronic 
  33629293 G> A c.504+1779 C>T 0.03  Intronic 
  33629364 G> A c.504+1708 C>T 0.04  Intronic 
  33629486 G> A c.504+1586 C>T 0.03  Intronic 
  33629668 TC> CA c.504+1404 GA>TG 0.5  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D12 INV 33630854 C> T c.504+218 G>A 0.05  Intronic 
  33636289 G> A c.409-5122 C>T 0.03  Intronic 
  33638552 C> T c.409-7385 G>A 0.03  Intronic 
  33638564 C> T c.409-7397 G>A 0.06  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 0.5  Intronic 
  33646088 C> T c.408+538 G>A 0.04  Intronic 
  33646330 C> T c.408+296 G>A 0.03  Intronic 
  33648250 G> A Upstream 0.06  Upstream 
  33648859 T> C Upstream 0.08  Upstream 
  33658110 G> A Upstream 0.06  Upstream 
D13 DCIS 33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.409_410 delGA 1.00  Intronic 
  33647350 G> A Upstream 0.04  Upstream 
  33647595 C> T Upstream 0.03  Upstream 
  33648237 A> G Upstream 0.03  Upstream 
 INV 33612099 CCCT>GGGA c.*676 AGGG>TCCC 0.68  3'UTR 
  33612473 T> C c.*305 A>G 0.64  3'UTR 
  33616851 G> A c.878-3523 C>T 0.03  Intronic 
  33618447 G> A c.878-5119 C>T 0.03  Intronic 
  33618956 C> T c.877+4898 G>A 
 
0.04  Intronic 
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  33628201 G> A c.505-2656 C>T 0.04  Intronic 
  33630834 C> T c.504+238 G>A 0.03  Intronic 
  33630919 C> T c.504+153 G>A 0.04  Intronic 
  33638087 G> A c.409-6920 C>T 0.04  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.409_410 delAG 1.00  Intronic 
  33645977 T> C c.408+649 A>G 0.05  Intronic 
  33646036 T> C c.408+590 A>G 0.10  Intronic 
  33646374 G> A c.408+252 C>T 0.04  Intronic 
  33646644 G> A p.Asp130Asp 
c.390C>T 
0.06  Exonic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D13 INV 33648206 T> C Upstream 0.29  Upstream 
  33648210 T> C Upstream 0.02  Upstream 
  33648234 T> A Upstream 0.03  Upstream 
  33658110 G> A Upstream 0.03  Upstream 
D14 DCIS 33611109 G> A c.*1669 C>T 0.06  3'UTR 
  33612172 T> A c.*606 A>T 0.04  3'UTR 
  33613114 C> T p.Val364Val 
c.1092G>A 
0.03  Exonic 
  33616864 G> A c.878-3536 C>T 0.05  Intronic 
  33618915 C> T c.877+4939 G>A 0.04  Intronic 
  33623992 G> A c.762-23 C>T 0.05  Intronic 
  33625665 G> A c.505-120 C>T 0.02  Intronic 
  33627255 C>  T c.505-1710 G>A 0.03  Intronic 
  33627263 G> A c.505-1718 C>T 0.03  Intronic 
  33627382 C> T c.505-1837 G>A 0.04  Intronic 
  33629315 G> A c.504+1757 C>T 0.05  Intronic 
  33629316 G> A c.504+1756 C>T 0.04  Intronic 
  33629860 G> A c.504+1212 C>T 0.03  Intronic 
  33629867 G> A c.504+1205 C>T 0.04  Intronic 
  33630777 C> T c.504+295 G>C 0.08  Intronic 
  33638081 G> A c.409-6914 C>T 0.04  Intronic 
  33638087 G> A c.409-6920 C>T 0.04  Intronic 
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  33638177 G> A c.409-7010 C>T 0.03  Intronic 
  33638270 C> T c.409-7103 G>A 0.04  Intronic 
  33638793 C> T c.409-7626 G>A 0.03  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33648237 A> G Upstream 0.03  Upstream 
  33648760 G> A Upstream 0.04  Upstream 
  33653022 G> A Upstream 0.04  Upstream 
  33657846 C> T Upstream 0.04  Upstream 
  33658110 G>A Upstream 0.03  Upstream 
  33681433 C> T Upstream 0.03  Upstream 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D14 INV 33611113 G> A c.*1665 C>T 0.04  3'UTR 
  33612422 C> T c.*356 G>A 0.06  3'UTR 
  33629305 G> A c.504+1767 C>T 0.02  Intronic 
  33638005 G> A c.409-6838 C>T 0.04  Intronic 
  33638085 G> A c.409-6918 C>T 0.05  Intronic 
  33638086 G> A c.409-6919 C>T 0.04  Intronic 
  33638753 C> T c.409-7586 G>A 0.04  Intronic 
  33638879 C> T c.409-7712 G>A 0.04  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33648234 T> A Upstream 0.03  Upstream 
D15 DCIS 33612419 G> A c.*359 C>T 0.04  3'UTR 
  33616155 G> A c.878-2827 C>T 0.04  Intronic 
  33616467 G> A c.878-3139 C>T 0.04  Intronic 
  33616858 G> A c.878-3530 C>T 0.04  Intronic 
  33627372 C> T c.505-1827 G>A 0.53  Intronic 
  33629316 G> A c.504+1756 C>T 0.06  Intronic 
  33630847 C> T c.504+225 G>A 0.05  Intronic 
  33643872 G> A c.408+2754 C>T 0.03  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
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  33646036 T> A c.408+590 A>G 0.04  Intronic 
  33648206 T> A Upstream 0.09  Upstream 
 INV 33616482 G> A c.878-3154 C>T 0.04  Intronic 
  33627236 G> A c.505-1691 C>T 0.09  Intronic 
  33627372 C> T c.505-1827 G>A 0.40  Intronic 
  33629305 G> A c.504+1767 C>T 0.02  Intronic 
  33630714 G> A c.504+358 C>T 0.03  Intronic 
  33630924 C> T c.504+148 G>A 0.05  Intronic 
  33638081 G> A c.409-6914 C>T 0.04  Intronic 
  33638082 G> A c.409-6915 C>T 0.03  Intronic 
  33638083 G> A c.409-6916 C>T 0.04  Intronic 
  33638352 G> A c.409-7185 C>T 0.04  Intronic 
Sample Lesion 
Type 
Chromosome 1  
Hg19 location 
Nucleotide 
Change 
Variant  Variant 
Frequency 
Validated Area within DEAR1 
D15 INV 33638568 C> T c.409-7401 G>A 0.03  Intronic 
  33638868 C> T c.409-7701 G>A 0.03  Intronic 
  33639129 T> A c.408+7497 A>T 0.04  Intronic 
  33641960 C> T c.45+49 G>A 0.03  Intronic 
  33642121 G> A c.408+4505 C>T 0.02  Intronic 
  33644798 AA> GC c.408+1828 TT>GC 1.00  Intronic 
  33645661 GCT> G c.408+963_408+964 delAG 1.00  Intronic 
  33645977 T> A c.408+649A>G 0.03  Intronic 
  33647354 G> A Upstream 0.03  Upstream 
  33648250 G> A Upstream 0.05  Upstream 
  33658110 G> A Upstream 0.04  Upstream 
D16 DCIS 33639129 T> A c.408+7497 A>T 0.03  Intronic 
  33648859 T> C Upstream 0.05  Upstream 
 INV 33612040 C> G c.*738 G>C 0.03  3'UTR 
  33639129 T> A c.408+7497 A>T 0.04  Intronic 
  33656988 T> C Upstream 0.02  Upstream 
D17 DCIS 33639129 T> A c.408+7497 A>T 0.03  Intronic 
  33648237 A> G Upstream 0.03  Upstream 
 INV 33648859 T> C Upstream 0.04  Upstream 
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Appendix XI- Detailed List of DEAR1 Variants Shared Between the In Situ and Invasive Components of Ductal Carcinoma In Situ. This table describes 
the variants that shared between the in situ and invasive components of adjacent DCIS lesions. The vast majority of these variants were within DEAR1’s 
introns. Shared variants with stable variant frequencies at or around 50% or 100% within both lesion components are contained in samples for which the 
normal breast tissue was unable to be sequenced, and most likely reflect germline variants.  
Sample Chromosome1 Hg19 location Lesion Type Nucleotide Change Variant % Variant Frequency Area within DEAR1 
D01 33639129 DCIS T> A c.408+7497A>T 0.03 Intronic 
  INV   0.07  
D02 33639129  DCIS T >A c.408+7497 A>T 0.04 Intronic 
  INV   0.04  
D04 33630779 DCIS G >A c.504+293 C>T 0.03 Intronic 
  INV   0.03  
 33648250 DCIS G> A Upstream 0.10 Upstream 
  INV   0.05  
 33658110 DCIS G> A Upstream 0.05 Upstream 
  INV   0.04  
D05 33629313 DCIS G> A c.504+1759 C>T 0.04 Intronic 
  INV   0.05  
 33630850 DCIS C> T c.504+222 G>A 0.04 Intronic 
  INV   0.04  
 33638864 DCIS C> T c.409-7697 G>A 0.06 Intronic 
186 
 
  INV   0.04  
Sample Chromosome1 Hg19 location Lesion Type Nucleotide Change Variant % Variant Frequency Area within DEAR1 
D05 33645855 DCIS C> T c.408+771 G>A 0.02 Intronic 
  INV   0.04  
 33646036 DCIS T> C c.408+590 A>G 0.09 Intronic 
  INV   0.06  
 33648206 DCIS T> C Upstream 0.03 Upstream 
  INV   0.15  
 33648250 DCIS G> A Upstream 0.09 Upstream 
  INV   0.09  
 33639129 DCIS T> A Upstream 0.05 Upstream 
  INV   0.05  
D09 33629668 DCIS TC> CA c.504+1404 GA>TG 0.46 Intronic 
  INV   0.49  
 33644798 DCIS AA> GC  c.408+1828 TT>GC 1.00 Intronic 
  INV   1.00  
 33645661 DCIS GCT> G c.408+963_408+964 delAG 0.51 Intronic 
  INV   0.52  
D11 33644798 DCIS AA> GC c.408+1828 TT>GC 1.00 Intronic 
187 
 
  INV   1.00  
 33645661 DCIS GCT> G c.408+963_408+964 delAG 1.00 Intronic 
Sample Chromosome1 Hg19 location Lesion Type Nucleotide Change Variant % Variant Frequency Area within DEAR1 
D11 33645661 INV   1.00  
 33645897 DCIS C> T c.408+729 G>A 0.04 Intronic 
  INV   0.03  
 33653032 DCIS G> A Upstream 0.05 Upstream 
  INV   0.05  
D12 33629668 DCIS TC> CA c.504+1404 GA>TG 0.50 Intronic 
  INV   0.50  
 33644798 DCIS AA> GC c.408+1828 TT>GC 1.00 Intronic 
  INV   1.00  
 33645661 DCIS GCT> G c.408+963_408+964 delAG 0.50 Intronic 
  INV   0.50  
 33648250 DCIS G> A Upstream 0.80 Upstream 
  INV   0.06  
 33648859 DCIS T> C Upstream 0.06 Upstream 
  INV   0.08  
 33658110 DCIS G> A Upstream 0.06 Upstream 
188 
 
  INV   0.06  
D13 33644798 DCIS AA> GC c.408+1828 TT>GC 1.00 Intronic 
  INV   1.00  
Sample Chromosome1 Hg19 location Lesion Type Nucleotide Change Variant Variant Frequency Area within DEAR1 
D13 33645661 DCIS GCT> G c.409_410 delGA 1.00 Intronic 
  INV   1.00  
D14 33644798 DCIS AA> GC c.408+1828 TT>GC 1.00 Intronic 
  INV   1.00  
 33645661 DCIS GCT> G c.408+963_408+964 delAG 1.00 Intronic 
  INV   1.00  
D15 33627372 DCIS C> T c.505-1827 G>A 0.53 Intronic 
  INV   0.40  
 33644798 DCIS AA> GC c.408+1828 TT>GC 1.00 Intronic 
  INV   1.00  
 33645661 DCIS GCT> G c.408+963_408+964 delAG 1.00 Intronic 
  INV   1.00  
D16 33639129 DCIS T> A c.408+7497 A>T 0.03 Intronic 
  INV   0.04  
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